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Abstract 
 
Neurodegenerative diseases are among the most complex and puzzling human 
disorders. These devastating disorders currently do not have any effective therapies or 
treatments, and thus are a social and economic burden for modern society. Intense 
efforts are being made to unravel the mechanisms underlying this group of diseases, 
however there is still much to be learnt and discovered. Therefore, it is of utmost 
importance to better understand the biological mechanisms involved in disease 
pathogenesis, and more importantly, to discover novel avenues for therapeutic 
intervention. Budding yeast have been successfully used to perform studies on these 
diseases that have resulted in the identification of several promising therapeutic drugs 
and targets. The ease of experimental manipulation, the high conservation in basic 
cellular mechanisms between yeast and humans, and the well defined genome are 
three of the numerous characteristics that make yeast so attractive to researchers 
studying neurodegenerative disorders. Here, we used the budding yeast to study the 
molecular basis of two neurodegenerative diseases: Huntington’s (HD) and Parkinson’s 
disease (PD). 
HD is a fatal neurodegenerative disorder caused by a well defined genetic 
cause, which is an expansion of a polyglutamine tract in the huntingtin (Htt) protein. We 
have used a yeast HD model to find differentially expressed genes (DEGs) in wild-type 
yeast in response to mutant Htt toxicity, as well as in three Htt toxicity suppressor 
strains: bna4∆, mbf1∆, and ume1∆. We found common DEGs in the suppressor strains 
involved in stress response, translation elongation, and mitochondrial transport. We 
then tested whether overexpression of the DEGs suppress mutant Htt toxicity. We 
identified 12 novel suppressors, including genes that play a role in stress response and 
rRNA processing. We have integrated the microarray and the genetic screening data 
that allowed us to generate a robust network that showed enrichment in genes involved 
in rRNA processing and ribosome biogenesis. Altogether, our results suggest that 
dysfunctional translation is implicated in HD. Ultimately pharmacological manipulation of 
translation may have therapeutic value in HD.  
PD is the most common progressive neurodegenerative movement disorder. 
One of the proteins that when mutated leads to autosomal recessive forms of PD is DJ-
1. The precise function of this protein and how this protein leads to PD is unclear. Yeast 
has four proteins that belong to the conserved DJ-1 superfamily: Hsp31, Hsp32, Hsp33 
and Hsp34. Very little is known about their function. Here, we show that the yeast DJ-1 
vi 
homologs are required for diauxic-shift, an important metabolic reprogramming stage in 
yeast that is triggered by glucose limitation. We found that the Hsp31 genes are 
strongly induced in diauxic-shift and in stationary phase, and that deletion of these 
genes leads to reduced chronological lifespan, an inability to reprogram gene 
transcription at diauxic-shift, and failure to acquire several typical characteristics of 
stationary phase, including defective autophagy induction. Furthermore, we showed that 
these proteins contribute to TORC1 regulation, a central signaling pathway involved in 
diauxic-shift reprogramming and, importantly, in autophagy. As dysregulation of both 
autophagy and TORC1 are associated with several disorders – including PD – our work 
may have broad relevance to understanding these processes in health and disease. 
These novel insights into the function of the yeast DJ-1 homologs contribute to the 
understanding of the normal function of both human DJ-1 and the remaining DJ-1 
superfamily members, and may therefore bear therapeutic implications in various 
human diseases.  
The human DJ-1 is thought to act as a redox-dependent chaperone by 
preventing the aggregation of misfolded proteins in oxidative stress conditions. One of 
the potential targets of DJ-1 is α-synuclein, which is the major component of Lewy 
bodies in PD. Oxidative stress is linked to several neurodegenerative diseases including 
HD. Here, we show that DJ-1 plays a potential role in the pathogenesis of HD, by 
modulating Htt aggregation and toxicity likely, by acting as a redox-dependent 
chaperone. We found that DJ-1 is upregulated and abnormally oxidized in the brains of 
HD patients, which is how DJ-1 is found in brains of patients with PD and Alzheimer’s 
disease. Our results suggest a general role for DJ-1 as a redox-dependent chaperone 
that may have an impact in the pathogenesis of several protein misfolding diseases. 
Furthermore, it establishes DJ-1 as a potential therapeutic target for HD.  
Overall, the work presented in this thesis opens novel avenues of research and 
therapeutics for HD and PD and proposes that DJ-1 has broad relevance in the 
pathogenesis of neurodegenerative diseases.   
 
Keywords: Parkinson’s disease, Huntington’s disease, yeast, diauxic-shift, 
autophagy, translation, TORC1, protein misfolding 
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Resumo 
 
As doenças neurodegenerativas estão entre as doenças humanas mais 
complexas e enigmáticas. As terapias e tratamentos actualmente existentes não são 
eficazes, causando um impacto negativo na sociedade moderna, tanto a nível social 
como económico. Apesar do esforço empregue na compreensão dos mecanismos 
patogénicos associados a este grupo de doenças, ainda há muito por explorar e 
aprender. É urgente investigar os mecanismos moleculares que levam a essas 
patologias e descobrir novos alvos terapêuticos. A levedura Saccharomyces cerevisiae 
tem sido usada com sucesso no estudo de doenças neurodegenerativas e já resultou 
na identificação de vários alvos terapêuticos bem como de compostos com potencial 
terapêutico bastante promissor. As leveduras, como modelo biológico, apresentam 
várias vantagens que as tornam atractivas para estudar estas doenças, incluindo a sua 
fácil manipulação laboratorial, a conservação dos mecanismos celulares básicos até 
aos humanos, e extensa caracterização do seu genoma. Nesta tese, as leveduras 
foram o modelo escolhido para estudar os mecanismos moleculares associados a duas 
doenças neurodegenerativas: a doença de Huntington (DH) e a doença de Parkinson 
(DP).  
A DH é uma doença neurodegenerativa fatal, geneticamente bem 
caracterizada, causada por uma mutação genética no gene IT15, que consiste na 
repetição anormal da sequência de nucleotídeos CAG, originando a expansão de uma 
região rica em glutaminas na proteína huntingtina (Htt). O modelo de levedura para a 
DH foi usado para detectar genes diferencialmente expressos (GDE) em células a 
expressar a proteína Htt mutada, assim como em três estirpes supressoras de 
toxicidade de Htt: bna4∆, mbf1∆, e ume1∆. Nestas estirpes supressoras da toxicidade 
foram encontrados GDE envolvidos na resposta ao stress, no alongamento durante a 
tradução do mRNA e no transporte mitocondrial. A sobre-expressão dos GDEs levou à 
identificação de 12 novos genes supressores da toxicidade provocada pela Htt, 
incluindo genes envolvidos na resposta ao stress e no processamento do rRNA. Pela 
integração dos resultados provenientes de microarrays e do screening genético, 
através de ferramentas informáticas, construiu-se uma rede de interacções que mostra 
um enriquecimento de genes envolvidos no processamento do rRNA e na biogénese 
de ribossomas associado à toxicidade da Htt. Estes resultados sugerem que a 
desregulação do processo de tradução está associado à DH e que novas terapias 
podem surgir pela modulação farmacológica deste processo.  
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 A DP é a doença neurodenegerativa motora progressiva mais comum. Um dos 
genes geneticamente associados à DP, transmitida de uma forma autossómica 
recessiva, codifica a proteína DJ-1. A função normal desta proteína é ainda pouco clara 
e não se conhece ainda o papel da mutação desta proteína no desenvolvimento da DP. 
As leveduras têm quatro proteínas que pertencem à conservada superfamília da DJ-1: 
Hsp31, Hsp32, Hsp33 e a Hsp34, no entanto pouco se conhece sobre a sua função. 
Nesta tese, mostra-se que os homólogos da DJ-1 são necessários para a transição do 
metabolismo fermentativo para o respiratório, uma importante reprogramação 
metabólica nas leveduras originada pela falta de glucose. A deleção dos genes HSP31-
34 leva a um envelhecimento mais rápido de leveduras em fase estacionária e à 
ausência de várias características desta fase, que incluem a ausência de indução do 
processo autofágico. Em particular, mostramos que estas proteínas contribuem para a 
regulação da TORC1, uma via de sinalização envolvida nesta reprogramação, e mais 
importante ainda, na autofagia. Tendo em conta, que tanto a desregulação da TORC1 
como da autofagia estão associadas a várias doenças, incluindo a DP, este trabalho 
pode ser relevante para a compreensão destes processos não só em condições 
normais, como também patológicas. Estas novas descobertas associadas à função dos 
homólogos em leveduras da DJ-1 contribuem para a compreensão da função da 
proteína humana e dos outros membros da superfamília DJ-1, podendo trazer 
implicações terapêuticas em várias doenças humanas.  
Uma das funções propostas para a DJ-1 humana é a de actuar como uma 
chaperone dependente do estado redox, que previne a agregação de proteínas sem 
conformação definida em condições de stress oxidativo. Um dos potenciais alvos da 
DJ-1 é a α-sinucleína, o componente mais importante dos corpos de Lewy, na DP. 
O stress oxidativo é um mecanismo molecular associado a diversas doenças 
neurodegenerativas, incluindo a DH. Neste estudo, demonstramos que a DJ-1 poderá 
ter um papel importante na patogénese da DH, pois consegue modular a agregação e 
toxicidade da Htt, possivelmente através da sua função como chaperone. Neste 
trabalho demonstramos que a DJ-1 está mais expressa e anormalmente oxidada em 
cérebros de doentes com DH, à semelhança do que acontece nos doentes com DP e 
doença de Alzheimer. Os nossos resultados sugerem que a DJ-1 apresenta um papel 
geral como chaperone, dependente do estado redox, e cujo impacto na patogénese de 
diversas doenças relacionadas com a agregação de proteínas não deve ser 
desvalorizado. Para além disso, determina a DJ-1 como um potencial alvo terapêutico 
para a DH.   
ix 
O trabalho apresentado nesta tese abre novos campos de investigação e 
estratégias terapêuticas, sugerindo que a proteína DJ-1 está associada à patogénese 
de várias doenças neurodegenerativas como a DP e DH. 
 
Palavras-chave: Doença de Parkinson, Doença de Huntington, leveduras, TORC1, 
tradução proteica 
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Chapter 1. Introduction 
 
Protein misfolding diseases 
Protein aggregation disorders are a group of diseases characterized by the 
misfolding and aggregation of one or more proteins, which includes Alzheimer’s disease 
(AD), Parkinson’s disease (PD) and Huntington’s disease (HD).  
Proteins are constantly in risk of becoming unfolded, especially in stress 
conditions 1. Intermediate folding species typically expose hydrophobic residues which 
have higher tendency to lead to aggregation. Once certain proteins are misfolded they 
can act as a seed, leading to the misfolding of others and ultimately resulting in the 
formation of aggregates 2 (Fig. 1.1).  
 
 
Figure 1.1. Schematic representation of protein folding/misfolding processes.  
Following synthesis, each protein needs to adopt a specific three dimensional structure (native 
conformation) in order to become biologically functional. Proteins often acquire intermediate 
states before being completely folded. The different species may be prone to misfolding, leading 
to their accumulation and, in certain cases, to the formation of aggregates, which can be 
amorphous or amyloid-like. Some of the intermediates and/or aggregates are likely to be 
cytotoxic, and therapeutic intervention might be possible at different levels along these pathways 
to prevent their accumulation. 
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To deal with protein misfolding cells have developed a protein quality control 
(QC) system, which includes molecular chaperones, the ubiquitin proteasome system 
(UPS) and autophagy (Fig. 1.2). While chaperones help proteins to fold or refold, the 
UPS and autophagy are responsible for protein turnover. The degradation of proteins is 
critical not only to remove the damaged proteins and recycle amino acids but also to 
clear proteins that play essential roles in cellular processes such as signal transduction 
and cell division. Protein degradation by the UPS, the key mechanism to degrade short-
lived proteins, consists in covalently linking the target proteins to multiple ubiquitin 
molecules (polyubiquitination) as a signal for degradation, which will subsequently be 
recognized and degraded by the 26S proteasome (Fig 1.2)3. Autophagy is a catabolic 
process essential to recycle cellular components that allows survival under nutrient-
limited conditions. It is also required to eliminate dysfunctional organelles or other 
materials. Autophagy can be divided in three types: macroautophagy (hereafter 
autophagy), in which the cargo to be eliminated is engulfed by a double membrane 
vesicle, the autophagosome, and is transported to the vacuole, where it is degraded 
(Fig. 1.2); chaperone-mediated autophagy (CMA) which is characterized by selective 
translocation of the cargo across the lysosome through a specific receptor mediated by 
a chaperone (Fig. 1.2); and microautophagy, in which the material to be degraded 
directly enters the lysosome 4. 
When the capacity of the protein QC system is exceeded or the system just fails, 
proteins may become toxic to the cell due to its accumulation and possible aggregation. 
Protein aggregation may be caused by additional factors, such as: mutations that 
increase the protein tendency to misfold and aggregate, errors in translation, 
environmental stresses such as oxidative stress and ageing (which is correlated with an 
increase in oxidation of proteins) 1. The accumulation of abnormally folded proteins 
results, on one hand, in the loss of the normal biological role of the protein and, on the 
other hand, in a putative gain of cytotoxic function (Fig. 1.1). The ‘amyloid hypothesis’ 
(developed originally for AD) states that the aggregation of proteins into an ordered 
fibrillar structure is causally related to aberrant protein interactions that culminate in 
neuronal dysfunction and ultimately neurodegeneration 5–7. However, it is still unclear 
which species correlate with toxicity, whether the aggregates or the intermediate 
species. It has been observed that cells can direct the aggregated proteins to specific 
cellular sites, which can be considered as the second line of protection against the 
potential toxic species upon failure of the QC system 1. Nevertheless, the presence of 
large aggregates can still contribute for cellular toxicity.  
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Since neurons are post-mitotic cells and highly metabolic active they are more 
sensitive to the accumulation of misfolded proteins and this may explain the high 
number of brain diseases associated with protein misfolding.  
  
 
Figure 1.2. Protein quality control systems.  
Following protein synthesis, chaperones help proteins to fold. If folding fails or the protein needs 
to be turned over, a chain of ubiquitin molecules is attached to the target protein by the action of 
a series of enzymes: ubiquitin activating (E1), conjugating (E2) and ligating (E3) enzymes. The 
ubiquitin molecules are usually linked between the terminal residue (G76) of one ubiquitin and a 
lysine of another ubiquitin molecule, usually lysine 48. The polyubiquitinated proteins are then 
recognized by the 26S proteasome and degraded. Ubiquitin molecules can instead be linked 
through the lysine 63, which promotes protein aggregation. Aggregates may be, engulfed by a 
double membrane – autophagosome – which will then fuse with the lysosome. Upon fusion, the 
cargo is degraded by the acidic lysosomal hydrolases (macroautophagy). Proteins can also be 
degraded by entering into the lysosome with the help of the chaperone Hsc70 through the 
receptor LAMP 2A (chaperone-mediated autophagy). poly-Ub – polyubiquitin chain. 
 
 
 
 
 
Chapter 1 
4 
Huntington’s disease 
HD is a fatal adult onset neurodegenerative disorder that has a worldwide 
prevalence of ~1 in 10,000 people. The onset of the symptoms is typically around 45-50 
years old but there are also juvenile forms of the disease. Death usually occurs 10-15 
years after the onset of the disease. This disorder is inherited in an autosomal dominant 
manner and is characterized by abnormal motor movements, personality changes and 
cognitive decline 8. The neuropathology of HD is characterized by the loss of specific 
neuronal types in several brain regions, and can be related to specific symptoms and 
progression of the disease. However, neuronal loss can be detected before the clinical 
symptoms start to appear 9. The most striking pathology in HD is the cell loss observed 
in the striatal region of the basal ganglia, of which medium spiny neurons are the most 
affected.  
HD is caused by a mutation in the IT15 gene (localized in exon 1) that consists 
in the expansion of CAG repeats beyond a critical length. This causes an expansion of 
the polyglutamine (polyQ) tract in the huntingtin (Htt) protein and consequently results in 
its misfolding. The CAG repeat in the IT15 is polymorphic in the general population and 
expanded in individuals affected by HD, which have repeat lengths greater than 35 10. 
HD genes carrying expansions in the range of 36-39 CAG repeats show an increasing 
risk of developing HD, while expansions of 40 CAG repeats and higher are fully 
penetrant 11. The length of the CAG repeat has also been found to be inversely 
correlated to the age of onset 12, with expansions of 70 CAG repeats or longer inevitably 
leading to juvenile onset HD 10,13. Though increased size of the triplet repeat expansion 
correlates to an earlier age of onset, there is great variability in the age of onset of HD, 
even when controlling for repeat length. Indeed, work by the U.S.-Venezuela 
Collaborative Research Project with HD kindreds containing over 18,000 individuals has 
found that approximately 40% of variation in age of onset in HD patients is due to 
several genetic modifiers 14. Although HD has a well-defined genetic cause, the 
molecular pathways that lead to neurodegeneration remain poorly understood and so 
far there is no therapy that prevents, delays or reverses this disease. However, the fact 
that several genetic modifiers can affect the HD age of onset suggest that many 
therapeutic targets may be available for treating progression of this devastating 
disorder. 
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Htt aggregation and inclusion bodies 
The discovery of the polyQ expansion allowed the generation of several 
transgenic mice models expressing the first exon of the human Htt 15. The most studied 
HD model is the R6/2 model that exhibits some characteristics of HD, such as 
progressive neurodegeneration, motor abnormalities and reduced lifespan 15. The study 
of mouse models together with the analysis of HD brains led to discover the 
pathological hallmark of HD which consists in intraneuronal inclusion bodies (IB) 
containing aggregated Htt. IB are found in the nucleus, cytoplasm and neuronal 
processes 16–19. Although these aggregates have been causally related to HD 
pathology, there is great debate as to their role in this disorder. Mutant Htt could lead to 
neuronal loss through sequestration of crucial proteins into IB, such as transcription 
factors, which could explain why transcription is dysregulated in HD 20–23. On the other 
hand, sequestration into IB could also be biologically irrelevant 24,25, and soluble 
oligomeric species could be the actual cause of transcriptional dysregulation and 
mutant Htt neurotoxicity. Compelling evidence indicates that IB are not correlated with 
cell death. The cerebral cortex of HD patients has a high number of IB, whereas their 
striatum, which is where neuronal death is higher, shows only a few 16. Formation of 
aggregates could be a protective mechanism to scavenge more neurotoxic Htt 
oligomeric species 26–28. 
The most important intrinsic factor affecting the aggregation of mutant Htt is the 
length of the polyQ tract, but there are other factors, such as the amino acids flanking 
the polyQ stretch 29–31. For instance, deleting the flanking proline rich region changes 
from non-toxic Htt to toxic one and it leads to changes in the aggregates shape and 
number 29,30. The proteolytic cleavage of Htt is also thought to promote aggregation 17,32 
and influence the localization of IB to the cytosol or nucleus 33. Interestingly, transgenic 
mice expressing a caspase 6-resistant version of mutant Htt do not exhibit striatal 
degeneration 34, suggesting that proteolysis of Htt at the caspase-6 cleavage site is 
important for neurodegeneration in HD. Post translational modifications of Htt, such as 
ubiquitination, phosphorylation and sumoylation can influence Htt degradation and 
subsequently its aggregation 35.  
 
Pathogenic mechanisms in HD 
Since the cloning of the HD gene in 1993 10, a great deal has been learned 
about the cellular dysfunction caused by mutant Htt expression, and several 
mechanisms have been uncovered that likely contribute to the selective 
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neurodegeneration observed in the disease. The Htt protein is a large cytoplasmic 
protein that is ubiquitously expressed 36 and is required for embryogenesis and 
development 37–39. The precise function of this protein is still not clear, but it has been 
shown to be involved in several pathways and interact with multiple proteins that are 
involved in diverse mechanisms including intracellular transport, clathrin-mediated 
endocytosis, transcriptional regulation, RNA trafficking and cell survival  39–46. Therefore, 
the loss of Htt interactions with binding partners or anomalous interactions may 
contribute to Htt neurotoxicity.  
Neurodegeneration in HD occurs not only by dysregulation of intrinsic 
mechanisms of the vulnerable cells (cell-autonomous) (Fig. 1.3), but also by 
contribution of other cell types (non-cell-autonomous) (Fig. 1.4). The cell-autonomous 
mechanisms affected in HD include transcriptional dysregulation, mitochondrial 
dysfunction, defective vesicle trafficking in axons and impairment of ubiquitination and 
proteasomal function, whereas the non-cell-autonomous mechanims include 
excitotoxicity, perturbations in the kynurenine pathway (Chapter 2), and inflammation.  
Transcriptional dysregulation has long been implicated in the pathogenesis of 
HD. Early studies on post mortem HD brains showed that several mRNAs of 
neurotransmitter receptors and signaling neuropeptides are decreased in striatal 
neurons 47–49. The idea that transcription was affected by mutant Htt was further 
supported by the fact that wild-type Htt was mainly a cytosolic protein, while cleaved 
mutant Htt was strongly localized to the nucleus causing enhanced toxicity 32,50,51. 
Mutant Htt can interact with transcription factors, such as SP1 and members of the core 
transcription machinery, and by this way affects transcription 52–55. BDNF was one of the 
transcripts that was found reduced in the brains of HD patients 56. BDNF (Brain-derived 
neurotrophic factor) is important for the survival of striatal neurons and was shown to 
have beneficial effects on mouse models of HD when overexpressed 57,58. BDNF 
expression is regulated by the repressor element-1 transcription factor/neuron-
restrictive silencer factor (REST/NRSF), which recognizes and binds to the neuron 
restrictive silencer element (NRSE) present in the BDNF promoter 59,60. Wild-type Htt 
regulates BDNF transcription by sequestering REST/NRSF in the cytosol, preventing its 
translocation into the nucleus and binding to NRSE. In the presence of mutant Htt, the 
REST/NRSF is not sequestered anymore and enters into the nucleus leading to the 
repression of NRSE regulated genes, including BDNF 59,60, explaining why this gene is 
decreased in striatal neurons, and suggesting a mechanism for the unique sensitivity of 
these neurons in HD.  
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Compelling evidence from patients and several models of HD suggest that 
mitochondrial dysfunction contributes to the pathogenesis of HD. The weight loss that 
patients suffer at early stages of the disease is indicative of mitochondrial impairment 61. 
The postmortem HD brain tissues show dysfunctional complex II, III, IV of the electron 
transport chain, mtDNA mutations 62–65, a reduced number of mitochondria and different 
morphology from controls 66. Defects in calcium homeostasis in mitochondria from HD 
patients and HD transgenic mice has also been observed 67. One hypothesis that 
explains how mutant Htt causes mitochondrial dysfunction is through its direct 
interaction with mitochondria67–70. Mutant Htt can also bind to the promoter of the 
Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) and 
repress its expression 71. PGC-1α is a transcriptional coactivator of mitochondrial genes 
involved in respiration and mitochondrial biogenesis. The repression of PGC-1α can 
cause a defect in the energy homeostasis of the cell that may lead to cell death 71. 
Interestingly, a correlation between the number of CAG repeats with the production of 
mitochondrial ATP has also been observed72.  
 
 
Figure 1.3. Cell autonomous mechanisms underlying HD. 
Mutant huntingtin (HTT) can be cleaved by caspase-6 and interfere with essential neuronal 
processes, such as proteasomal function, autophagy and transcription. Moreover, it can lead to 
mitochondrial dysfunction and lead to an increase in oxidative stress.  
Image from Ross et al., Lancet Neurology, 2011 
73
. 
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Excitotoxicity, one of the non-cell-autonomous mechanisms implicated in HD, is 
caused by overstimulation of glutamate receptors, especially the ionotropic N-methyl-D-
aspartate (NMDA) receptors, which leads to an increase in calcium influx and ultimately 
neuronal death (Fig. 1.4) 74. Excitotoxicity is thought to be caused by reduced glutamate 
uptake by glutamate transporter 1 in astrocytes or increased glutamate release from 
cortical neurons 75,76. Overactivation of NMDA receptors may also result from 
mitochondrial dysfunction and the consequent deficient energy production. The entry of 
calcium ions by NMDA receptors is blocked by Mg2+, which is released by 
depolarization of the cell. Mitochondria are required to sustain the membrane potential. 
Upon its dysfunction, there is less energy to maintain the Na+/K+ pump working, leading 
to cell depolarization, loss of Mg2+ and consequently entry of calcium into the cell 77.   
 
 
Figure 1.4. Non-cell-autonomous mechanisms underlying HD 
Mutant huntingtin can lead to dysregulation of several mechanisms in different cell types, which 
will contribute for neuronal cell death. These mechanisms include excitotoxicity, perturbations in 
the kynurenine pathway and increase in neuroinflammation.  
Image from Ross et al., Lancet Neurology, 2011 
73
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Parkinson’s disease 
PD is the second most common progressive neurodegenerative disorder, after 
AD. It affects about 2% of people over 65 years old and 4–5% of people over 85 78. PD 
was originally characterized in the monograph “An Essay on the Shaking Palsy” by 
James Parkinson in 1817, in which he described the major symptoms of PD: muscle 
rigidity, bradykinesia (slowness of voluntary movement), resting tremor and postural 
instability. Non-motor symptoms are also characteristic of the disease, such as 
hyposmia (reduced ability to smell), depression and rapid eye movement sleep behavior 
disorder. At later stages the patients can eventually suffer from dementia 79. 
The major pathological hallmarks of PD are the presence of intraneuronal 
concentric hyaline cytoplasmic inclusions called Lewy bodies (LB) and loss of 
dopaminergic neurons in the substantia nigra pars compacta (SNpc). LBs contain 
fibrillar forms of α-synuclein (α-syn), as well as proteasomal and lysosomal subunits 
and molecular chaperones 80,81. Curiously, LBs can also be found in patients with other 
neurodegenerative disorders, such as dementia with LBs and AD 82, and even in 
clinically normal people over 60 years old (10%), although in this case it is thought to be 
pre-symptomatic 83. Surprisingly, LBs are not present in the brains of some patients with 
autosomal recessive PD. There is a great debate regarding whether LBs are cytotoxic 
or a protective mechanism to preclude the accumulation of the pathogenic 
intermediates, which have been proposed to be α-syn oligomers 84.  
PD was first thought to affect essentially dopaminergic neurons, but nowadays is 
considered a multisystem disorder that affects several regions of the nervous system 79. 
In the majority of idiopathic cases, it is possible to predict the spreading of LBs and thus 
it has been divided in 6 stages 85. However, how exactly this pathology is spread is still 
unclear.  
Despite the intense research on PD, there are still no effective therapies, neither 
a way to slow down the progression of the disease 86. Dopamine replacement therapy 
(with the drug levodopa) ameliorates the motor symptoms (especially at the beginning), 
but generally causes severe secondary effects 87. When the patients do not respond 
well to the drug treatment, they are candidates for an alternative procedure, deep brain 
stimulation, which consists in surgically inserting an electrode in the subthalamic 
nucleus or the internal global pallidus, both localized in basal ganglia. This electrode, by 
sending electric stimulus, can block the brain impulses that cause PD symptoms. 
However, it cannot slow the progression of the disease 87. It is therefore of extreme 
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importance to understand the molecular mechanisms that underlie PD so that effective 
therapies can be discovered in a near future. 
 
ETIOLOGY OF PD 
The etiology of PD is complex and unclear and in many cases the cause is 
completely unknown (idiopathic). The majority of PD cases arise sporadically 88. The 
major risk factor to develop this disease is clearly ageing, but there also some 
environmental factors associated to PD. For instance, subjects that continuously self-
injected “synthetic heroin” with the contaminant MPTP (1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine) developed typical symptoms of parkinsonism. Interestingly, although 
their brains showed nigrostriatal degeneration, LBs were not found 89. In addition, 
chronic exposure to agricultural chemicals, such us rotenone, manganese 
ethylenebis(dithiocarbamate) (maneb) and paraquat, is considered a potential risk 
factor of PD 90. Caffeine and nicotine have also been shown to be inversely correlated 
with the incidence of PD 91. Until 1977, PD was considered to be a non-genetic disease, 
but today it is known that approximately 10% of PD cases are familial 88, and that 
genetics may also affect susceptibility to disease onset 92. 
 
GENETICS OF PD 
The first gene to be associated with PD was SNCA, the gene that encodes α-
syn. Since then 18 loci named PARK have been genetically linked to PD. However, only 
6 genes have been clearly found to cause monogenic PD: SNCA (PARK1/4), LRRK2 
(PARK8), Parkin (PARK2), PINK1 (PARK6), DJ-1 (PARK7), and ATP13A2 (PARK9) 93 
(Table 1.1). Mutations in these genes only explain around 30% of familial cases and 3% 
of sporadic 93.  
Mutations in SNCA and LRRK2 (Leucine-rich repeat kinase 2) are associated 
with autosomal dominant cases of PD. Although it is rare to find mutations in SNCA, five 
missense mutations (A53T, A30P, E46K, H50Q and G51D) have been identified in 
patients with familial PD or Dementia with LBs 94–98 as well as duplications and 
triplications of the genomic region of SNCA 99,100. In addition, two genome-wide 
association studies showed that several single nucleotide polymorphisms in SNCA are 
risk factors to develop sporadic PD 101,102. LRRK2 mutations are the most frequent 
cause of familial and sporadic PD 103. Patients with mutations in this gene present late-
onset PD, clinically indistinguishable from sporadic cases 103.  
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Table 1.1. Loci associated with PD   
  Locus Gene Disorder Inheritance Status 
PARK1 SNCA EOPD AD Confirmed 
PARK2 Parkin EOPD AR Confirmed 
PARK3 Unknown Classical PD AD 
Unconfirmed; may 
represent a risk factor 
PARK4 SNCA EOPD AD Identical to Park1 (error) 
PARK5 UCHL1 Classical PD AD Unconfirmed 
PARK6 PINK1 EOPD AR Confirmed 
PARK7 DJ-1 EOPD AR Confirmed 
PARK8 LRRK2 Classical PD AD Confirmed 
PARK9 ATP13A2 
Kufor-Rakeb syndrome; 
atypical PD 
AR Confirmed 
PARK10 Unknown Classical PD Risk factor Confirmed 
PARK11 Unknown LOPD AD Possibly is a risk factor 
PARK12 Unknown Classical PD Risk factor Possibly is a risk factor 
PARK13 HTRA2 Classical PD 
AD or Risk 
factor 
Unconfirmed 
PARK14 PLA2G6 
Early-onset dystonia-
parkinsonism 
AR Confirmed 
PARK15 FBX07 
Early-onset parkinsonian-
pyramidal syndrome 
AR Confirmed 
PARK16 Unknown Classical PD Risk factor Confirmed 
PARK17 VPS35 Classical PD AD Confirmed 
PARK18 EIF4G1 Classical PD AD Unconfirmed 
Table adapted from Corti et al, Physiol Rev, 2011 
86
 and Klein and Westenberger, Cold Spring Harbor 
Persp in Med, 2012 
93
.  
 
The remaining genes Parkin, PINK1, DJ-1 and ATP13A2 are associated with 
juvenile (≤ 20 years-old) and early-onset (≤ 45 years-old) autosomal recessive PD. 
Mutations in Parkin are the most frequent cause of autosomal recessive PD, followed 
by mutations in PINK1 104–106. An intriguing aspect of the autosomal recessive cases is 
that LBs are absent in the majority of cases with Parkin mutations and so far only one 
case with mutations in PINK1 was reported to show LBs 107. There are still no autopsy 
reports of patients with DJ-1 or ATP13A2 mutations. Additional genes have been linked 
to PD but need further confirmation: UCHL1 (PARK5), GYGYF2 (PARK11), 
OMI/HTRA2 (PARK13), PLA2G6 (PARK14), and FBXO7 (PARK15) 93.  
 
PATHOGENESIS OF PD 
Although familial and sporadic forms of PD have certain differences, these likely 
share several pathogenic mechanisms. Therefore, intense research is focusing on 
investigating the proteins involved in familial PD, both in terms of their normal 
physiological role as well as their role in the disease. The discovery of PD genes and 
environmental factors such as MPTP have allowed the PD research community to 
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generate in vivo and in vitro models of the disease, which together with epidemiological 
studies and post-mortem analysis has already provided several insights into the 
molecular pathways and mechanisms that underlie PD. The fact that most genes linked 
to PD result in similar phenotypes, suggests that at least some of the proteins encoded 
by these may work in a single pathway (Fig. 1.5). Therefore, one of the goals of the PD 
research is to understand the relationship between these genes.  
The key mechanisms that contribute for PD pathology are thought to be the loss 
of protein homeostasis and mitochondrial dysfunction (Fig. 1.5). These pathogenic 
factors do not act independently and it is not known exactly if their dysfunction is a 
cause or consequence of neurodegeneration.  
 
α-synuclein and proteostasis imbalance 
The fact that mutations in SNCA cause familial PD and that α-syn is the major 
component of LB strongly indicates that α-syn has a central role in the pathogenesis of 
PD. Therefore, much research attention is being devoted to this protein. α-syn is a small 
protein of 140 amino acids, enriched at presynaptic terminals 108. The role of α-syn is 
still unclear, but it is thought to play a role in synaptic vesicle recycling, 
neurotransmission, and synaptic plasticity 109. 
α-syn is natively unfolded with very little secondary structure and once it 
interacts with phospholipid membranes, its N-terminal region acquires an amphipathic 
α-helical structure 110. The central region of α-syn contains a highly hydrophobic motif 
known as the non-amyloid-β component (NAC), which is highly aggregation prone 111. A 
recent study reported that α-syn exists as an α-helical tetramer, suggesting that the 
protein can be stabilized by interacting with the neighboring subunits 112. Nevertheless, 
it was further suggested that α-syn exists predominantly as an unfolded protein in the 
central nervous system 113. Aggregation of α-syn starts by the formation of assembly 
intermediates, followed by oligomers, soluble protofibrils and amyloid fibrils that are 
deposited in LBs. The propensity of α-syn to aggregate increases with several factors, 
such as: familial point mutations, excess of α-syn caused by higher expression (gene 
duplications, triplications or polymorphisms) or defective clearance, oxidative stress or 
post-translational modifications 114.  
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Figure 1.5. Pathogenic mechanisms that underlie Parkinson’s disease.  
The study of the genes associated with the familial forms of Parkinson’s disease (PD) has been 
helping in elucidating the pathways that lead to neurodegeneration. Dysfunctional mitochondria, 
ubiquitin proteasome system or autophagy can promote the formation of intermediate α-
synuclein species and aggregation, which in turn can impair the proteasome, mitochondria or 
autophagy. Dysfunctional mitochondria lead to higher generation of reactive oxygen species 
(ROS), which might cause further mitochondrial impairment and promote further aggregation.   
 
Increasing evidence shows that the three protein QC systems – molecular 
chaperones, UPS and autophagy (especially macroautophagy and chaperone mediated 
autophagy) – are involved in α-syn homeostasis (Fig. 1.2) 115. However, there are 
conflicting results regarding the exact mechanism by which α-syn is degraded and it is 
still unknown how the cell decides the route of protein degradation. The different results 
obtained in different labs seem to be dependent on the model system used and also on 
which kind of α-syn species the system has to deal with 116. Nevertheless, several 
studies show that α-syn is degraded by both UPS and autophagy 116 and when one of 
these systems is inhibited causes α-syn accumulation and aggregation 116. Conversely, 
the increase in α-syn and the consequent generation of toxic species may affect the QC 
systems and disturb cell homeostasis.  
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Ebrahimi-Fakhari and colleagues have proposed a model for α-syn degradation 
that hypothesizes that in non-pathological conditions, in which the levels of α-syn are 
maintained homeostatic, α-syn is degraded by both UPS and CMA; if the levels of α-syn 
increase in a way that exceeds the capacity of the QC system, toxic species may 
appear, blocking UPS and CMA (at initial stages of the disease). At this point, a vicious 
cycle begins, in which the dysfunction of UPS and CMA further increases the levels of 
toxic α-syn species (Fig 1.5). In order to cope with this dysfunction, cells upregulate 
macroautophagy, however in later stages of the disease, macroautophagy may also 
become impaired 117.  
A strong indication that UPS and autophagy are implicated in PD pathogenesis 
and are responsible for α-syn degradation is the fact that among the genes linked to 
PD, three are strongly associated with these mechanisms: parkin, ATP13A2 and 
UCHL1. Parkin is an E3 ubiquitin ligase that is involved in UPS and more recently it was 
shown that it plays a role in mitochondria (discussed below). The role of an E3 ubiquitin 
ligase is to covalently link ubiquitin to a specific target protein. Parkin is capable of 
mediating either polyubiquitination through the ubiquitin lysine 48 (targets to the 
proteasome) or lysine 63 (targets to non degradative processes) or monoubiquitination 
(targets to non degradative processes) 118.  
 
Mitochondria and PD 
Mitochondria are essential organelles for the function and survival of neurons. 
These are the major energy suppliers and play a role in other critical mechanisms, such 
as calcium buffering and apoptosis. Importantly, mitochondria are the major source of 
reactive oxygen species (ROS). These are very mobile and dynamic organelles, 
constantly undergoing fission and fusion. These two mechanisms are required to 
maintain the mitochondrial network functional. While fusion is responsible for 
redistributing the mitochondrial components (which is a strategy of functional 
mitochondria to complement the damaged ones), fission occurs to create new 
mitochondria or remove the damaged components. When the damage is irreparable, 
mitochondria are removed by mitophagy.  
Mounting evidence suggests that mitochondrial dysfunction is implicated in the 
pathogenesis of PD. However, whether it is a cause or consequence of 
neurodegeneration is still unclear. The first finding that led researchers to investigate 
the role of mitochondria in PD was that MPTP led to progressive and irreversible 
parkinsonism in humans 89,119. Oxidation of MPTP in glial cells leads to formation of 
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MPP+ – an inhibitor of complex I – which is then released and selectively uptaken by 
dopaminergic neurons via the dopamine transporter. Within dopaminergic neurons this 
will inhibit complex I and thus impair the electron flux. As a consequence, ATP 
production decreases and both ROS and reactive nitrogen species (RNS) increase 119. 
This finding raised the question whether complex I was impaired in idiopathic PD 
patients and in fact post-mortem analysis of the brains of PD patients showed reduced 
complex I activity in the SNpc 120. The administration of MPTP and other complex I 
inhibitors, such as rotenone or paraquat, in rodents can also induce dopaminergic 
degeneration, further supporting that mitochondrial dysfunction has a central role in PD 
pathogenesis 121. Additionally, many of the proteins encoded by the genes associated to 
PD (α-syn, PINK1, parkin, DJ-1, LRRK2) play a role directly or indirectly in 
mitochondrial functions and at least PINK1 and parkin act in a common pathway.  
PINK1 (PTEN-induced kinase 1) is a nuclear encoded kinase that is localized in 
the outer mitochondrial membrane, with the kinase domain turned to the cytosol 122,123. 
Mutations in PINK1 are thought to be loss of function; the majority of mutations are 
localized in the kinase domain and result in impairment of the kinase activity. So far, 
only three PINK1 substrates have been identified: the mitochondrial chaperone TNF-
receptor-associated protein 1 (TRAP1), the mitochondrial serine protease Omi/HtrA2 
and parkin 124–126. Both TRAP1 and Omi/HtrA2 are involved in protecting cells against 
cell death in stress conditions 126,127. Interestingly, the knockout mouse for Omi/HtrA2 
develops a parkinsonian phenotype and dies after one month 127. PINK1 and parkin 
were elegantly shown to function in the same pathway using Drosophila as a model 
system 128,129. Drosophila deleted for PINK1 or Parkin exhibit similar phenotypes due to 
mitochondrial defects, including male sterility, apoptotic muscle degeneration, higher 
sensitivity to several stresses and locomotive impairment 128,129. The overexpression of 
parkin complements the phenotypes caused by deletion of PINK1, but not vice-versa, 
indicating that PINK1 is an upstream regulator of parkin. Compelling evidence shows 
that PINK1-parkin pathway is involved in maintaining the integrity of the mitochondrial 
network by modulating mitochondrial dynamics and promoting degradation of damaged 
mitochondria through mitophagy 130,131. More recently it was shown that it can also 
induce the selective degradation of respiratory subunits 132. It is not clear whether 
dysfunctional quality control of mitochondria is involved in the pathogenesis of sporadic 
PD, however parkin was found impaired even when it was not mutated 133,134, 
supporting this idea.  
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How DJ-1 is related to mitochondria is also unclear. DJ-1 is a cytosolic, nuclear 
and mitochondrial protein 135,136. Localization of DJ-1 to mitochondria increases upon 
oxidative stress and is neuroprotective 137,138. The precise cellular role of DJ-1 is 
unknown, but compelling evidence indicates that it is involved in cellular responses of 
oxidative stress (further discussed in Chapter 3). The link between mitochondria 
protection and DJ-1 may be in fact the protection against oxidative stress 139. 
Nevertheless, multiple studies have shown that loss of DJ-1 leads to several 
mitochondrial defects, including mitochondria fragmentation 140–144. Interestingly, fruit 
flies deleted for DJ-1 (both orthologs DJ-1a and DJ-1b) exhibited similar phenotypes to 
flies deleted for pink1 or parkin 145. Overexpression of DJ-1 was able to complement the 
loss of PINK1, but not parkin 145. These results suggest that DJ-1 acts in a parallel 
pathway or downstream PINK1, but likely is independent of PINK1-parkin pathway.  
Finally, overexpression of wild-type or familial mutant forms of α-syn in 
transgenic mouse and cell culture models results in mitochondrial dysfunction 146–148. 
Taking all this into account, it is clear that dissecting further the role of these 
proteins in the mitochondrial function will contribute for a better understanding of PD 
pathogenesis.  
 
Oxidative stress 
Oxidative stress occurs when the generation of ROS and RNS exceeds the cell 
antioxidant defense mechanisms. These reactive species have the capacity to 
chemically modify cell constituents such as proteins, lipids and nucleic acids, which may 
result in their irreversible damage and ultimately trigger neuronal injury 149. High levels 
of ROS can even trigger apoptosis or autophagy leading to cell death 150. Apart from its 
toxic effect in the cell, ROS have also an important signaling role under normal 
conditions 151. Therefore, it is essential to control the levels of ROS and RNS in the cell.  
Mitochondria are the major source of ROS. Electrons leak from the electron 
transport chain and partially reduce oxygen resulting in the formation of superoxide, 
which subsequently can be converted to hydrogen peroxide. Hydrogen peroxide by 
reacting with iron (Fenton reaction) results in the formation of the hydroxyl radical 150. 
Superoxide can also be transformed into peroxynitrite by reacting with nitric oxide 152,153. 
The accumulation of ROS in mitochondria leads a vicious cycle in which dysfunctional 
mitochondria result in higher production of ROS that in turn enhance mitochondrial 
impairment.  
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The brain is thought to be more susceptible to oxidative stress since is highly 
metabolically active and has a low capacity to regenerate the post mitotic neurons 
compared to other organs. Oxidative stress has been implicated as one of the 
mechanisms that contribute to the pathogenesis of several neurodegenerative diseases 
including PD, as well as one of the causes of ageing, proposed as the “free radical 
theory of ageing” 149,154.  
Several observations indicate that dopaminergic neurons in SNpc are 
particularly exposed to oxidative stress, making them more vulnerable for cell death. As 
mentioned already, post mortem PD brains show decreased complex I activity in SNpc 
when compared with healthy controls, 120 as well as increased lipid peroxidation, protein 
carbonylation, DNA and RNA oxidation and decreased antioxidant defenses, such as 
glutathione 155–158. Dopaminergic neurons in SNpc contain higher concentrations of iron, 
which can be toxic if iron reacts with hydrogen peroxide and the hydroxyl radical is 
generated 159–161. In addition, these neurons contain dopamine, which oxidation 
products are potentially toxic 162. An additional hypothesis that explains why nigral 
dopaminergic neurons have higher levels of oxidative stress is the presence of L-type 
calcium channels. These channels help to maintain the pacemaking activity which is 
characteristic of SNpc dopaminergic neurons and consists in maintaining neuronal 
activity autonomously, i.e. without any synaptic input 163. L-type calcium channels are 
open frequently, since they open at relatively hyperpolarized state. This comes with an 
energetic cost, since the calcium concentration has to be under tight control and this is 
maintained by ATP dependent pumps. Since this is an energy dependent mechanism, 
mitochondria activity increases and subsequently the basal ROS also increase, turning 
the dopaminergic neurons more vulnerable for stressors 163. 
In addition to the intracellular sources of ROS, these species can also come 
from activated microglial cells. Microglia are generally on a resting state, but become 
activated upon several insults, such as factors released by damaged neurons. 
Microglial cells are found activated in the brains of PD patients 164,165. Activation of 
microglia may result in a vicious cycle, since these cells release neurotoxic factors 
(such as ROS) which will potentiate neuronal cell death 164. Several studies have shown 
that neuroinflammation also contributes to the pathogenesis of PD 164. Therefore, 
dissecting the mechanisms that control neuroinflammation may help in finding novel 
strategies to control PD. Excitingly, we have recently found that SIRT2 is a promising 
target to prevent sustained inflammation and neurotoxicity. We showed that reduction of 
SIRT2 expression in mouse models and microglial cell lines leads to enhanced 
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neuroinflammation and neurotoxicity induced by higher generation of ROS and RNS. 
Conversely, SIRT2 overexpression in microglial cell lines inhibits microglial activation166. 
The gene implicated in PD that predominantly supports the role of oxidative stress in 
the pathogenesis of PD is DJ-1 (see Chapter 3).  
 
Baker’s yeast: a versatile “toolbox” for molecular biology 
studies  
Since ancient times the budding yeast Saccharomyces cerevisiae has been 
used in baking and brewing 167. This unicellular eukaryotic organism is extremely useful 
for molecular biologists and our knowledge about fundamental cellular mechanisms has 
greatly benefited from the use of yeast as a model 168. It has been extensively used in 
the study of numerous complex and devastating disorders, such as HD and PD and has 
provided insight into the molecular events underlying these disorders 169–171.  
Multiple characteristics make this simple eukaryote a model system of choice. 
First of all, it is well defined genetically and genomically (S. cerevisiae was the first 
eukaryote organism to be fully sequenced). Of the 6000 genes predicted to be encoded 
by its 12,000-kilobase genome, ~80% are functionally characterized 172. Since the 
electronic release of its genomic sequence several highly annotated online databases 
have become available, which provide multitudes of detailed information on yeast genes 
and proteins, such as protein-protein interactions, genetic interactions, protein function, 
and predicted orthologs in other organisms. The remarkably high degree of 
conservation between yeast and higher eukaryotes, with respect to basic processes 
such as cell cycle, intracellular transport, and cellular QC systems is another feature 
that makes yeast so attractive. Therefore, yeast studies may shed light into the 
conserved mechanisms involved in human diseases. In fact, yeast has been extensively 
used as an informative organism for human gene function, since approximately half of 
the genes involved in human heritable diseases are predicted to have yeast 
homologues 173.   
Genetic and biochemical manipulations in yeast are extremely simple, rather 
quick, and inexpensive when compared to manipulations in other eukaryotes. Yeast is 
easy to grow on appropriate media, with a doubling time of approximately 90 minutes 
on rich medium, and survive indefinitely in frozen glycerol stocks. Strains can be 
maintained as stable haploids or diploids, allowing the study of lethal mutations in 
heterozygous diploids and recessive mutations in haploids. It is easy to mate the 
haploid strains and to sporulate diploid strains, making classical genetics extremely 
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facile. Other versatile characteristics of this organism are the ease of transformation 
and the ability to integrate genes by homologous recombination 167,174,175. The 
experimental tractability of yeast has allowed the development of several sophisticated 
functional tools, such as yeast two-hybrid variants, affinity purification and mass-
spectrometry identification providing substantial amounts of information about protein-
protein interactions 176,177. In addition, several yeast strain collections have been 
created, permitting rapid genomic systematic screenings and the identification of 
genetic interactions. These libraries include the yeast open reading frame (ORF) 
collection (YOC) and the yeast gene knock-out collection (YKO), which is available in 
haploid, homozygous diploid and heterozygous diploid strains 175. So far, such screens 
have allowed the identification of several possible genetic modifiers (suppressors or 
enhancers) of amyloid diseases, the identification of new therapeutic targets, and the 
dissection of the pathogenic mechanisms and pathways involved in these diseases. 
Although the simplicity of yeast is an advantage for experimental manipulation 
and interpretation of data, it does present a caveat of this model. For obvious reasons, 
several mechanisms and biological pathways present in higher eukaryotes are absent 
in yeast and, on the other hand, some pathways, such as cell wall biosynthesis, have 
no counterpart in mammals. Therefore, all findings in yeast related to human disease 
ultimately must be validated in more physiologically relevant systems prior to their trial 
in humans. 
 
Modeling neurodegenerative diseases in yeast 
Despite the obvious absence of a nervous system in yeast, basic mechanisms 
and pathways underlying neurodegenerative diseases, such as mitochondrial 
dysfunction, transcriptional dysregulation, trafficking defects and proteasomal 
dysfunction, are extremely well conserved between humans and yeast, enabling 
detailed studies of the molecular events involved in those conditions. In fact, several 
remarkable insights into the understanding of brain diseases have been recently 
achieved 171,178–180. In order to develop disease models, it is essential that some relevant 
aspects of the disease phenotype are recapitulated. If the gene implicated in the 
disease has a yeast homolog, it is possible to study its function directly. If, on the other 
hand, the gene underlying the disease is absent in yeast but causes disease by a toxic 
gain-of-function mechanism in humans, it can still be modeled via the heterologous 
expression of the human gene in yeast cells.  
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Yeast models of HD 
Several yeast models of HD have been developed to study the folding and 
behavior of mutant Htt as well as to dissect the underlying conserved mechanisms of 
mutant Htt-dependent toxicity 81,181–183. Expression in yeast of an amino-terminal 
fragment of Htt fused to GFP results in polyQ length-dependent formation of 
cytoplasmic inclusions that can be visualized in cells via fluorescence microscopy 81,182. 
A simple filter-retention assay has also been used to isolate detergent-insoluble 
aggregates formed by expression in yeast of a mutant Htt fragment 181. One of these 
models exhibits polyQ length-dependent toxicity, such that expression of a Htt fragment 
with polyQ length in the pathogenic range (Htt103Q) produces cellular toxicity within 
yeast, while expression of the same construct containing a non-expanded polyQ tract 
(Htt25Q) shows no negative effect upon growth 182. Recent work suggests that several 
factors are contributing to toxicity in this yeast model of HD, including perturbations in 
the kynurenine pathway (discussed in Chapter 2) 171, defects in endocytosis 184,185, 
apoptotic-like events 186, increased levels of ROS 171,187, and mitochondrial dysfunction 
186,187. Interestingly, the polyQ-length dependent toxicity observed in the Meriin et al. 
model requires the presence of the yeast prion Rnq1 in its prion conformation 182. 
Several other glutamine-rich proteins play an additional role in modulating toxicity 29,171. 
In addition, it was observed that the flanking amino acid sequences are required for 
modulating toxic conformations of these Htt fragments in yeast 29,30. This conversion of 
benign species to toxic species (and vice-versa) can operate in cis or in trans 29.  
The availability of yeast models of HD has facilitated the identification of 
candidate therapeutic targets for HD in the form of gene deletions that either enhance 
or suppress toxicity of a mutant Htt fragment 170,171,188. Additionally, this model has 
allowed screening and individual testing of small molecules to identify novel candidate 
therapeutic compounds which have been validated in higher eukaryotes 189–191. The 
YKO was screened for loss-of-function suppressors of the toxic Htt103Q construct 
171,182. Of the genes identified in this screen, 25% encode proteins that cluster into the 
functionally related categories of vesicular transport, vacuolar protein sorting, and 
vacuolar import; 25% encode proteins that are involved directly in transcription or in 
establishment/maintenance of chromatin architecture; and ~21% encode known yeast 
prions or proteins containing Q/N-rich regions that may mediate prion-like aggregation. 
Over half of the genes isolated are annotated as having one or more human orthologs. 
This suggests that there are conserved biological pathways associated to mutant Htt 
that ultimately may be relevant to HD. One of the identified suppressors was BNA4, 
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which encodes the yeast homolog of the mammalian kynurenine 3-monooxygenase 
(KMO) 171. This enzyme functions in the conserved kynurenine pathway, which is 
activated in HD patients and in animal models of this disorder (discussed in further 
detail in Chapter 2) 192. In humans this pathway is linked directly to HD by a mechanism 
that may involve ROS. It is intriguing that deletion or pharmacological inhibition of KMO 
activity reduces levels of ROS and strongly suppresses mutant Htt-mediated toxicity 171. 
Excitingly, recent published trials of KMO inhibitors in HD model mice have found that 
treatment with these compounds significantly ameliorates several disease-relevant 
phenotypes in these mice 193. Recently, a Htt suppressor screen was conducted in 
which 317 ORFs that protect yeast from Htt toxicity were identified 188. Among these 
ORFs, two encode glutathione peroxidases (GPx), which are conserved cellular 
antioxidants. These results were further validated in Drosophila and mammalian model 
systems. Importantly, GPx mimetics were previously shown to be well tolerated in 
humans, further supporting the value of using yeast as a starting platform to identify 
novel therapeutic strategies for HD 188.  
 
Yeast models of PD 
To gain insight into the biology of α-syn a yeast model of PD was developed, 
which successfully reproduced several hallmarks of this disease 169. Heterologous 
expression of the wild-type (WT) α-syn and the mutant A53T induces toxicity in yeast 
and formation of inclusion bodies in a concentration-dependent way. At moderate levels 
α-syn is initially associated with the plasma membrane, but when it is overexpressed 
the protein is recruited into cytoplasmic inclusions 169. The toxicity of α-syn is consistent 
with the identification of duplications and triplications of the α-syn locus in PD patients 
99,100 and with the observation that dopaminergic cells of mice and Drosophila die when 
α-syn is overexpressed 194,195. It has also been found that WT and A53T α-syn are 
directed to the plasma membrane through the secretory pathway 196 and cause 
endoplasmic reticulum (ER) stress. In addition, it was found that A30P is directed to the 
vacuole, through the endocytic pathway, where it is proteolytically degraded 197. The 
involvement of cellular QC systems was also investigated. While ubiquitination is 
dispensable for the formation of α-syn inclusion bodies in yeast, the proteasome activity 
is impaired 169. The involvement of proteasome dysfunction in α-syn aggregates is 
further supported by the indication that mutations in proteasome 20S enhance toxicity 
196. It has been recently observed that α-syn toxicity in yeast leads to shorter 
chronological life span and induction of autophagy and mitophagy (mediated by Sir2) 
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198. Surprisingly, upon mitophagy impairment, α-syn toxicity is alleviated 198. It was also 
shown that heterologous expression of α-syn also leads to impairment of endocytosis 
169, mitochondria 199 and mitophagy 198 and to the accumulation of lipid droplets 169.The 
generation of ROS and apoptosis were also successfully reproduced in yeast 200, further 
validating these models. One important question in the PD field is whether 
phosphorylation of α-syn on the serine 129 is associated with α-syn aggregation and/or 
toxicity, since 90% of α-syn in LB is phosphorylated in this residue 201. Interestingly, 
Basso et al. showed that phosphorylation of this residue mediated by the human PLK2 
in yeast leads to an increase in cytotoxicity and higher number of α-syn inclusions. In 
addition, they showed that PLK2 in mammalian cell lines causes an increase in 
inclusions size 202, however, PLK3 despite phosphorylating α-syn in the same residue 
does not affect toxicity or the formation of foci, suggesting that phosphorylation of serine 
129 is not modulating the formation of α-syn inclusions 202. Interestingly, a recent study 
performed in yeast and validated in human cells demonstrated that α-syn leads to 
toxicity by impairing PLK2 function and consequently disrupting a stress response 
pathway 203.  
The validation of these yeast α-syn models allowed performing several high-
throughput studies. An overexpression screen identified genetic modifiers of α-syn. 
Genes inducing ER-Golgi transport were identified as suppressors, whereas genes that 
inhibit this transport were identified as enhancers of α-syn toxicity. Remarkably, Rab1 – 
the human homolog of YPT1 – found among the suppressors, rescued the loss of 
dopaminergic neurons in animal models of PD 204.  
Yeast has also been used as a model system to gain insights into the function of 
other PD-related genes: LRRK2 and ATP13A2. To investigate the role of LRRK2, a 
yeast model was developed which expresses the full length protein or only domain 
fragments 205. It was found that LRRK2 toxicity in yeast depends on its GTPase activity 
and is related with impairment of endocytic vesicular trafficking and autophagy 205. 
These results were further validated in mice primary neuronal cultures 205. Ypk9, the 
yeast homolog of ATP13A2, was found to interact genetically with α-syn by suppressing 
its toxicity 206. This result was conserved in higher complex models 206. Ypk9 has a role 
in the homeostasis of manganese and other divalent heavy metal ions, which are 
environmental PD risk factors 206–208. ATP13A2 is thus a potential link between genetic 
and environmental risk factors for PD.  
 
 
Introduction 
23 
References 
 
1. Tyedmers, J., Mogk, A. & Bukau, B. Cellular strategies for controlling protein aggregation. Nat. 
Rev. Mol. Cell Biol. 11, 777–88 (2010). 
2. Ben-Zvi, A. P. & Goloubinoff, P. Proteinaceous infectious behavior in non-pathogenic proteins is 
controlled by molecular chaperones. J. Biol. Chem. 277, 49422–7 (2002). 
3. Hershko, A. & Ciechanover, A. The ubiquitin-proteasome system. 31, 137–155 (2006). 
4. Yorimitsu, T. & Klionsky, D. J. Autophagy: molecular machinery for self-eating. Cell Death Differ. 12 
Suppl 2, 1542–52 (2005). 
5. Chiti, F. & Dobson, C. M. Protein misfolding, functional amyloid, and human disease. Annu. Rev. 
Biochem. 75, 333–66 (2006). 
6. Ross, C. A. & Poirier, M. A. Protein aggregation and neurodegenerative disease. Nat. Med. 10 
Suppl, S10–7 (2004). 
7. Hardy, J. & Selkoe, D. J. The amyloid hypothesis of Alzheimer’s disease: progress and problems 
on the road to therapeutics. Science 297, 353–6 (2002). 
8. Martin, J. B. & Gusella, J. F. Huntington’s disease. Pathogenesis and management. N. Engl. J. 
Med. 315, 1267–76 (1986). 
9. Rosas, H. D. et al. Complexity and heterogeneity: what drives the ever-changing brain in 
Huntington’s disease? Ann. N. Y. Acad. Sci. 1147, 196–205 (2008). 
10. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s 
disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 72, 971–83 
(1993). 
11. Rubinsztein, D. C. et al. Phenotypic characterization of individuals with 30-40 CAG repeats in the 
Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly 
individuals with 36-39 repeats. Am. J. Hum. Genet. 59, 16–22 (1996). 
12. Duyao, M. et al. Trinucleotide repeat length instability and age of onset in Huntington’s disease. 
Nat. Genet. 4, 387–92 (1993). 
13. Telenius, H. et al. Molecular analysis of juvenile Huntington disease: the major influence on (CAG)n 
repeat length is the sex of the affected parent. Hum. Mol. Genet. 2, 1535–40 (1993). 
14. Wexler, N. S. et al. Venezuelan kindreds reveal that genetic and environmental factors modulate 
Huntington’s disease age of onset. Proc. Natl. Acad. Sci. U.S.A. 101, 3498–503 (2004). 
15. Mangiarini, L. et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a 
progressive neurological phenotype in transgenic mice. Cell 87, 493–506 (1996). 
16. Gutekunst, C. A. et al. Nuclear and neuropil aggregates in Huntington’s disease: relationship to 
neuropathology. J. Neurosci. 19, 2522–34 (1999). 
17. DiFiglia, M. et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic 
neurites in brain. Science 277, 1990–3 (1997). 
18. Becher, M. W. et al. Intranuclear neuronal inclusions in Huntington’s disease and dentatorubral and 
pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat 
length. Neurobiol. Dis. 4, 387–97 (1998). 
19. Davies, S. W. et al. Formation of neuronal intranuclear inclusions underlies the neurological 
dysfunction in mice transgenic for the HD mutation. Cell 90, 537–48 (1997). 
20. Suhr, S. T. et al. Identities of sequestered proteins in aggregates from cells with induced 
polyglutamine expression. J. Cell Biol. 153, 283–94 (2001). 
21. Donaldson, K. M. et al. Ubiquitin-mediated sequestration of normal cellular proteins into 
polyglutamine aggregates. Proc. Natl. Acad. Sci. U.S.A. 100, 8892–7 (2003). 
22. Nucifora, F. C. et al. Interference by huntingtin and atrophin-1 with cbp-mediated transcription 
leading to cellular toxicity. Science 291, 2423–8 (2001). 
23. McCampbell, A. et al. CREB-binding protein sequestration by expanded polyglutamine. Hum. Mol. 
Genet. 9, 2197–202 (2000). 
24. Bennett, E. J., Bence, N. F., Jayakumar, R. & Kopito, R. R. Global impairment of the ubiquitin-
proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body 
formation. Mol. Cell 17, 351–65 (2005). 
25. Yu, Z.-X., Li, S.-H., Nguyen, H.-P. & Li, X.-J. Huntingtin inclusions do not deplete polyglutamine-
containing transcription factors in HD mice. Hum. Mol. Genet. 11, 905–14 (2002). 
26. Arrasate, M., Mitra, S., Schweitzer, E. S., Segal, M. R. & Finkbeiner, S. Inclusion body formation 
reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431, 805–10 (2004). 
27. Miller, J. et al. Quantitative relationships between huntingtin levels, polyglutamine length, inclusion 
body formation, and neuronal death provide novel insight into huntington’s disease molecular 
pathogenesis. J. Neurosci. 30, 10541–50 (2010). 
 
Chapter 1 
24 
 
 
28. Truant, R., Atwal, R. S., Desmond, C., Munsie, L. & Tran, T. Huntington’s disease: revisiting the 
aggregation hypothesis in polyglutamine neurodegenerative diseases. FEBS J. 275, 4252–62 
(2008). 
29. Duennwald, M. L., Jagadish, S., Muchowski, P. J. & Lindquist, S. Flanking sequences profoundly 
alter polyglutamine toxicity in yeast. Proc. Natl. Acad. Sci. U.S.A. 103, 11045–50 (2006). 
30. Dehay, B. & Bertolotti, A. Critical role of the proline-rich region in Huntingtin for aggregation and 
cytotoxicity in yeast. J. Biol. Chem. 281, 35608–15 (2006). 
31. Lakhani, V. V, Ding, F. & Dokholyan, N. V. Polyglutamine induced misfolding of huntingtin exon1 is 
modulated by the flanking sequences. PLoS Comput. Biol. 6, e1000772 (2010). 
32. Martindale, D. et al. Length of huntingtin and its polyglutamine tract influences localization and 
frequency of intracellular aggregates. Nat. Genet. 18, 150–4 (1998). 
33. Lunkes, A. et al. Proteases acting on mutant huntingtin generate cleaved products that differentially 
build up cytoplasmic and nuclear inclusions. Mol. Cell 10, 259–69 (2002). 
34. Graham, R. K. et al. Cleavage at the caspase-6 site is required for neuronal dysfunction and 
degeneration due to mutant huntingtin. Cell 125, 1179–91 (2006). 
35. Pennuto, M., Palazzolo, I. & Poletti, A. Post-translational modifications of expanded polyglutamine 
proteins: impact on neurotoxicity. Hum. Mol. Genet. 18, R40–7 (2009). 
36. DiFiglia, M. et al. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat 
brain neurons. Neuron 14, 1075–81 (1995). 
37. Zeitlin, S., Liu, J. P., Chapman, D. L., Papaioannou, V. E. & Efstratiadis, A. Increased apoptosis 
and early embryonic lethality in mice nullizygous for the Huntington’s disease gene homologue. 
Nat. Genet. 11, 155–63 (1995). 
38. Nasir, J. et al. Targeted disruption of the Huntington’s disease gene results in embryonic lethality 
and behavioral and morphological changes in heterozygotes. Cell 81, 811–23 (1995). 
39. Gauthier, L. R. et al. Huntingtin controls neurotrophic support and survival of neurons by enhancing 
BDNF vesicular transport along microtubules. Cell 118, 127–38 (2004). 
40. Singaraja, R. R. et al. HIP14, a novel ankyrin domain-containing protein, links huntingtin to 
intracellular trafficking and endocytosis. Hum. Mol. Genet. 11, 2815–28 (2002). 
41. Metzler, M. et al. NMDA receptor function and NMDA receptor-dependent phosphorylation of 
huntingtin is altered by the endocytic protein HIP1. J. Neurosci. 27, 2298–308 (2007). 
42. Borrell-Pagès, M., Zala, D., Humbert, S. & Saudou, F. Huntington’s disease: from huntingtin 
function and dysfunction to therapeutic strategies. Cell. Mol. Life Sci. 63, 2642–60 (2006). 
43. Savas, J. N. et al. A role for huntington disease protein in dendritic RNA granules. J. Biol. Chem. 
285, 13142–53 (2010). 
44. Zhang, Y. et al. Huntingtin inhibits caspase-3 activation. EMBO J. 25, 5896–906 (2006). 
45. Leavitt, B. R. et al. Wild-type huntingtin protects neurons from excitotoxicity. J. Neurochem. 96, 
1121–9 (2006). 
46. Imarisio, S. et al. Huntington’s disease: from pathology and genetics to potential therapies. 
Biochem. J. 412, 191–209 (2008). 
47. Augood, S. J., Faull, R. L., Love, D. R. & Emson, P. C. Reduction in enkephalin and substance P 
messenger RNA in the striatum of early grade Huntington’s disease: a detailed cellular in situ 
hybridization study. Neuroscience 72, 1023–36 (1996). 
48. Augood, S. J., Faull, R. L. & Emson, P. C. Dopamine D1 and D2 receptor gene expression in the 
striatum in Huntington’s disease. Ann. Neurol. 42, 215–21 (1997). 
49. Arzberger, T., Krampfl, K., Leimgruber, S. & Weindl, A. Changes of NMDA receptor subunit (NR1, 
NR2B) and glutamate transporter (GLT1) mRNA expression in Huntington’s disease--an in situ 
hybridization study. J. Neuropathol. Exp. Neurol. 56, 440–54 (1997). 
50. Schilling, G. et al. Nuclear-targeting of mutant huntingtin fragments produces Huntington’s disease-
like phenotypes in transgenic mice. Hum. Mol. Genet. 13, 1599–610 (2004). 
51. Saudou, F., Finkbeiner, S., Devys, D. & Greenberg, M. E. Huntingtin acts in the nucleus to induce 
apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95, 55–66 
(1998). 
52. Li, X. et al. Targeting mitochondrial reactive oxygen species as novel therapy for inflammatory 
diseases and cancers. J Hematol Oncol 6, 19 (2013). 
53. Zhai, W., Jeong, H., Cui, L., Krainc, D. & Tjian, R. In vitro analysis of huntingtin-mediated 
transcriptional repression reveals multiple transcription factor targets. Cell 123, 1241–53 (2005). 
54. Li, S.-H. et al. Interaction of Huntington disease protein with transcriptional activator Sp1. Mol. Cell. 
Biol. 22, 1277–87 (2002). 
55. Dunah, A. W. et al. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington’s 
disease. Science 296, 2238–43 (2002). 
56. Ferrer, I., Goutan, E., Mar  n, C., Rey, M. . & Ribalta, T. Brain-derived neurotrophic factor in 
Huntington disease. Brain Res. 866, 257–261 (2000). 
Introduction 
25 
57. Simmons, D. A. et al. Up-regulating BDNF with an ampakine rescues synaptic plasticity and 
memory in Huntington’s disease knockin mice. Proc. Natl. Acad. Sci. U.S.A. 106, 4906–11 (2009). 
58. Gharami, K., Xie, Y., An, J. J., Tonegawa, S. & Xu, B. Brain-derived neurotrophic factor over-
expression in the forebrain ameliorates Huntington’s disease phenotypes in mice. J. Neurochem. 
105, 369–79 (2008). 
59. Zuccato, C. et al. Widespread disruption of repressor element-1 silencing transcription 
factor/neuron-restrictive silencer factor occupancy at its target genes in Huntington’s disease. J. 
Neurosci. 27, 6972–83 (2007). 
60. Zuccato, C. et al. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-
controlled neuronal genes. Nat. Genet. 35, 76–83 (2003). 
61. Aziz, N. A. et al. Weight loss in Huntington disease increases with higher CAG repeat number. 
Neurology 71, 1506–13 (2008). 
62. Mann, V. M. et al. Mitochondrial function and parental sex effect in Huntington’s disease. Lancet 
336, 749 (1990). 
63. Gu, M. et al. Mitochondrial defect in Huntington’s disease caudate nucleus. Ann. Neurol. 39, 385–9 
(1996). 
64. Benchoua, A. et al. Involvement of mitochondrial complex II defects in neuronal death produced by 
N-terminus fragment of mutated huntingtin. Mol. Biol. Cell 17, 1652–63 (2006). 
65. Horton, T. M. et al. Marked increase in mitochondrial DNA deletion levels in the cerebral cortex of 
Huntington’s disease patients. Neurology 45, 1879–83 (1995). 
66. Kim, J. et al. Mitochondrial loss, dysfunction and altered dynamics in Huntington’s disease. Hum. 
Mol. Genet. 19, 3919–35 (2010). 
67. Panov, A. V et al. Early mitochondrial calcium defects in Huntington’s disease are a direct effect of 
polyglutamines. Nat. Neurosci. 5, 731–6 (2002). 
68. Trushina, E. et al. Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in 
vitro. Mol. Cell. Biol. 24, 8195–209 (2004). 
69. Orr, A. L. et al. N-terminal mutant huntingtin associates with mitochondria and impairs 
mitochondrial trafficking. J. Neurosci. 28, 2783–92 (2008). 
70. Choo, Y. S., Johnson, G. V. W., MacDonald, M., Detloff, P. J. & Lesort, M. Mutant huntingtin 
directly increases susceptibility of mitochondria to the calcium-induced permeability transition and 
cytochrome c release. Hum. Mol. Genet. 13, 1407–20 (2004). 
71. Cui, L. et al. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial 
dysfunction and neurodegeneration. Cell 127, 59–69 (2006). 
72. Seong, I. S. et al. HD CAG repeat implicates a dominant property of huntingtin in mitochondrial 
energy metabolism. Hum. Mol. Genet. 14, 2871–80 (2005). 
73. Ross, C. a & Tabrizi, S. J. Huntington’s disease: from molecular pathogenesis to clinical treatment. 
Lancet Neurol 10, 83–98 (2011). 
74. Thevandavakkam, M. A., Schwarcz, R., Muchowski, P. J. & Giorgini, F. Targeting Kynurenine 3-
Monooxygenase Therapy in Huntington ’ s Disease ( KMO ): Implications for. (2010). 
75. Hassel, B., Tessler, S., Faull, R. L. M. & Emson, P. C. Glutamate uptake is reduced in prefrontal 
cortex in Huntington’s disease. Neurochem. Res. 33, 232–7 (2008). 
76. Zuccato, C., Valenza, M. & Cattaneo, E. Molecular Mechanisms and Potential Therapeutical 
Targets in Huntington ’ s Disease. 905–981 (2010). doi:10.1152/physrev.00041.2009. 
77. Hara, M. R. & Snyder, S. H. Cell signaling and neuronal death. Annu. Rev. Pharmacol. Toxicol. 47, 
117–41 (2007). 
78. De Lau, L. M. L. & Breteler, M. M. B. Epidemiology of Parkinson’s disease. Lancet Neurol 5, 525–
35 (2006). 
79. Goedert, M., Spillantini, M. G., Del Tredici, K. & Braak, H. 100 years of Lewy pathology. Nat Rev 
Neurol 1–12 (2012). doi:10.1038/nrneurol.2012.242 
80. Chernoff, Y. O., Lindquist, S. L., Ono, B., Inge-Vechtomov, S. G. & Liebman, S. W. Role of the 
chaperone protein Hsp104 in propagation of the yeast prion-like factor [psi+]. Science 268, 880–4 
(1995). 
81. Krobitsch, S. & Lindquist, S. Aggregation of huntingtin in yeast varies with the length of the 
polyglutamine expansion and the expression of chaperone proteins. Proc. Natl. Acad. Sci. U.S.A. 
97, 1589–94 (2000). 
82. Dauer, W. & Przedborski, S. Parkinson’s disease: mechanisms and models. Neuron 39, 889–909 
(2003). 
83. Dickson, D. W. et al. Evidence that incidental Lewy body disease is pre-symptomatic Parkinson’s 
disease. Acta Neuropathol. 115, 437–44 (2008). 
84. Caine, J. et al. Alzheimer’s Abeta fused to green fluorescent protein induces growth stress and a 
heat shock response. FEMS Yeast Res. 7, 1230–6 (2007). 
85. Braak, H. et al. Stageing of brain pathology related to sporadic Parkinson’s disease. Neurobiology 
of Ageing 24, 197–211 (2003). 
86. Corti, O., Lesage, S. & Brice, A. What genetics tells us about the causes and mechanisms of 
Parkinson’s disease. Physiol. Rev. 91, 1161–218 (2011). 
Chapter 1 
26 
87. Smith, K. Treatment frontiers. Nature 466, S15–8 (2010). 
88. Thomas, B. & Beal, M. F. Parkinson’s disease. Hum. Mol. Genet. 16 Spec No, R183–94 (2007). 
89. Langston, J. W. et al. Evidence of active nerve cell degeneration in the substantia nigra of humans 
years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann. Neurol. 46, 598–605 
(1999). 
90. Monte, D. A. Di, Lavasani, M. & Manning-bog, A. B. Environmental Factors in Parkinson ’ s 
Disease. 23, 487–502 (2002). 
91. Ross, G. W. et al. Association of coffee and caffeine intake with the risk of Parkinson disease. 
JAMA 283, 2674–9 
92. Lesage, S. & Brice, A. Parkinson’s disease: from monogenic forms to genetic susceptibility factors. 
Hum. Mol. Genet. 18, R48–59 (2009). 
93. Klein, C. & Westenberger, A. Genetics of Parkinson’s disease. Cold Spring Harbor perspectives in 
medicine 2, a008888 (2012). 
94. Polymeropoulos, M. H. et al. Mutation in the alpha-synuclein gene identified in families with 
Parkinson’s disease. Science 276, 2045–7 (1997). 
95. Krüger, R. et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s disease. 
Nat. Genet. 18, 106–8 (1998). 
96. Zarranz, J. J. et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body 
dementia. Ann. Neurol. 55, 164–73 (2004). 
97. Proukakis, C. et al. A novel α-synuclein missense mutation in Parkinson disease. Neurology 80, 
1062–4 (2013). 
98. Lesage, S. et al. G51D α-synuclein mutation causes a novel parkinsonian-pyramidal syndrome. 
Ann. Neurol. (2013). doi:10.1002/ana.23894 
99. Chartier-Harlin, M.-C. et al. Alpha-synuclein locus duplication as a cause of familial Parkinson’s 
disease. Lancet 364, 1167–9 
100. Singleton, A. B. et al. alpha-Synuclein locus triplication causes Parkinson’s disease. Science 302, 
841 (2003). 
101. Simón-Sánchez, J. et al. Genome-wide association study reveals genetic risk underlying 
Parkinson’s disease. Nat. Genet. 41, 1308–12 (2009). 
102. Do, C. B. et al. Web-based genome-wide association study identifies two novel loci and a 
substantial genetic component for Parkinson’s disease. PLoS Genet. 7, e1002141 (2011). 
103. Haugarvoll, K. & Wszolek, Z. K. PARK8 LRRK2 parkinsonism. Current Neurology and 
Neuroscience Reports 6, 287–294 (2006). 
104. Nuytemans, K., Theuns, J., Cruts, M. & Van Broeckhoven, C. Genetic etiology of Parkinson 
disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a 
mutation update. Hum. Mutat. 31, 763–80 (2010). 
105. Kitada, T. et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. 
Nature 392, 605–8 (1998). 
106. Kawajiri, S., Saiki, S., Sato, S. & Hattori, N. Genetic mutations and functions of PINK1. Trends 
Pharmacol. Sci. 32, 573–80 (2011). 
107. Poulopoulos, M., Levy, O. A. & Alcalay, R. N. The neuropathology of genetic Parkinson’s disease. 
Mov. Disord. 27, 831–42 (2012). 
108. Iwai, A. et al. The precursor protein of non-A beta component of Alzheimer’s disease amyloid is a 
presynaptic protein of the central nervous system. Neuron 14, 467–75 (1995). 
109. Cheng, F., Vivacqua, G. & Yu, S. The role of α-synuclein in neurotransmission and synaptic 
plasticity. J. Chem. Neuroanat. 42, 242–8 (2011). 
110. Davidson, W. S. Stabilization of alpha -Synuclein Secondary Structure upon Binding to Synthetic 
Membranes. J. Biol. Chem. 273, 9443–9449 (1998). 
111. HAN, H. The core Alzheimer’s peptide NAC forms amyloid fibrils which seed and are seeded by ?-
amyloid: is NAC a common trigger or target in neurodegenerative disease? Chemistry & Biology 2, 
163–169 (1995). 
112. Bartels, T., Choi, J. G. & Selkoe, D. J. α-Synuclein occurs physiologically as a helically folded 
tetramer that resists aggregation. Nature 477, 107–10 (2011). 
113. Fauvet, B. et al. α-Synuclein in central nervous system and from erythrocytes, mammalian cells, 
and Escherichia coli exists predominantly as disordered monomer. J. Biol. Chem. 287, 15345–64 
(2012). 
114. Kalia, L. V, Kalia, S. K., McLean, P. J., Lozano, A. M. & Lang, A. E. α-Synuclein oligomers and 
clinical implications for Parkinson disease. Ann. Neurol. 73, 155–69 (2013). 
115. Lynch-Day, M. A., Mao, K., Wang, K., Zhao, M. & Klionsky, D. J. The role of autophagy in 
Parkinson’s disease. Cold Spring Harbor perspectives in medicine 2, a009357 (2012). 
116. Xilouri, M., Brekk, O. R. & Stefanis, L. Alpha-synuclein and protein degradation systems: a 
reciprocal relationship. Mol. Neurobiol. 47, 537–51 (2013). 
117. Ebrahimi-Fakhari, D., McLean, P. J. & Unni, V. K. Alpha-synuclein’s degradation in vivo: opening a 
new (cranial) window on the roles of degradation pathways in Parkinson disease. Autophagy 8, 
281–3 (2012). 
Introduction 
27 
118. Dawson, T. M. & Dawson, V. L. The role of parkin in familial and sporadic Parkinson’s disease. 
Mov. Disord. 25 Suppl 1, S32–9 (2010). 
119. Winklhofer, K. F. & Haass, C. Mitochondrial dysfunction in Parkinson’s disease. Biochim. Biophys. 
Acta 1802, 29–44 (2010). 
120. Schapira, A. H. et al. Mitochondrial complex I deficiency in Parkinson’s disease. J. Neurochem. 54, 
823–7 (1990). 
121. Bové, J., Prou, D., Perier, C. & Przedborski, S. Toxin-induced models of Parkinson’s disease. 
NeuroRx 2, 484–94 (2005). 
122. Silvestri, L. et al. Mitochondrial import and enzymatic activity of PINK1 mutants associated to 
recessive parkinsonism. Hum. Mol. Genet. 14, 3477–92 (2005). 
123. Zhou, C. et al. The kinase domain of mitochondrial PINK1 faces the cytoplasm. Proc. Natl. Acad. 
Sci. U.S.A. 105, 12022–7 (2008). 
124. Kim, Y. et al. PINK1 controls mitochondrial localization of Parkin through direct phosphorylation. 
Biochem. Biophys. Res. Commun. 377, 975–80 (2008). 
125. Plun-Favreau, H. et al. The mitochondrial protease HtrA2 is regulated by Parkinson’s disease-
associated kinase PINK1. Nat. Cell Biol. 9, 1243–52 (2007). 
126. Pridgeon, J. W., Olzmann, J. A., Chin, L.-S. & Li, L. PINK1 protects against oxidative stress by 
phosphorylating mitochondrial chaperone TRAP1. PLoS Biol. 5, e172 (2007). 
127. Martins, L. M. et al. Neuroprotective role of the Reaper-related serine protease HtrA2/Omi revealed 
by targeted deletion in mice. Mol. Cell. Biol. 24, 9848–62 (2004). 
128. Park, J. et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. 
Nature 441, 1157–61 (2006). 
129. Clark, I. E. et al. Drosophila pink1 is required for mitochondrial function and interacts genetically 
with parkin. Nature 441, 1162–6 (2006). 
130. Deas, E., Wood, N. W. & Plun-Favreau, H. Mitophagy and Parkinson’s disease: the PINK1-parkin 
link. Biochim. Biophys. Acta 1813, 623–33 (2011). 
131. Whitworth, A. J. & Pallanck, L. J. The PINK1/Parkin pathway: a mitochondrial quality control 
system? J. Bioenerg. Biomembr. (2009). 
132. Vincow, E. S. et al. The PINK1-Parkin pathway promotes both mitophagy and selective respiratory 
chain turnover in vivo. Proc. Natl. Acad. Sci. U.S.A. 110, 6400–5 (2013). 
133. LaVoie, M. J., Ostaszewski, B. L., Weihofen, A., Schlossmacher, M. G. & Selkoe, D. J. Dopamine 
covalently modifies and functionally inactivates parkin. Nat. Med. 11, 1214–21 (2005). 
134. Wang, C. et al. Stress-induced alterations in parkin solubility promote parkin aggregation and 
compromise parkin’s protective function. Hum. Mol. Genet. 14, 3885–97 (2005). 
135. Zhang, L. et al. Mitochondrial localization of the Parkinson’s disease related protein DJ-1: 
implications for pathogenesis. Hum. Mol. Genet. 14, 2063–73 (2005). 
136. Miller, D. W. et al. L166P mutant DJ-1, causative for recessive Parkinson’s disease, is degraded 
through the ubiquitin-proteasome system. J. Biol. Chem. 278, 36588–95 (2003). 
137. Li, H.-M., Niki, T., Taira, T., Iguchi-Ariga, S. & Ariga, H. Association of DJ-1 with chaperones and 
enhanced association and colocalization with mitochondrial Hsp70 by oxidative stress. (2005). 
138. Junn, E., Jang, W. H., Zhao, X., Jeong, B. S. & Mouradian, M. M. Mitochondrial localization of DJ-1 
leads to enhanced neuroprotection. J. Neurosci. Res. 87, 123–9 (2009). 
139. Cookson, M. R. Parkinsonism due to mutations in PINK1, parkin, and DJ-1 and oxidative stress 
and mitochondrial pathways. Cold Spring Harbor perspectives in medicine 2, a009415 (2012). 
140. Wang, X. et al. Parkinson’s disease-associated DJ-1 mutations impair mitochondrial dynamics and 
cause mitochondrial dysfunction. J. Neurochem. 121, 830–9 (2012). 
141. Krebiehl, G. et al. Reduced basal autophagy and impaired mitochondrial dynamics due to loss of 
Parkinson’s disease-associated protein DJ-1. PLoS ONE 5, e9367 (2010). 
142. Irrcher, I. et al. Loss of the Parkinson’s disease-linked gene DJ-1 perturbs mitochondrial dynamics. 
Hum. Mol. Genet. 19, 3734–46 (2010). 
143. Larsen, N. J., Ambrosi, G., Mullett, S. J., Berman, S. B. & Hinkle, D. A. DJ-1 knock-down impairs 
astrocyte mitochondrial function. Neuroscience 196, 251–64 (2011). 
144. Giaime, E., Yamaguchi, H., Gautier, C. A., Kitada, T. & Shen, J. Loss of DJ-1 does not affect 
mitochondrial respiration but increases ROS production and mitochondrial permeability transition 
pore opening. PLoS ONE 7, e40501 (2012). 
145. Hao, L.-Y., Giasson, B. I. & Bonini, N. M. DJ-1 is critical for mitochondrial function and rescues 
PINK1 loss of function. Proc. Natl. Acad. Sci. U.S.A. 107, 9747–52 (2010). 
146. Song, D. D., Shults, C. W., Sisk, A., Rockenstein, E. & Masliah, E. Enhanced substantia nigra 
mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP. Exp. 
Neurol. 186, 158–72 (2004). 
147. Martin, L. J. et al. Parkinson’s disease alpha-synuclein transgenic mice develop neuronal 
mitochondrial degeneration and cell death. J. Neurosci. 26, 41–50 (2006). 
148. Hsu, L. J. et al. alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am. J. Pathol. 
157, 401–10 (2000). 
 
Chapter 1 
28 
 
149. Wang, X. & Michaelis, E. K. Selective neuronal vulnerability to oxidative stress in the brain. Front 
Ageing Neurosci 2, 12 (2010). 
150. Finkel, T. Signal transduction by mitochondrial oxidants. J. Biol. Chem. 287, 4434–40 (2012). 
151. D’Autréaux, B. & Toledano, M. B. ROS as signalling molecules: mechanisms that generate 
specificity in ROS homeostasis. Nat. Rev. Mol. Cell Biol. 8, 813–24 (2007). 
152. Adam-Vizi, V. & Chinopoulos, C. Bioenergetics and the formation of mitochondrial reactive oxygen 
species. Trends Pharmacol. Sci. 27, 639–45 (2006). 
153. Trushina, E. & McMurray, C. T. Oxidative stress and mitochondrial dysfunction in 
neurodegenerative diseases. Neuroscience 145, 1233–48 (2007). 
154. Harman, D. Free radical theory of ageing. Mutat. Res. 275, 257–66 (1992). 
155. Zhang, J. et al. Parkinson’s disease is associated with oxidative damage to cytoplasmic DNA and 
RNA in substantia nigra neurons. Am. J. Pathol. 154, 1423–9 (1999). 
156. Alam, Z. I. et al. A generalised increase in protein carbonyls in the brain in Parkinson’s but not 
incidental Lewy body disease. J. Neurochem. 69, 1326–9 (1997). 
157. Alam, Z. I. et al. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase 
in 8-hydroxyguanine levels in substantia nigra. J. Neurochem. 69, 1196–203 (1997). 
158. Perry, T. L., Godin, D. V & Hansen, S. Parkinson’s disease: a disorder due to nigral glutathione 
deficiency? Neurosci. Lett. 33, 305–10 (1982). 
159. Hirsch, E. C., Brandel, J. P., Galle, P., Javoy-Agid, F. & Agid, Y. Iron and aluminum increase in the 
substantia nigra of patients with Parkinson’s disease: an X-ray microanalysis. J. Neurochem. 56, 
446–51 (1991). 
160. Dexter, D. T. et al. Increased nigral iron content and alterations in other metal ions occurring in 
brain in Parkinson’s disease. J. Neurochem. 52, 1830–6 (1989). 
161. Oakley, A. E. et al. Individual dopaminergic neurons show raised iron levels in Parkinson disease. 
Neurology 68, 1820–5 (2007). 
162. Graham, D. G., Tiffany, S. M., Bell, W. R. & Gutknecht, W. F. Autoxidation versus covalent binding 
of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related 
compounds toward C1300 neuroblastoma cells in vitro. Mol. Pharmacol. 14, 644–53 (1978). 
163. Chan, C. S. et al. “Rejuvenation” protects neurons in mouse models of Parkinson’s disease. Nature 
447, 1081–6 (2007). 
164. Block, M. L., Zecca, L. & Hong, J.-S. Microglia-mediated neurotoxicity: uncovering the molecular 
mechanisms. Nat. Rev. Neurosci. 8, 57–69 (2007). 
165. McGeer, P. L., Itagaki, S., Boyes, B. E. & McGeer, E. G. Reactive microglia are positive for HLA-
DR in the substantia nigra of Parkinson’s and Alzheimer's disease brains. Neurology 38, 1285–91 
(1988). 
166. Pais, T. F. et al. The NAD-dependent deacetylase sirtuin 2 is a suppressor of microglial activation 
and brain inflammation. The EMBO Journal advance on, (2013). 
167. Botstein, D. & Fink, G. Yeast: an experimental organism for modern biology. Science (80- ) 240, 
1439–1443 (1988). 
168. Fields, S. & Johnston, M. Cell biology. Whither model organism research? Science 307, 1885–6 
(2005). 
169. Outeiro, T. F. & Lindquist, S. Yeast cells provide insight into alpha-synuclein biology and 
pathobiology. Science 302, 1772–5 (2003). 
170. Willingham, S., Outeiro, T. F., DeVit, M. J., Lindquist, S. L. & Muchowski, P. J. Yeast genes that 
enhance the toxicity of a mutant huntingtin fragment or alpha-synuclein. Science 302, 1769–72 
(2003). 
171. Giorgini, F., Guidetti, P., Nguyen, Q., Bennett, S. C. & Muchowski, P. J. A genomic screen in yeast 
implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease. Nat. 
Genet. 37, 526–31 (2005). 
172. Peña-Castillo, L. & Hughes, T. R. Why are there still over 1000 uncharacterized yeast genes? 
Genetics 176, 7–14 (2007). 
173. Lecture, N. & Hutchinson, F. Yeast and cancer. 246–265 (2001). 
174. Sherman, F. Getting started with yeast. Meth. Enzymol. 194, 3–21 (1991). 
175. Giorgini, F. & Muchowski, P. J. Screening for genetic modifiers of amyloid toxicity in yeast. Meth. 
Enzymol. 412, 201–22 (2006). 
176. Stagljar, I. Finding partners: emerging protein interaction technologies applied to signaling 
networks. Sci. STKE 2003, pe56 (2003). 
177. Kumar, A. & Snyder, M. Emerging technologies in yeast genomics. Nat. Rev. Genet. 2, 302–12 
(2001). 
178. Cavadini, P., Gellera, C., Patel, P. I. & Isaya, G. Human frataxin maintains mitochondrial iron 
homeostasis in Saccharomyces cerevisiae. Hum. Mol. Genet. 9, 2523–30 (2000). 
179. Lindquist, S., Krobitsch, S., Li, L. & Sondheimer, N. Investigating protein conformation-based 
inheritance and disease in yeast. Philos. Trans. R. Soc. Lond., B, Biol. Sci. 356, 169–76 (2001). 
Introduction 
29 
180. Knight, S. A., Kim, R., Pain, D. & Dancis, A. The yeast connection to Friedreich ataxia. Am. J. Hum. 
Genet. 64, 365–71 (1999). 
181. Muchowski, P. J. et al. Hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine 
proteins into amyloid-like fibrils. Proc. Natl. Acad. Sci. U.S.A. 97, 7841–6 (2000). 
182. Meriin, A. B. et al. Huntington toxicity in yeast model depends on polyglutamine aggregation 
mediated by a prion-like protein Rnq1. J. Cell Biol. 157, 997–1004 (2002). 
183. Hughes, R. E. et al. Altered transcription in yeast expressing expanded polyglutamine. Proc. Natl. 
Acad. Sci. U.S.A. 98, 13201–6 (2001). 
184. Meriin, A. B. et al. Aggregation of expanded polyglutamine domain in yeast leads to defects in 
endocytosis. Mol. Cell. Biol. 23, 7554–65 (2003). 
185. Meriin, A. B. et al. Endocytosis machinery is involved in aggregation of proteins with expanded 
polyglutamine domains. FASEB journal : official publication of the Federation of American Societies 
for Experimental Biology 21, 1915–25 (2007). 
186. Sokolov, S., Pozniakovsky, A., Bocharova, N., Knorre, D. & Severin, F. Expression of an expanded 
polyglutamine domain in yeast causes death with apoptotic markers. Biochim. Biophys. Acta 1757, 
660–6 (2006). 
187. Solans, A., Zambrano, A., Rodríguez, M. & Barrientos, A. Cytotoxicity of a mutant huntingtin 
fragment in yeast involves early alterations in mitochondrial OXPHOS complexes II and III. Hum. 
Mol. Genet. 15, 3063–81 (2006). 
188. Mason, R. P. et al. Glutathione peroxidase activity is neuroprotective in models of Huntington’s 
disease. Nat. Genet. 1–8 (2013). doi:10.1038/ng.2732 
189. Zhang, X. et al. A potent small molecule inhibits polyglutamine aggregation in Huntington’s disease 
neurons and suppresses neurodegeneration in vivo. Proc. Natl. Acad. Sci. U.S.A. 102, 892–7 
(2005). 
190. Bodner, R. a et al. Pharmacological promotion of inclusion formation: a therapeutic approach for 
Huntington’s and Parkinson's diseases. Proc. Natl. Acad. Sci. U.S.A. 103, 4246–51 (2006). 
191. Ehrnhoefer, D. E. et al. Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin 
misfolding and reduces toxicity in Huntington’s disease models. Hum. Mol. Genet. 15, 2743–51 
(2006). 
192. Schwarcz, R. The kynurenine pathway of tryptophan degradation as a drug target. Curr Opin 
Pharmacol 4, 12–7 (2004). 
193. Zwilling, D. et al. Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. 
Cell 145, 863–74 (2011). 
194. Masliah, E. et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: 
implications for neurodegenerative disorders. Science 287, 1265–9 (2000). 
195. Feany, M. B. & Bender, W. W. A Drosophila model of Parkinson’s disease. Nature 404, 394–8 
(2000). 
196. Dixon, C., Mathias, N., Zweig, R. M., Davis, D. a & Gross, D. S. Alpha-synuclein targets the plasma 
membrane via the secretory pathway and induces toxicity in yeast. Genetics 170, 47–59 (2005). 
197. Flower, T. R. et al. YGR198w (YPP1) targets A30P alpha-synuclein to the vacuole for degradation. 
J. Cell Biol. 177, 1091–104 (2007). 
198. Sampaio-Marques, B. et al. SNCA (α-synuclein)-induced toxicity in yeast cells is dependent on 
sirtuin 2 (Sir2)-mediated mitophagy. Autophagy 8, 1494–509 (2012). 
199. Su, L. J. et al. Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking 
defects and mitochondrial dysfunction in Parkinson’s disease models. Dis Model Mech 3, 194–208 
200. Flower, T. R., Chesnokova, L. S., Froelich, C. a, Dixon, C. & Witt, S. N. Heat shock prevents alpha-
synuclein-induced apoptosis in a yeast model of Parkinson’s disease. J. Mol. Biol. 351, 1081–100 
(2005). 
201. Anderson, J. P. et al. Phosphorylation of Ser-129 is the dominant pathological modification of 
alpha-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 281, 29739–52 (2006). 
202. Basso, E. et al. PLK2 Modulates α-Synuclein Aggregation in Yeast and Mammalian Cells. Mol. 
Neurobiol. (2013). doi:10.1007/s12035-013-8473-z 
203. Wang, S. et al. α-Synuclein disrupts stress signaling by inhibiting polo-like kinase Cdc5/Plk2. Proc. 
Natl. Acad. Sci. U.S.A. 109, 16119–24 (2012). 
204. Cooper, A. A. et al. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in 
Parkinson’s models. Science 313, 324–8 (2006). 
205. Xiong, Y. et al. GTPase activity plays a key role in the pathobiology of LRRK2. PLoS Genet. 6, 
e1000902 (2010). 
206. Gitler, A. D. et al. Alpha-synuclein is part of a diverse and highly conserved interaction network that 
includes PARK9 and manganese toxicity. Nat. Genet. 41, 308–15 (2009). 
207. Chesi, A., Kilaru, A., Fang, X., Cooper, A. A. & Gitler, A. D. The role of the Parkinson’s disease 
gene PARK9 in essential cellular pathways and the manganese homeostasis network in yeast. 
PLoS ONE 7, e34178 (2012). 
Chapter 1 
30 
208. Schmidt, K., Wolfe, D. M., Stiller, B. & Pearce, D. A. Cd2+, Mn2+, Ni2+ and Se2+ toxicity to 
Saccharomyces cerevisiae lacking YPK9p the orthologue of human ATP13A2. Biochem. Biophys. 
Res. Commun. 383, 198–202 (2009).  
 
 31 
Aims of the thesis 
Neurodegenerative diseases are among the most complex and puzzling of 
human disorders. These devastating illnesses currently do not have any effective 
therapies or treatments, and are thus a social and economic burden for modern society. 
Intense efforts are being made to unravel the mysteries underlying this group of 
diseases, however there is still much to be learnt and discovered. Therefore, it is of 
utmost importance to better understand the biological mechanisms involved in disease 
pathogenesis, and more importantly, to discover novel avenues for therapeutic 
intervention. Budding yeast have been successfully used to perform studies on these 
diseases that have resulted in the identification of several promising therapeutic drugs 
and compounds. The ease of experimental manipulation, the high conservation in basic 
cellular mechanisms between yeast and humans, and the well-defined genome are 
three of the numerous characteristics that make yeast so attractive to study 
neurodegenerative disorders.  
 
The work described in this thesis has taken advantage of this simple organism to 
achieve the following goals: 
 
1. Identify critical genes and major pathways or networks involved in suppression of 
mutant huntingtin toxicity using yeast as a model system (Chapter 2) 
1.1. Identify the genes that are differentially expressed in wild-type yeast cells 
and gene deletion suppressor strains expressing mutant huntingtin protein  
1.2. Find novel suppressor genes of mutant huntingtin toxicity  
1.3. Find novel pathways or networks that underlie mutant Htt toxicity 
suppression  
 
2. Provide novel insights into the function of the yeast DJ-1 homologues (Chapter 3) 
2.1. Characterize the phenotypes associated with the lack of DJ-1 homologues  
2.2. Identify and characterize the pathways and biological processes that are 
affected by the loss of the yeast DJ-1 homologues. 
 
3.  Investigate whether DJ-1 plays a role in HD 
3.1. Characterize the levels of DJ-1 and its oxidation state in HD brains and R6/2 
mouse model of HD 
3.2. Investigate the effect of DJ-1 on Htt toxicity and aggregation 
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Functional gene expression profiling in 
yeast implicates translational dysfunction in 
mutant huntingtin toxicity 
 
 
 
 
 
 
 
 
 
 
 
This chapter contains parts of the following publication:  
 
Functional gene expression profiling in yeast implicates translational dysfunction in 
mutant huntingtin toxicity. 
 
Eran Tauber
1*
, Leonor Miller-Fleming
1,2*
, Robert P. Mason
1*
, Wanda Kwan
3
, Jannine Clapp
1
, 
Nicola J. Butler
1
, Tiago F. Outeiro
2,4
, Paul J. Muchowski
3
, and Flaviano Giorgini
1 
 
J. Biol. Chem. 2011 Jan 7;286(1):410–9. 
 
*Contributed equally to the work. 
 
 
1
Department of Genetics, University of Leicester, Leicester LE1 7RH, UK,  
2
Cell and Molecular Neuroscience Unit, Instituto de Medicina Molecular, Av. Prof. Egas Moniz, 1649-028, Lisboa, 
Portugal,  
3
Gladstone Institute of Neurological Disease, Departments of Biochemistry and Biophysics, and Neurology, University of 
California, San Francisco, California, 94158, USA,  
4
Instituto de Fisiologia, Faculdade de Medicina da Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisboa, 
Portugal 
 
  
 
  
 35 
Chapter 2. Functional gene expression profiling in yeast 
implicates translational dysfunction in mutant huntingtin 
toxicity 
 
Abstract 
Huntington’s disease (HD) is a neurodegenerative disorder caused by the 
expansion of a polyglutamine tract in the huntingtin (Htt) protein. To uncover candidate 
therapeutic targets and networks involved in pathogenesis we integrated gene 
expression profiling and functional genetic screening to identify genes critical for mutant 
Htt toxicity in yeast. Using mRNA profiling we have identified genes differentially 
expressed in wild-type yeast in response to mutant Htt toxicity, as well as in three 
toxicity suppressor strains: bna4∆, mbf1∆, and ume1∆. BNA4 encodes the yeast 
homolog of kynurenine 3-monooxygenase (KMO), a promising drug target for HD. 
Intriguingly, despite playing diverse cellular roles, these three suppressors share 
common differentially expressed genes involved in stress response, translation 
elongation, and mitochondrial transport. We then systematically tested the ability of the 
differentially expressed genes to suppress mutant Htt toxicity when overexpressed, and 
have thereby identified 12 novel suppressors, including genes that play a role in stress 
response, Golgi to endosome transport, and rRNA processing. Integrating the mRNA 
profiling data and the genetic screening data we have generated a robust network 
which shows enrichment in genes involved in rRNA processing and ribosome 
biogenesis. Strikingly, these observations implicate dysfunction of translation in the 
pathology of HD. Recent work has shown that regulation of translation is critical for 
lifespan extension in Drosophila and that manipulation of this process is protective in 
Parkinson’s disease models. In total these observations suggest that pharmacological 
manipulation of translation may have therapeutic value in HD.  
 
Introduction 
Since the cloning of the HD disease gene in 1993, several transgenic models of 
HD have been generated in a variety of organisms, including yeast, Caenorhabditis 
elegans, Drosophila, and mice. These models have allowed researchers to explore the 
underlying mechanisms of HD pathogenesis, as well as to perform genetic screens and 
to test candidate therapeutic compounds. Yeast models have proven to be particularly 
powerful and facile for high-throughput approaches as well as for molecular genetic 
manipulations 1. While not all aspects of pathogenesis can be studied in a single-cell 
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organism like yeast, expression of a mutant Htt fragment in yeast produces several HD-
relevant phenotypes such as formation of mutant Htt-containing aggregates, 
transcriptional dysregulation, cellular toxicity, perturbations in kynurenine pathway 
metabolites, increased levels of reactive oxygen species (ROS), mitochondrial 
dysfunction, defects in endocytosis, and apoptotic events 2. 
In a genome-wide screen we identified 28 gene deletions that suppress toxicity 
of a mutant Htt fragment (Htt103Q) in yeast 3. We focus on three of these suppressor 
genes in this study: BNA4, UME1 and MBF1. 
 
The suppressor BNA4 
BNA4 encodes the yeast homolog of the mammalian enzyme kynurenine 3-
mononygenase (KMO), a promising therapeutic target for HD. KMO is an enzyme that 
catalyzes the hydroxylation of kynurenine in the kynurenine pathway (KP), the major 
route for tryptophan degradation (Fig. 2.1) 4. In the brain, KMO is predominantly 
expressed in microglia 5. The KP is implicated in several other diseases, including 
cerebral malaria and Alzheimer’s disease (AD) 6.  
Three KP metabolites are known to be neuroactive: quinolinic acid (QUIN), 
3-hydroxykynurenine (3-HK), and kynurenic acid (KYNA). Increased levels of 3-HK 
and QUIN, which are downstream of KMO, have both been shown to be neurotoxic and 
have been implicated in the pathophysiology of HD (reviewed in 5). QUIN is a weak, 
though specific agonist of NMDA receptors, present in low concentrations in brain tissue 
(Fig. 1.4). It exerts an excitatory effect when levels are elevated, and it has been 
observed in high levels in the brain of patients with initial stages of HD 7. Interestingly, 
intrastriatal injection of QUIN in rodents recapitulates some of the cardinal features of 
the disease 8. In addition to the activation of NMDA receptors, QUIN is thought to cause 
toxicity by the generation of free radicals 9. Unlike QUIN, 3-HK is not known to bind 
directly to any receptor, but it leads to the production of reactive oxygen species and 
potentiates QUIN-induced neurotoxicity 10. In contrast, the kynurenic acid (KYNA) is 
neuroprotective, acting as an NMDA receptor antagonist 11. 
The KP metabolites and enzymes are well conserved between yeast and 
humans, and the genetics of the pathway has been extensively characterized in yeast 
(Fig. 2.1) 4. This pathway has been dissected in yeast with regards to its influence on 
mutant Htt toxicity, and it was found that much like in HD patients the levels of 3-HK and 
QUIN are increased in cells expressing a toxic mutant Htt fragment 3,12.  It was found 
that genetic or pharmacological inhibition of Bna4 in yeast lowers the levels of these 
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metabolites and ameliorates disease-relevant phenotypes. These results were further 
validated in a HD Drosophila model 13 and, excitingly, it was shown that the oral 
administration of a prodrug which releases a KMO inhibitor leads to neuroprotection in 
HD and AD mouse models 14.  
 
 
Figure 2.1. Kynurenine pathway in mammalian and yeast.  
The enzymes playing a role in kynurenine pathway are represented on the left side of the 
arrows. In green is shown the yeast gene that encodes the respective enzyme.   
 
The suppressor UME1 
Ume1 is a component of the Rpd3 histone deacetylase (HDAC) complex in 
yeast. Several studies in fly and mouse models of HD have shown that inhibition of 
HDAC function either pharmacologically or genetically ameliorates HD-relevant 
phenotypes 15. In addition, HDAC inhibitors decrease the levels of 3-HK and KMO 
activity in R6/2 HD model mice and in primary microglia cultured from these animals 16. 
Interestingly, HDAC5 expression is increased in the cerebellum of HD patients, whereas 
several acetylated core histones are decreased, suggesting that indeed acetylation and 
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consequently transcription are dysregulated in patients 17. Ume1 is required for full 
transcriptional repression of a subset of genes in yeast, in a mechanism requiring Rpd3 
and Sin3 18, suggesting that genetic inhibition of the yeast Rpd3 HDAC complex 
relieves polyQ toxicity in a mechanism similar to that observed in fly and mouse polyQ 
disease models. It was previously found that in ume1∆ cells expressing Htt103Q both 
kynurenine pathway genes (BNA1, BNA2, BNA4, BNA5) and kynurenine pathway 
metabolites (3-HK and QUIN) are downregulated as compared to wild-type cells 
expressing the same construct 8. Interestingly, the genes downregulated in wild-type 
cells expressing Htt103Q cells are enriched for Rpd3-target genes. These observations 
directly link transcriptional dysregulation and perturbations in the kynurenine pathway in 
HD 8.   
 
The suppressor MBF1 
MBF1 encodes a transcriptional coactivator conserved from yeast to humans 
that bridges the DNA-binding region of transcriptional activator Gcn4 and TATA-binding 
protein (TBP) Spt15, a general transcription factor required for transcription by the three 
nuclear RNA polymerases (I, II, III) 19,20. Interestingly, a polyQ expansion in TBP in 
humans leads to Spinocerebellar ataxia 17, which in many patients has phenotypes 
indistinguishable from HD 21. Gcn4 is considered to be the master regulator of amino 
acid metabolism in yeast. It is a member of the AP-1 family of transcription factors, and 
regulates the expression of genes involved in 19 out of 20 amino acid biosynthetic 
pathways, purine biosynthesis, autophagy (ATG1, ATG13, ATG14), and multiple stress 
responses 22. In addition, it has been observed that ~90 RPL (Ribosomal Protein, Large 
subunit) and RPS (Ribosomal Protein, Small subunit) genes which encode ribosomal 
proteins are repressed by activation of Gcn4 under stress conditions 22.  
  
 Here, we expand on our previous studies by using a unique combination of 
functional approaches and differential gene expression analysis on a genome-wide 
scale. In order to identify critical genes/pathways/networks involved in suppression of 
mutant Htt toxicity, we employ oligonucleotide microarray analysis to identify genes 
differentially expressed in mutant Htt expressing cells compared to controls, as well as 
in three suppressor deletion strains expressing a toxic mutant Htt fragment: bna4, 
mbf1, and ume1We next functionally interrogate 380 of these differentially 
expressed genes (DEGs) by testing the effect of overexpression of the respective ORFs 
on mutant Htt toxicity in yeast, and thereby identify 14 DEGs that modulate mutant Htt 
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toxicity. In total this work identifies ribosomal biogenesis and rRNA processing as 
critical cellular processes modulated in eukaryotic cells expressing a mutant Htt 
fragment, which suggests these processes are likely relevant to HD pathophysiology 
and therapy.  
 
 
Results 
 
Yeast expressing a mutant Htt fragment differentially express genes 
involved in ribosome biogenesis and rRNA processing 
 
We recently performed oligonucleotide microarray hybridization assays to 
compare mRNA expression profiles of isogenic parental yeast (BY4741, MAT a) 
expressing either a wild-type or mutant Htt fragment (Htt25Q or Htt103Q, respectively) 
16. Here we re-analysed the data from this experiment using the limma package 
implemented in R/Bioconductor 23,24.This analysis showed that in Htt103Q-expressing 
cells, expression of 226 genes was up-regulated when compared to Htt25Q-expressing 
cells, whereas expression of 244 genes was down-regulated (q value < 0.2) (Fig. 2.2). 
A subset of these DEGs were analysed and confirmed via quantitative real-time PCR 
(QPCR) (Appendix 2.1).  
We used the DAVID Bioinformatics Resources Functional Annotation Tool 
(http://david.abcc.ncifcrf.gov) to test whether the DEGs were enriched by known or 
predicted function using gene ontology (GO) 25. In a manner similar to our previous 
analysis, functional groups upregulated significantly in the Htt103Q expressing cells 
included genes involved in protein folding (p < 1.0 x 10-3) and response to stress (p <  
0.01) (Appendix 2.2) 16. In addition, the new analysis found enrichment in the GO terms 
of response to unfolded protein (p < 1.0 x 10-5), ubiquitin cycle (p < 0.01), post-
translational protein modification (p < 0.01), and vacuolar protein catabolic process (p < 
0.05). We previously described that downregulated genes in Htt103Q-expressing cells 
were involved in the functional groups of ribosome biogenesis (p < 1.0 x 10-39) and 
rRNA processing and metabolism (p < 1.0 x 10-20) 16, and we have confirmed those 
observations in our new analyses (Appendix 2.3). These data suggest that yeast cells 
expressing Htt103Q mount a response to deal with this toxic, misfolded protein, via 
upregulation of proteins involved with protein misfolding, protein degradation, 
autophagy, and stress response. At the same time, in a manner similar to classic heat 
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shock response, the presence of Htt103Q in yeast cells causes a dramatic reduction in 
expression of genes involved in rRNA metabolism and ribosome biogenesis, suggesting 
that general protein synthesis in these cells is significantly repressed, ultimately 
contributing to Htt103Q-dependent toxicity.  
 
 
Figure 2.2. Identification of DEGs in wild-type and gene deletion suppressor 
strains expressing Htt103Q. 
(A) Volcano plot of DEGs. The log2 of the fold change (Htt103Q versus Htt25Q) is represented 
on the x-axis and the negative log of P-values from t-test analyses is represented on the y-axis. 
Upregulated genes due to Htt103Q have positive fold-changes. Red indicates DEGs at the FDR 
of q < 0.1, orange indicates 0.1 < q < 0.2, and blue indicates q > 0.2. (B) Venn diagram 
indicating the overlap in DEGs between bna4∆ mbf1∆, and ume1∆ strains expressing Htt103Q 
compared to the parental BY4741 strain expressing Htt103Q. 15 DEGs are shared among the 
three deletion strains. (C) Inverse correlation of log fold change (M) in DEGs in suppressors 
expressing Htt103Q on the y-axis and in a wild-type strain expressing Htt103Q (compared with 
Htt25Q-expressing cells) on the x-axis. Blue: bna4∆ (r=-0.77, t = -4.19, df = 12, P < 0.01), Red: 
mbf1∆ (r= -0.74, t = -4.10, df = 14, P = 0.01), Green: ume1∆ (r=-0.67, t = -4.84, df = 29, P < 
0.0001). 
 
Common mechanisms underlie mutant Htt toxicity suppression in gene 
deletion suppressor strains  
 
In order to discern if there are common mechanisms underlying toxicity suppression in 
mutant Htt suppressor strains, we next monitored gene expression perturbations in 
three gene deletion Htt103Q suppressor strains: bna4, mbf1, and ume1. Thus, we 
performed microarray experiments to identify DEGs in bna4, mbf1, or ume1 yeast 
expressing Htt103Q versus parental wild-type cells expressing Htt103Q. We tested the 
200 DEGs which showed the highest fold change (and q < 0.1) from each deletion 
suppressor for enrichment of GO terms. We found that in bna4 cells expressing 
Htt103Q there is an enrichment of several GO terms as compared to control cells, 
including carboxylic acid metabolism (p < 1.0 x 10-4), translation elongation (p <  1.0 x 
10-3), nitrogen compound metabolism (p < 1.0 x 10-3), water-soluble vitamin 
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biosynthesis (p < 0.01), and vesicle organization and biogenesis (p < 0.05)(Appendix 
2.4). DEGs in mbf1 cells showed enrichment in many GO term categories, including 
amino acid metabolism (p < 1.0 x 10-11), nitrogen compound metabolism (p < 1.0 x 10-9), 
carboxylic acid metabolism (p < 1.0 x 10-7), and urea cycle intermediate metabolic 
process (p < 1.0 x 10-4) (Appendix 2.5). The ume1 suppressor strain exhibited DEGs 
with enrichment in GO term categories of water-soluble vitamin biosynthesis (p < 0.01), 
NAD biosynthesis (p < 0.01), nitrogen compound metabolism (p < 0.01), carboxylic acid 
metabolism (p < 0.05), among others (Appendix 2.6). The four genes present within the 
NAD biosynthesis GO group are the central kynurenine pathway genes of BNA1, BNA2, 
BNA4, and BNA5, confirming our original analysis with this data set 16. It is critical to 
note that while some of the GO groups enriched in these data are specific to individual 
suppressors, several categories are common amongst these suppressors, such as 
nitrogen compound metabolism and carboxylic acid metabolism. 
As full levels of Htt103Q toxicity are dependent upon the presence of the Rnq1 
yeast prion [RNQ+] 26, we analysed Rnq1 prion status in the three gene deletion strains 
to ensure that the DEGs identified above are independent of Rnq1 prion. To this end, 
we analysed Rnq1 by sedimentation analysis in all three suppressor strains (Fig. 
2.3A,B). We found that in all three strains Rnq1 was present in the pellet fraction of cells 
expressing Htt103Q or carrying empty vector (pYES2), indicating that Rnq1 is present 
in its prion form independent of Htt103Q expression. Interestingly, in the case of the 
bna4 strain, we observed that Rnq1 is also present in the soluble fraction, suggesting 
that this population of cells contains both prion and non-prion forms of Rnq1 (Fig. 2.3B). 
A similar phenotype has been described with other deletion strains from this library(30). 
Treatment with the prion curing agent GuHCl shifted Rnq1 from the pellet fraction to the 
soluble fraction, providing further support that Rnq1 status is “mixed” in the bna4strain 
(Fig. 2.3B). To test whether prion status was directly altered by the deletion of BNA4 we 
analysed a second bna4 strain, and consistent with previously published work 27, we 
found that Rnq1 was entirely in prion form, indicating that the “mixed” prion phenotype 
is independent of BNA4 deletion (Fig. 2.3C). In total this data suggests that DEGs 
identified in the mbf1 and ume1strains are independent of Rnq1 prion status, while a 
subset of DEGs from the BY4741 bna4strain may arise from [RNQ+]-dependent 
modulation of Htt103Q.  
In order to filter out DEGs dependent upon modulation of Rnq1 prion status, and 
to ascertain if common genes/mechanisms underlie suppression in the three 
suppressor strains, we cross-compared the three sets of DEGs identified above (Fig. 
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2.2B). Strikingly, we found that 15 annotated genes were common among these three 
groups, seven of which are also differentially expressed in wild-type cells expressing 
Htt103Q (Table 2.1). Assuming independence, the probability of finding 15 genes 
shared amongst these three groups is < 1.0 x 10-13, which supports the notion that the 
suppressors share common mechanisms of mutant Htt suppression. The genes shared 
among the suppressor strains function in a variety of cellular processes, including 
translation elongation (ANB1), stress response (DAK2), amino acid transport (DIP5), 
lactate metabolism (DLD3), and mitochondrial transport (YMC2). Interestingly, 3 of the 
15 genes are predicted to encode tRNAs, all of which are down-regulated in the 
suppressor strains. Of these genes, 2 encode tRNAs for tRNA-Pro and one encodes 
tRNA-Lys (Table 2.1). In 13/15 cases the genes are differentially expressed in the same 
direction in all three suppressor strains, reinforcing the notion that the shared DEGs 
represent common underlying mechanisms involved in mutant Htt toxicity. Intriguingly, 
of these 13 genes, 5 are differentially expressed in the opposite direction in Htt103Q-
expressing cells (AQR1, DAK2, YGR035C, YMC2, YOR338W)(Table 2.1 and Appendix 
2.7). 
 
Figure 2.3. Rnq1p is present in prion conformation in gene deletion suppressor 
strains. 
[RNQ
+
] prion status in wild-type yeast and deletion suppressors (BY4741 parental strain) 
carrying the pYES2 empty vector or expressing Htt103Q was determined by a combination of 
high-speed centrifugation and immunoblotting. “T” indicates total extract for each yeast strain, 
while “S” indicates supernatant fraction (soluble form of Rnq1), and “P” indicates pellet fraction 
(prion form of Rnq1, [RNQ
+
]). (A) Immunoblotting with -Rnq1 antibody showed that Rnq1 is 
found exclusively in the pellet fraction of the BY4741 wild-type strain, as well as the mbf1 and 
ume1 strains, indicating the protein is in the prion conformation. (B) In the BY4741 bna4 
strain, [RNQ
+
] prion status is “mixed”, with protein present in both pellet and supernatant 
fractions. Treatment of BY4741 bna4 and parental cells carrying pYES2 with guanidine 
hydrochloride (GuHCL) cures [RNQ
+
] prion, shifting Rnq1p from the pellet fraction to the 
supernatant fraction. (C) [RNQ
+
] prion status is independent of BNA4 deletion. In Y5563 bna4 
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cells all Rnq1 is found in the pellet fraction. Treatment of Y5563 bna4 cells with GuHCL cured 
[RNQ
+
] prion present in the pellet fraction of untreated cells carrying pYES2, moving Rnq1 to the 
supernatant fraction. 
This observation led us to compare the DEGs from the individual suppressor 
strains to the top 200 DEGs from Htt103Q expressing cells to ascertain if a negative 
correlation exists in expression between these groups of DEGs. Strikingly, in all three 
comparisons we found a significant negative correlation in differential expression of the 
overlapping genes (Fig. 2.2C). This suggests that the differential expression observed 
in the parental wild-type strain due to expression of Htt103Q is relieved in the three 
deletion suppressor strains. Though it is likely that these changes in expression profiles 
directly contribute to mutant Htt toxicity, we cannot exclude the possibility that the 
changes are simply a downstream consequence of cellular toxicity. 
 
Table 2.1. Common DEGs between bna4, mbf1, and ume1 suppressor strains 
expressing Htt103Q as compared to the parental BY4741 wild-type strain 
expressing Htt103Q.  
Shaded areas indicate genes differentially expressed in all three suppressor strains, as well as in 
Htt103Q-expressing parental cells (in the opposite direction). Htt103Q differential expression is 
related to Htt25Q-expressing parental cells (q < 0.2). DEGs in the three suppressor strains 
expressing Htt103Q (bna4∆, mbf1∆, and ume1∆ are relative to parental cells expressing 
Htt103Q (top 200 annotated genes, q < 0.1). 
 
 
 
 
Gene Htt103Q bna4∆ mbf1∆ ume1∆ Function 
ANB1 n/c Up Up Up Translation elongation factor eIF-5A 
AQR1 Down Up Up Up Plasma membrane multidrug transporter 
COS7 Up Up Up Down Mitochondrial protein of unknown function 
DAK2 Up Down Down Down Dihydroxyacetone kinase 
DIP5 n/c Up Up Up Dicarboxylic amino acid permease 
DLD3 n/c Up Up Up D-lactate dehydrogenase 
LYS20 n/c Up Up Up Homocitrate synthase isozyme 
MMP1 n/c Up Up Up High-affinity S-methylmethionine permease 
SPG4 Up Up Down Down Protein required for survival at high temperatures 
SUF2 n/c Down Down Down tRNA-Pro, 1 of 3 nuclear tRNAs; anticodon AGG 
SUF10 n/c Down Down Down tRNA-Pro, 1 of 3 nuclear tRNAs; anticodon AGG 
tK(CUU)J n/c Down Down Down tRNA-Lys, imported into mitochondria; AAG 
YGR035C Down Up Up Up Protein of unknown function, Cdc28 substrate 
YMC2 Down Up Up Up Mitochondrial inner membrane transporter 
YOR338W Down Up Up Up Protein of unknown function; regulated by Azf1 
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Cis-regulatory domain analysis of DEGs identifies enriched elements 
 
To clarify whether common regulatory mechanisms were affected in Htt103Q-
expressing cells as compared to Htt25Q controls, the DEGs with local false discovery 
rate (FDR) < 2%, as estimated by the Rank product algorithm (n=46), were analysed for 
shared regulatory motifs using the MUSA algorithm. This analysis revealed 14 families 
of de novo motifs that were significantly over-represented in these sequences 28 (Table 
2.2). Aligning the Position Weight Matrix (PWM) of each family with the PWM of known 
transcription factors revealed several matches. Interestingly, Gcn4 was among the 
transcription factors identified, suggesting a link between response to Htt103Q-
dependent toxicity and this transcription factor. The list of transcription factors identified 
includes several zinc transcription factors such as Hap1 (which responds to heme and 
oxygen levels), Azf1 (responds to glucose) and Zap1 (responds to zinc levels).  
 
Table 2.2. Families of over-represented motifs in promoter regions of genes 
differentitally expressed in Htt103Q versus Htt25Q yeast cells 
 
Other candidate transcription factors include Cup2, a copper-binding transcription  
factor which responds to copper levels, and Ime1, which is the master regulator of 
meiosis, and activates early meiotic genes through interactions with Ume6 29, another 
transcription factor whose binding site was over-represented in the DEGs (Table 2.2). 
Family  Count* P-value Transcription factors** 
TTTATAT      26 1.77e-06 Mig2p, Hap1p, Fzf1p, Zap1p 
TTCTTTTC 17 3.59e-06 Azf1p, Cup2p, Zap1p, Ime1p 
AAAAGAAA 22 9.24e-06 Azf1p, Zap1p,  Cup2p, Tec1p 
CATCGC 22 3.33e-05 Hap1p, Rfx1p, Ime1p, Rox1p, 
GCGATG 22 3.33e-05 Hap1p, Rfx1p, Ime1p, Rox1p 
CGCACA      21 0.000104 Crz1p, Hap1p, Aft2p, Stp2p 
TGTGCG      21 0.000104 Crz1p, Aft2p, Stp2p, Hap1p 
AAGAAG      39 0.000146 Tec1p, Azf1p, Zap1p, Azf1p 
ATATTAT      24 0.000166 Arg81p, Arr1p, Mig1p,Mig3p 
TTCTTC      39 0.000257 Tec1p, Zap1p, Abf1p, Ime1p 
GCACGT      18 0.000573 Gcn4p, Met4p, Mig3p, Pho4p 
ACGTGC      18 0.000573 Gcn4p, Pho4p, Met4p, Mig1p 
GCGGCT      16 0.000988 Ume6p, Abf1p, Mig2p, Mig3p 
AGCCGC      16 0.000988 Ume6p, Stp1p, Mig1p, Stp2p 
* Count represents the number of sequences containing at least one motif in the family 
(out of 46). 
** Only top four matches are listed for each family. 
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Ume6 recruits the Rpd3-Sin3 HDAC complex during mitosis to repress early meiosis-
specific genes via hypoacetylation of histones H3 and H4 30. Critically, Ume6 has been 
shown by affinity mass spectrometry to be a component of the Rpd3-Sin3 corepressor 
complex along with the loss-of-function Htt103Q suppressors Ume1 and Rxt3 3,31. Thus, 
this observation further implicates transcriptional dysregulation in mutant Htt toxicity and 
HDACs as candidate therapeutic targets. 
 
A unique subset of differential expressed, highly interconnected genes 
modulate mutant Htt toxicity 
 
In order to ascertain the potential role of the DEGs in mutant Htt toxicity, we 
individually tested the ability of these genes to suppress toxicity of Htt103Q when 
individually overexpressed in yeast. The genes available as ORFs constructs from the 
Yeast ORF Collection (380/470, 80.9%) were individually tested via growth assays for 
suppression of Htt103Q toxicity. We found that 12 of the DEGs suppressed toxicity of 
Htt103Q when overexpressed (Fig. 2.4A, Table 2.3). To eliminate the possibility that the 
DEGs suppressed toxicity by silencing Htt103Q expression, we analysed expression 
levels by Western and dot blotting, and found that Htt103Q expression was unchanged 
(Fig. 2.4B,C). However, an increase in soluble Htt103Q-GFP is observed in suppressor 
strains (Fig. 2.3B), suggesting decreased levels of aggregated Htt103Q-GFP. In 
addition, we confirmed that Rnq1 remains in its prion conformation when expression of 
a DEG is induced (Fig. 2.4D).  
Interestingly, these overexpression suppressors include genes whose 
expression is upregulated as well as genes whose expression is downregulated in cells 
expressing Htt103Q, indicating two different models for overexpression protection: 1) 
ORF overexpression mimics upregulation of genes exerting a protective role against 
mutant Htt toxicity, or 2) ORF overexpression is rescuing a depletion of a critical factor 
(Table 2.3). Excitingly, these overexpression suppressors are potential candidate 
therapeutic targets for HD. Of the 12 novel suppressors, 7 (~ 58%) have human 
orthologs as determined by Ensembl Genome Browser (http://www.emsembl.org). 
We next compared our list of DEGs with our previously published gene deletion 
enhancers and suppressors of mutant Htt toxicity, and identified another two common 
genes (MBF1, APJ1) 3,32. Thus, in total we identified 14 DEGs that modify mutant Htt 
toxicity when overexpressed or deleted (Table 2.3). Amongst these 14 genes, we 
observed enrichment of genes within seemingly unrelated functional groups. 
Approximately half of the genes (BUD23, DBP2, IPI3, NSA2, RRP9, UTP9) are involved 
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in the processing of rRNAs. Interestingly, these were all significantly downregulated. 
The remaining genes are involved in stress/heat shock response (APJ1, JJJ3), and 
transcription (CSE2 and MBF1) (Table 2.3). Aside from rRNA processing, all of these 
functional groups have been extensively implicated in HD pathology.  
 
 
Figure 2.4. Suppression of Htt103Q toxicity in yeast overexpression strains.  
(A) Wild-type Y258 strain overexpressing YOR1, ENT3, IPI3 and RRP9 were independently 
transformed with p425-Htt25Q and p425-Htt103Q. Cellular viability was determined by growth 
assays. Five-fold serial dilutions starting with equal number of cells are shown. Expression of Htt 
and the indicated yeast ORF was induced by galactose. (B) Expression levels of soluble 
Htt103Q-GFP in the wild-type strain expressing the indicated ORFs or carrying an empty vector 
(p425) were analysed by immunoblotting with a GFP antibody. GAPDH levels, detected with a 
GAPDH antibody, were used as loading control. (C) Equal amounts of the extracts in panel B 
were analysed by dot immunoblotting to quantify total levels of Htt103Q-GFP (soluble and 
aggregated), which showed no change in total Htt103Q-GFP expression levels in the suppressor 
strains (D) Rnq1 prion status with ORF suppressors (Y258 parental strain) expressing Htt103Q 
was determined by a combination of high-speed centrifugation and immunoblotting. “T” indicates 
total extract for each yeast strain, while “S” indicates supernatant fraction (soluble form of Rnq1), 
and “P” indicates pellet fraction (prion form of Rnq1). Immunoblotting with α-Rnq1 antibody 
showed that Rnq1 is found in the pellet fraction for all suppressors, indicating the protein is in the 
prion conformation. The Y258 strain carrying empty vector (p425) or Htt103Q serve as a positive 
control, and treatment of cells carrying p425 with guanidine hydrochloride (GuHCL) cures Rnq1 
prion, shifting this protein from the pellet fraction to the supernatant fraction.  
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Table 2.3. DEGs in Htt103Q expressing cells modulate mutant Htt toxicity 
*Human orthologs determined via the Ensembl Genome Browser. Orthologs may be either 1-to-1, 1-to-
many, or many-many. BUD23, ENT3, NSA2, RRP9, and MBF1 have 1-to-1 orthologs in humans which 
could potentially be targeted for therapeutics. **Refers to direction of differential expression in Htt103 
versus Htt25Q cells.  
 
To clarify the functional connectivity amongst this functionally validated list of 
DEGs we performed network analysis using the Osprey Network Visualization System 
(Version 1.2.0), which allows visualization of complex interaction networks 33. This 
software is powered by the BioGRID database (http://www.thebiogrid.org), which 
houses and distributes data collections of protein and genetic interactions of model 
organisms, including yeast via the Saccharomyces Genome Database 
(http://www.yeastgenome.org). Via these databases, Osprey allows insertion of all 
known interactions for each “node” (gene of interest). The interactions types (or 
“edges”) include data from affinity capture experiments, two-hybrid screens, and 
synthetic lethality analyses, among others. Here, we have used Osprey to investigate all 
the known genetic and physical interactions of the 14 functionally validated DEGs. As 
an initial test, we asked for all the interactions within these 14 nodes. Interestingly, we 
found only one interaction amongst these nodes, a physical interaction between Rrp9 
and Utp9, both of which are components of the small ribosomal subunit (SSU) 
processome involved in pre-rRNA processing, as determined by affinity capture/mass 
spectroscopy studies 34–36 (data not shown). This result highlights our observations from 
Suppressor Ortholog(s)* Expression** Function 
BUD23 + Down rRNA processing 
CSE2 - Up RNA pol II transcription 
DBP2 + Down rRNA processing 
ENT3 + Up Golgi-endosome transport 
IPI3 - Down rRNA processing 
JJJ3 - Down HSP40 chaperone 
NSA2 + Down rRNA processing 
PRM7 - Down pheromone response 
RAS1 + Down G-protein signaling 
RRP9 + Down rRNA processing 
UTP9 - Down rRNA processing 
YOR1 + Down ABC  transporter 
Deletion Suppressor    
mbf1∆ + Up transcriptional coactivator 
Deletion Enhancer    
apj1∆ + Up HSP40 chaperone 
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the GO analysis that showed enrichment in genes from disparate functional groups. In 
order to determine if the above 14 genes function indirectly in the same network, we 
explored all of the interactions for these functionally validated nodes, and we found a 
total of 538 interactions among 464 nodes (data not shown). In order to select genes 
with higher level relationships, we processed the network data with an iterative 
minimum filter of two, which identified all of the nodes within this group which have a 
minimum of two interactions with other genes within the group, and then sorted the 
remaining nodes by GO function (Fig. 2.5). This analysis uncovered a highly 
interconnected network of genes, which surprisingly included 11/14 of the original 
functionally validated genes. Critically, this network of 81 nodes (with 156 edges) 
reinforced and expanded the GO groups enriched in the mutant Htt toxicity interaction 
network: ribosome biogenesis and assembly (71.6%, p = 1.2 x 10-49), rRNA processing 
(55.6%, p = 4.7 x 10-43), nuclear transport (12.3%, p = 1.5 x 10-4), and G-protein 
signaling (2.5%, p = 4.5 x 10-2). When a more stringent iterative minimum filter of three 
is applied, 5/14 modifiers are still present in the network (11 nodes; 23 edges), all of 
which are involved in ribosome biogenesis and assembly (p = 2.6 x 10-12), rRNA 
processing (p = 1.2 x 10-8), and related processes (data not shown). In total, this work 
suggests that though these modifiers of mutant Htt toxicity play roles in disparate 
functional groups, they function within a highly-interrelated network.  
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Figure 2.5. Network analysis uncovers a high degree of interconnectivity amongst 
functionally validated DEGs.   
(see previous page for figure) Osprey network analysis of 14 DEGs (indicated in bold) which 
suppress toxicity of Htt103Q when overexpressed. All interactions for these genes (both physical 
and genetic) were included in the analysis. Genes described by the same significantly enriched 
GO terms are color-coded and grouped together. Network data analysed with an iterative 
minimum filter of 2 (minimum of 2 interactions with other network genes). A total of 81 nodes and 
156 edges define this network, which contains 11 of the original 14 functionally validated genes. 
 
 
Discussion 
 
In this study we utilized a novel functional approach to gene profiling 
experiments in order to dissect the underlying mechanisms of mutant Htt toxicity in 
yeast. This work has not only highlighted the central role of rRNA processing and 
ribosome biogenesis in mutant Htt toxicity in yeast, but has also identified several novel 
suppressors of this toxicity which are candidate therapeutic targets for HD. Several 
gene profiling experiments with mammalian models of HD support our observations. 
Gene expression profiling in PC12 cells and rat striatal cells expressing mutant Htt 
fragments has found an enrichment in genes encoding ribosomal proteins and RNA 
processing proteins 37,38. In addition, analysis of gene expression in the striatum of R6/2 
HD model mice has found an enrichment in genes encoding ribosomal proteins as 
compared to wild-type controls 39. Recently, microarray profiling using a primary rat 
neuron model of HD found enrichment in genes involved in RNA splicing/RNA 
processing 40. Finally, an RNAi screen in Drosophila cells identified several modifiers of 
mutant Htt aggregation which play a role in RNA processing 41. In total, these 
observations suggest that the results described here are not likely to be yeast-specific, 
but may reflect cellular perturbations conserved in mammalian cells. In addition, in this 
study we identified DEGs from bna4∆, mbf1∆, and ume1∆ strains expressing Htt103Q 
versus control cells to learn more about underlying mechanisms contributing to Htt103Q 
toxicity suppression. Analysis of prion status in these strains found that in the bna4∆ 
strain Rnq1 is present in both prion and soluble forms, suggesting that a subset of these 
DEGs may arise from modulation of [RNQ+] status. Thus, in order to reduce [RNQ+]-
dependent effects we focused on the cross-section of these DEGs with the DEGs from 
the mbf1∆ and ume1∆ strains. By this approach we identified 15 common DEGs 
amongst these three gene deletion suppressor strains. These genes include 3 tRNA-
encoding genes, as well as genes involved in a variety of cellular pathways. What is 
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unclear in the examples above is the mechanism of these changes, and how these 
changes contribute to mutant Htt toxicity, and ultimately to HD pathology. These yeast 
studies will serve as a strong starting point for future studies elucidating these 
underlying mechanisms.  
A critical finding from this study is the identification of a robust network of 
interactions derived from 14 differentially expressed genes (nodes) that modulate 
toxicity of a mutant Htt fragment. Despite the original nodes playing roles in diverse 
cellular processes, the resulting network contains 11 of these nodes within a network of 
81 nodes and 156 edges, and has an enrichment of genes involved in rRNA processing 
and ribosome biogenesis. Intriguingly, several of the functionally validated nodes 
appear to be highly interconnected in the network (nodes indicated in bold in Figure 
2.5), underscoring the importance of these nodes within the context of the network.  
Several of our observations above implicate Gcn4 in mutant Htt toxicity in yeast. 
First, we found that Gcn4 binding sequences are over-represented in the upstream 
regions of genes differentially expressed in Htt103Q-expressing cells. Second, MBF1, 
which is a deletion suppressor of Htt103Q toxicity, encodes a transcriptional coactivator 
which can bridge Gcn4 and TBP. Third, expression of Htt103Q in yeast leads to 
downregulation of genes involved in ribosome biogenesis, and under stress conditions 
Gcn4 is known to repress transcription of ~90 RPL and RPS genes which encode 
ribosomal proteins 22. In total this work suggests that expression of Htt103Q in yeast 
may downregulate expression of ribosomal genes via induction of Gcn4 expression. As 
Mbf1 expression is required for Gcn4 function, these observations collectively suggest 
that deletion of MBF1 may suppress mutant Htt toxicity by impairing Gcn4 function. It 
must also be noted that induction of Gcn4 leads to upregulation of three kynurenine 
pathway genes, BNA1 (3-hydroxyanthranilate 3,4-dioxygenase), BNA4 (which encodes 
KMO), and BNA6 (quinolinate phosphoribosyl transferate) 22. Intriguingly, deletions of 
either BNA1 or BNA4 suppresses toxicity of Htt103Q 3. These observations also 
support a hypothesis in which Gcn4 induction due to Htt103Q expression contributes to 
toxicity. We did not, however, see differential expression of GCN4 in our present study 
in Htt103Q-expressing cells (data not shown). This is not particularly surprising as 
GCN4, which is under strict transcriptional control, is also under translational control, via 
four small upstream ORFs (uORFs) in the 5’ leader region of the GCN4 mRNA 42. 
Induction of translation occurs primarily under environmental stresses 43. In addition, as 
recruitment of TBP via Mbf1 is the rate-limiting step in Gcn4 activation 19, and MBF1 
expression is upregulated in Htt103Q-expressing yeast (Table 2.3), it is possible that 
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increased levels of Mbf1 alone may be sufficient to increase Gcn4 activity, without 
induction of Gcn4 expression. Interestingly, lifespan extension in yeast due to depletion 
of 60s ribosomal subunits, dietary restriction, or TOR inhibition appears to require 
induction of Gcn4 44. Thus, in the case of mutant Htt expression, Gcn4 induction may 
reflect a cellular coping mechanism gone awry. This pathway may play a similar role in 
humans as ATF4, the functional ortholog of Gcn4 in mammals 45, is regulated via a 
similar translational mechanism and activation of Gcn4 is analogous to the mammalian 
integrated stress response 46.  
In a related note, the yeast eIF4E-associated protein Eap1, which inhibits cap-
dependent translation initiation via the TOR signaling cascade, attenuates induction of 
Gcn4 translation 47. Recent work has shown that overexpression of eIF4E-BP, the Eap1 
functional equivalent in Drosophila, rescues parkinsonian phenotypes in fly models of 
PD by inhibiting cap-dependent translation, and thereby inducing expression of genes 
involved in stress response 48. It has also been seen that during dietary restriction in 
Drosophila 4E-BP promotes lifespan extension by activation of nuclear-encoded 
mitochondrial protein translation 49. Interestingly, in the present study we have found 
that the gene encoding eIF5A, a translation elongation factor, is upregulated in all three 
suppressor strains expressing Htt103Q, as compared to controls. Taken together, these 
data suggest that altered regulation of translation may be contributing to mutant Htt 
toxicity, and that pharmacological modulation of this process may have therapeutic 
relevance. Supporting this, it has been shown that rapamycin treatment of mouse 
embryonic fibroblast cells expressing mutant Htt abrogates HD-relevant phenotypes by 
inhibition of translation, independent of effects on autophagy 50. It has also been 
observed that normal Htt localizes to neuronal RNA granules – cellular structures 
involved in mRNA transport and storage 51. A recent study showed that mutant Htt 
interact with several ribosomal proteins and translation initiation factors and moreover 
that wild-type and mutant Htt impair the translation of a mRNA reporter 52. It is also 
important to note that while much interest in the HD community has been focused on 
transcriptional dysregulation in pathogenesis and as a target for therapeutics, our study 
suggests that the effect of mutant Htt on translational processes in the cell may also be 
critical. 
As most basic cellular mechanisms are conserved in yeast to higher eukaryotes, 
the work presented here will likely inform future studies on disease pathogenesis in HD. 
Due to the ease and rapidity of genetic screening in yeast, this organism is particularly 
amenable for integrated approaches to functional gene expression profiling. Yeast will 
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therefore likely provide an important platform for future analyses of disease genes, 
further evidenced by a recent study dissecting α-synuclein toxicity in yeast 53. It is 
important to mention that we have identified 12 novel suppressors of mutant Htt toxicity 
in yeast, 7 of which have human orthologs as determined by the Ensembl Genome 
Browser. Four of these yeast genes (BUD23, ENT3, NSA2, and RRP9) have clear 1-to-
1 orthologs in humans which could potentially be targeted for therapy if validated in 
other model systems. Interestingly, ENT3 has recently been identified as a suppressor 
of α-synuclein toxicity in yeast 54.  
In summary, our study has provided new insights into the mechanisms 
associated with mutant Htt toxicity in yeast which may be relevant to HD pathogenesis 
and has also identified novel candidate targets for therapeutic intervention in this 
disorder. Clearly it is now critical to test the above hypotheses and to validate the 
candidate HD targets identified in order to ascertain how our observations are linked to 
mutant Htt toxicity in yeast and how they may inform therapeutic strategies in HD 
patients. Finally, the power of using yeast to clarify mechanisms involved in HD 
pathogenesis and to identify candidate drug targets is underscored by the recent 
validation of KMO as a promising therapeutic target in HD model mice 14. 
 
 
Materials and Methods 
 
Yeast strains and DNA constructs 
The strains used for microarray experiments were from the yeast gene deletion set in 
the MATa (BY4741) [MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0] strain background (Open 
Biosystems). The Y258 strain background [MATa pep4-3, his4-580, ura3-53, leu2-
3,112] was used for the overexpression studies (Open Biosystems). The constructs 
pYES2-Htt25Q-GFP and pYES2-Htt103Q-GFP 55 were used for the microarray studies. 
Htt103Q is a galactose (GAL)-inducible, FLAG- and GFP-tagged construct encoding the 
first 17 amino acids of Htt fused to a polyQ tract of 103 glutamines. The constructs 
p425GALL-Htt25Q-GFP and p425GALL-Htt103Q-GFP were used in the yeast 
overexpression studies and were generated by amplifying the huntingtin constructs from 
pYES2-Htt25Q-GFP and pYES2-Htt103Q-GFP and cloning into the SpeI and XhoI sites 
of p425GALL(17). 
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Yeast total RNA preparation  
SC –Ura galactose (2%) cultures (12 ml) were inoculated at OD600 0.2 and incubated 
with shaking at 30º C until reaching an OD600 of ~1.0. Cells were harvested and lysed 
with acid-washed glass beads. Total RNA was isolated with Qiagen RNeasy Midi kits, 
following standard protocols. 
 
Gene expression analysis by DNA oligonucleotide arrays 
Double-stranded cDNA was synthesized from total RNA, amplified as cRNA, labeled 
with biotin, and hybridized to Affymetrix Yeast Genome S98 Array GeneChips, which 
were washed and scanned at the University of Washington Center for Expression 
Arrays and at the J. David Gladstone Institutes Genomics Core Laboratory, University of 
California, San Francisco according to manufacturer protocols. Images were processed 
with Affymetrix Microarray Suite 5.0 (MAS-5). The quality of hybridization and overall 
chip performance were determined from the MAS-5 generated report file.  
 
Analysis of Microarray Data 
The statistical computing language R 56 was used for quality controls, pre-processing  
and analyses of the data. The quality of the microarrays was assessed by inspecting 
pseudo-images of the arrays, MA scatter plots of the arrays versus a pseudo-median 
reference chip, and histogram and boxplot of raw log intensities. Expression data are 
available through the Gene Expression Omnibus (GEO) database, accession number 
GSE18644. The data were analysed using the R bioconductor package affylmGUI 
(version 1.8.0), the graphic interface to limma (version 2.9.17) 24. Data were normalized 
and summarised using the GCRMA method 57 DEGs were identified by using a 
moderated t-test (limma). To correct for multiple comparison we have estimated the 
false-discovery rate (FDR) using the QVALUE package 58 with a typical FDR threshold 
(q) of 10%. Gene ontology searches were performed with the DAVID Functional 
Annotation Tool (http://david.abcc.ncifcrf.gov/home.jsp). Network visualization was 
performed using the Osprey Network Visualization System (Version 1.2.0), which is  
powered by the BioGRID database (http://www.thebiogrid.org) 33. Cis-regulatory 
elements of the DEGs were identified using the MUSA algorithm 28 in the YEASTRACT 
suite 59. The Position Weight Matrix of each family was used to search for known 
transcription factor binding sites in the YEASTRACT database using the Smith-
Waterman local alignment algorithm (using the sum of the squared distances metric). 
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Real-Time Quantitative PCR 
The BY4741 yeast strain was transformed independently with pYES2-Htt103Q-GFP 
and pYES2-Htt25Q 55 by standard procedures. Yeast cells were grown overnight in 
complete media lacking uracil (SC-URA) containing glucose (2%) as a carbon source. 
Cultures were diluted back to optical density 0.4 and grown in SC-URA containing 
galactose (2%) to induce protein expression. Cells were harvested after growing until 
mid-log phase, pelleted and stored at -80ºC until needed. RNA was extracted using the 
Qiagen RNeasy Midi kits following manufacturer instructions. Genomic DNA 
contamination was removed from RNA using Turbo DNAse according to the 
manufacturer’s protocol. 500 ng of RNA was used as a template to synthesize cDNA 
with the Qiagen QuantiTect® Reverse Transcription kit. To ensure that RNA had no 
genomic DNA contamination a control reaction was included in which no reverse 
transcription was carried out. 17 genes were selected to analyse the mRNA expression 
levels by quantitative PCR and actin-1 was chosen as a reference. Reactions were 
carried out in a LightCycler Real-Time PCR System (Roche). cDNA was quantified 
using 5 ul of Sybr Green (Fermentas) and 0.3 uM of forward and reverse primers. 
Primers were analysed for specificity and efficiency by melting curve analysis. The 
efficiency was calculated at the end of each amplification reaction via relative standard 
curves. PCR efficiencies ranged from 0.80 to 1.0. Standard curves were calculated 
using the amplification of 5 serial dilutions of genomic DNA in triplicate. At least three 
independent cDNA samples were analysed. PCR reactions were run in duplicate. 
Relative quantification was performed using LightCycler® 480 Relative Quantification 
Software. The crossing points were calculated by the second derivative method and 
relative expression was calculated by the available advanced relative quantification. 
Further analysis and statistical tests were performed using the Relative Expression 
Software 2008 (REST) 60,61. The relative quantification was corrected for PCR efficiency 
via both methods.  
 
Functional Testing of DEGs 
Yeast strains containing plasmids for the overexpression of selected genes were 
obtained from the yeast ORF collection in the Y258 strain background. The relevant 
yeast strains were grown overnight in 96 well plates containing 100 µl of SC-URA 
supplemented with 2% glucose  per well and transformed with either p425GALL-
Htt25Q-GFP or p425GALL-Htt103Q-GFP using a high throughput transformation 
method 1. Transformants were grown to stationary phase in complete media lacking 
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uracil and leucine (SC–Ura–Leu) containing 2% glucose, serial diluted, and spotted 
onto SC-Ura-Leu media supplemented with either 2% glucose or 2% galactose and 2% 
raffinose. Plates were incubated at 30˚C for 3-5 days and yeast strains scored for 
growth. 
 
Determination of RNQ prion status 
20 ml cultures of suppressor strains were grown to approximately an OD600 1.0 in SC –
Ura GAL/RAF media, at which point cells were harvested by centrifugation at 3000 rpm 
for 5 min. Cell pellets were washed with 10 ml water and spun as above. The cell 
pellets were resuspended in 200 µl lysis buffer (100 mM Tris pH 7.0, 200 mM NaCl, 
1mM EDTA, 5% glycerol, 0.5 mM DTT, 1X protease inhibitor cocktail) and transferred to 
microfuge tubes. The cells were lysed by addition of ~200 µl of acid washed glass 
beads (425-600 µm, Sigma, St. Louis, MO), vortexing for 1 min, addition of 200 µl of 
RIPA buffer (50 mM Tris pH 7.0, 200 mM NaCl, 1% Triton, 0.5 % Na-deoxycholate, 
0.1% SDS), and further vortexing for 10 sec. Samples were then centrifuged at 3000 
rpm for 15 sec to pellet the glass beads and cell debris. 60 µl of supernatant was used 
as the “Total” sample, while 200 µl of the supernatant was centrifuged for 30 min at 
80,000 rpm in the Beckman TLA 100 Ultracentrifuge. 60 µl of the supernatant from this 
step was isolated and used at the “Soluble” fraction, while the “Pellet” fraction was 
prepared by resuspending the pellet in 100 µl of lysis buffer and 100 µl of RIPA buffer, 
adding 67 µl of 4X protein sample buffer (SB), and boiling for 5 minutes. 20 µl of 4X SB 
was added to the “Total” and “Soluble” fractions, and boiled for 5 min. The samples 
were resolved by SDS-PAGE and immunoblotting as described above. Curing yeast 
strains of endogenous prion cells was performed by growth for 5 passages on YPD 
supplemented with 5 mM guanidine hydrochloride (GuHCl) 62. 
 
Htt103Q Expression Levels 
In order to analyse the level of Htt103Q protein expression in the yeast strains, protein 
extracts were analysed by immunoblotting. SC –Ura -Leu GAL yeast cultures were 
inoculated from overnight SC –Ura -Leu raffinose (RAF) cultures to an OD600 ~0.4, and 
were grown under inducing conditions for 5-6 hours. Cells were lysed by mechanical 
disruption with acid washed glass beads (425-600 µm, Sigma, St. Louis, MO) and lysis 
buffer (50 mM Tris pH 7.5; 1X protease inhibitor cocktail, Roche), vortexing seven times 
for 30 sec each, with 1 min incubations on ice in between. Glass beads and cell debris 
were removed by centrifugation and protein extracts were quantified using the BioRad 
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Protein Assay (BioRad, Hercules, CA). For SDS-PAGE, extracts were mixed with 4x 
Protein Sample Buffer (200mM Tris-HCl, 8% SDS, 40% glycerol, 0.4% bromophenol 
blue, 6% -mercaptoethanol), boiled 10 min, and subjected to electrophoresis in 12% 
SDS-polyacrylamide gel. The proteins were transferred to nitrocellulose membranes. 
For dot blots, extracts were mixed with 2% SDS and captured in nitrocellulose 
membrane by vacuum. Htt103Q-GFP was identified by a monoclonal α-GFP antibody 
(Santa Cruz Biotechnology, Inc), used at a 1:1000 dilution while the GAPDH loading 
control was detected using α-GAPDH antibody (Ambion) at 1:4000 dilution. These 
incubations were followed by a α-Mouse Ig horseradish peroxidase conjugated antibody 
(Amersham Bioscience, Piscataway, NJ) at 1:10000 dilution. Detection was done by 
enhanced chemiluminescence (ECL) (Amersham Bioscience, Piscataway, NJ) and 
exposure to X-ray film.  
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Chapter 3. Yeast DJ-1 family members are required for diauxic-
shift reprogramming and cell survival in stationary phase 
 
Abstract 
The yeast Hsp31 mini-family – comprised of the four homologous proteins 
Hsp31, Hsp32, Hsp33 and Hsp34 – belongs to the conserved DJ-1 superfamily. 
Proteins from this superfamily are predominantly involved in protecting cells against 
various forms of cellular stress. DJ-1, the human homolog, is associated with autosomal 
recessive forms of Parkinson’s disease (PD) and is thought to be involved in oxidative 
stress response. Despite great interest in these proteins, the function of the Hsp31 mini-
family members remains unclear. In this study, we show that the Hsp31 mini-family has 
a role in diauxic-shift, which is characterized by metabolic reprogramming due to 
glucose limitation. We found that the Hsp31 genes are strongly induced in diauxic-shift 
and in stationary phase, and that deletion of these genes leads to reduced 
chronological lifespan, an inability to reprogram gene transcription at diauxic-shift, and 
failure to acquire several typical characteristics of stationary phase, including defective 
autophagy induction. In addition, carbon starvation of the gene deletion strains impaired 
autophagy and led to abnormal Atg13 phosphorylation mediated by TORC1. 
Repression of this kinase by rapamycin in the gene deletion strains completely reversed 
their sensitivity to heat shock. Altogether our data indicate the Hsp31 mini-family is 
required for diauxic-shift reprogramming and cell survival in stationary phase, and plays 
a role upstream of TORC1. The enhanced understanding of the cellular function of 
these genes sheds light on the biological role of other members of the family, including 
DJ-1, which is an attractive target for therapeutic intervention in cancer and in PD. 
 
Introduction 
The DJ-1 superfamily includes a vast number of conserved proteins with similar 
three dimensional structures distributed across Archaea, Bacteria, and Eukaryota 1–10. 
Special attention has been given to the members of this family, since it includes DJ-1, a 
human protein that has been implicated in two major global health problems: cancer 
and Parkinson’s disease (PD) 11–13. Other known members of the DJ-1 superfamily 
include the Escherichia coli proteins Hsp31 (EcHsp31), YajL and YhbO, the archeal 
Pyrococcus horikoshii protein PH1704 and four orthologs in the yeast Saccharomyces 
cerevisiae (Hsp31-34). These proteins have disparate functions however they are all 
implicated in cellular stress response. EcHsp31 is a chaperone 14–16 that has peptidase 
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17 and glyoxalase activities 18. YajL, which shares the highest homology with human DJ-
1 8, functions as a chaperone 19, while YbhO is required for stress protection 20 and 
PH1704 functions as protease 3.  
 
The human DJ-1 protein 
The human protein DJ-1 – the most extensively studied protein from the DJ-1 
superfamily – is a small protein of 189 amino acids that was first discovered as an 
oncogene that transformed NIH3T3 in association with H-Ras 13. DJ-1 expression is 
found elevated in several types of cancer, including leukemia, breast cancer, primary 
lung cancer, prostate cancer, cervical cancer and pancreatic cancer 21–29. The 
oncogenic potential is thought to be related to its role as regulator of the tumor 
suppressor phosphate and tensin homolog (PTEN) 22,30. 
DJ-1 was first implicated in neurodegeneration when it was found that mutations 
in the gene PARK7 cause autosomal-recessive early onset cases of PD 11. Mutations in 
DJ-1 are thought to destabilize its structure, which results in its degradation or to affect 
the normal homodimerization, which is critical for its function 31. DJ-1 is ubiquitously 
expressed in the body, including in the brain. It is localized mostly in the cytoplasm, but 
also in mitochondria and nucleus 32–36. Interestingly, DJ-1 is secreted by different cell 
types 21,37,38 and it may be a potential biomarker not only for PD 39, but also for several 
cancer types 40–42. In the brain, DJ-1 expression is increased in reactive astrocytes in 
sporadic PD patients as well as in reactive astrocytes that are under oxidative stress 
conditions 43,44. DJ-1 is not present in Lewy bodies but intriguingly it is found in Pick 
bodies, which are a hallmark of Pick’s disease that contain the tau protein 45,46.   
DJ-1 has three cysteine residues C46, C56 and C106. C106 is the most 
conserved residue among the members of DJ-1 superfamily and it has been proposed 
to regulate the function and localization of DJ-1 36,47. It is highly susceptible to oxidation 
and can be oxidized to cysteine-sulfenic (SOH) or to the irreversibly oxidized cysteine-
sulfinic (SO2H) or cysteine-sulfonic acid (SO3H); the oxidation of C106 to the SO3H form 
is thought to inactivate the protein function 36,48,49. Interestingly, DJ-1 is found oxidatively 
damaged in the brains of patients with idiopathic PD and Alzheimer’s disease (AD) 50. 
Recently, we found that DJ-1 is also highly oxidized and overexpressed in HD brains 
(Chapter 4) 51. These findings suggest that oxidatively damaged DJ-1 may contribute to 
the pathogenesis not only of the genetic DJ-1 linked PD cases but also of idiopathic PD 
cases, as well as AD and HD. To study DJ-1, several models have been generated, 
including DJ-1 knockout mice, DJ-1 knockdown zebrafish (Danio rerio) and double or 
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single knockout fruit flies (Drosophila melanogaster; has two DJ-1 orthologs: DJ-1α and 
DJ-1β). The DJ-1 null mouse does not present observable neurodegeneration, oxidative 
damage, or inclusion bodies, which shows that loss of DJ-1 does not cause higher 
oxidative stress in basal conditions 52–54. However, some abnormalities were observed, 
including increased levels of mitochondrial reactive oxygen species (ROS) in the SN 
and whole brain, higher vulnerability of dopaminergic neurons to MPTP and impaired 
dopamine signaling 52,55,56. The DJ-1 zebrafish knockdown and Drosophila knockout 
models although do not exhibit dopaminergic neurodegeneration under basal 
conditions, they are more sensitive to oxidative insults, indicating that DJ-1 has a role in 
the antioxidants defense mechanisms 57–61. The precise role of DJ-1 in the cell is not 
clear, however compelling evidence indicates that DJ-1 is a multifunctional protein 
associated with protection of cells from oxidative stress 62. It has been proposed that 
DJ-1 acts as a redox-dependent chaperone preventing -syn aggregation 48,63, however 
contradictory data raises the question of whether DJ-1 is in fact a chaperone. For 
instance, while one study showed that DJ-1 is able to inhibit heat-induced aggregation 
of citrate synthase and luciferase 64, another study employing similar experimental 
conditions did not replicate these results 65. Using different cellular models it was shown 
that DJ-1 suppresses the toxicity of -syn wild-type or A53T but required the heat shock 
protein 70 (Hsp70) activity, suggesting that the putative DJ-1 chaperone activity is weak 
47. DJ-1 was also shown to scavenge directly ROS 52, although it is not clear whether 
this capacity is relevant to reduce the load of ROS in the cell. Since the oxidation of DJ-
1 may be irreversible, new protein would need to be synthesized in order to scavenge 
more ROS and therefore this function does not seem physiologically relevant 66. Similar 
to the archaeal cysteine protease PH1704 from Pyrococcus horikoshii, several reports 
showed that DJ-1 is a cysteine protease 65,67,68, however others failed to detect this 
activity 63,69. The comparison between the crystal structures of human DJ-1 and the 
archaeal protein showed that DJ-1 has an additional α-helix at the C-terminal that 
blocks the putative catalytic domain of protease 70. However, it has been suggested that 
this helix is opened in vivo, allowing DJ-1 to act as a protease, namely on transthyretin 
– the protein associated with familial amyloidotic polyneuropathy 68,71. DJ-1 has also 
been identified as regulator of survival and oxidative stress signaling pathways. For 
instance, it negatively regulates the survival pathway PTEN/PI3K pathway by direct 
binding to PTEN inhibiting its activity 30,72. In addition, there are studies suggesting that 
DJ-1 positively regulates the nuclear factor erythroid 2-related factor 2 (Nrf2) 73–75, which 
is a major antioxidant transcription factor and would explain why loss of DJ-1 leads to 
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increased sensitivity to oxidative stress. However, contradictory results were obtained 
by another group that showed no physiological relation between DJ-1 and Nrf2, 
although the authors suggest that this interaction may be cell specific 76. Interestingly, 
DJ-1 was further suggested to play a role in regulating RNA, by binding several mRNAs 
that encode proteins involved in several processes such as glutathione metabolism, 
PTEN/PI3K pathway and mitochondrial function, which are released upon oxidative 
stress 77,78. This observation, if further confirmed, may explain the diversity in DJ-1 
functions in just one.  
Since there are many contradictory results regarding the function of DJ-1 as well as 
multiple proposed functions, further clarification is needed to fully understand the 
function of such a complex protein. 
 
The yeast Hsp31 mini-family 
The yeast Saccharomyces cerevisiae Hsp31 gene mini-family is comprised of Hsp31 
(YDR533C), Hsp32 (YMR322C), Hsp33 (YOR391C), and Hsp34 (YPL280W). Among 
the four yeast DJ-1 family members, Hsp31 is the most divergent and likely gave rise to 
the other three paralogous proteins by genome duplication 7 (Fig. 3.1). Hsp32, Hsp33 
and Hsp34 share strong sequence homology of over 90%. While HSP32, HSP33 and 
HSP34 localize within subtelomeric regions (within large blocks of conserved DNA that 
includes other genes), HSP31 is an interstitial gene.  
The name of these proteins was given after resolving the crystal structure of 
Hsp31. The Hsp31 standard name was based on the structural similarity it shares with 
the E. coli EcHsp31. The other three proteins were renamed due to the homology 
shared with Hsp31. The crystal structure of Hsp33 was later resolved and showed 
striking similarities with Hsp31 4,79. 
Though little is known about the function of these proteins, Hsp31 may play a 
role in cellular stress response as it is upregulated in oxidative stress conditions 80. 
Furthermore, hsp31∆ cells are more sensitive to oxidative stress and exhibit increased 
levels of reactive oxygen species (ROS) compared with the parental cells 80. Proteomic 
and transcriptomic studies have shown that HSP31 expression increases after 
exposure to misfolded proteins 7, sorbic acid 81, the pro-oxidant and neurotoxic fungicide 
mancozeb 82 and high pressure conditions 83.  
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Figure 3.1. Alignment of the protein sequences of the yeast DJ-1 superfamily 
members: Hsp31, Hsp32, Hsp33 and Hsp34.  
Hsp32, Hsp33 and Hsp34 share the highest homology amongst the family members. Hsp32 
shares ~99.6% protein identity with Hsp33, as they differ by only one amino acid. Hsp33 has two 
differing amino acids from Hsp34 (~ 99.2% amino acid identity) and Hsp34 differs in only one 
amino acid from Hsp32 (~99.6% identity). These three proteins are most diverged from Hsp31, 
sharing ~69% identity.  
 
Here, we show that the Hsp31 mini-family is required for normal transition from 
logarithmic (log) growth phase to post-diauxic phase and for the acquisition of typical 
hallmark features of stationary phase. In their absence, yeast cells lose the capacity to 
survive in stationary phase conditions and display TORC1 (target of rapamycin complex 
1) signaling dysfunction. Altogether, we provide novel insights into the function of the 
DJ-1-related Hsp31 mini-family, which may contribute to the understanding of the 
general function of the DJ-1 superfamily, opening novel perspectives for intervention in 
cancer, PD and, more generally, in lifespan extension.  
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Results  
 
The HSP31 mini-family is required for normal diauxic-shift and stationary 
phase  
As Hsp31 expression is induced in post-diauxic phase 80, we started by 
characterizing the expression levels of HSP31, HSP32 and HSP33 throughout the 
different phases of yeast growth in liquid medium (Fig. 3.2). Due to the extremely-high 
sequence similarity between HSP32, HSP33 and HSP34 (Fig. 3.1) it was not possible 
to design primers that distinguished HSP34 from the other two genes, and thus we 
excluded HSP34 from these analyses. In parallel, we determined the expression profile 
of GIS1, a transcription factor required for gene expression during nutrient limitation 84.  
 
Figure 3.2. Yeast growth in glucose-rich liquid culture.  
(A) Representative growth curves of wild-type and hsp31Δ, hsp32Δ, hsp33Δ and hsp34Δ. (B) 
Main characteristics of yeast growth. Yeast cells grown in glucose-rich media exhibit exponential 
division, known as logarithmic growth (Log phase). In this phase, cells obtain energy through 
fermentation and produce ethanol. When glucose becomes limiting (known as diauxic-shift) cells 
enter post-diauxic phase, in which growth rate decreases. Cells readjust their metabolism to 
aerobic respiration and consequently exhibit higher levels of reactive oxygen species. In parallel, 
cells upregulate stress response genes, induce autophagy, acquire thicker cell walls, accumulate 
trehalose and exhibit decreased protein translation. Upon exhaustion of the available carbon 
source, cells stop proliferating by arresting their cell cycle in G0 and enter stationary phase.  
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Our results showed that HSP31-33 and GIS1 had similar expression patterns (Fig. 3.3): 
the expression of these genes was highly induced when cells shifted from log phase to 
post-diauxic phase, and the levels were maintained in stationary phase. We detected 
slight differences in the timing and levels of expression between the members of the 
Hsp31 mini-family. HSP31 and HSP33 mRNAs reached maximum levels in early 
stationary phase, whereas HSP32 mRNA levels peaked at diauxic-shift (Fig. 3.3). 
 
 
Figure 3.3. HSP31, HSP32 and HSP33 expression is induced at diauxic-shift and 
is maintained in stationary phase.  
Gene expression quantification was performed via quantitative real time PCR in mid-log, diauxic-
shift, early stationary phase (1 day in culture) and stationary phase (2 days in culture). 
Expression levels of HSP31, HSP32 and HSP33 were normalized by TAF10 and UBC6. Error 
bars represent standard deviation (SD) of the mean (n=3). Fold induction is indicated on top of 
each bar. Pair-wise statistical analysis was performed using Student’s t-test (*** p<0.001; ** 
p<0.01; * p<0.05). 
 
As previously shown for hsp31 cells 80, we observed that deletion of HSP32, 
HSP33 and HSP34 had no effect on yeast growth in normal conditions, but resulted in 
higher sensitivity to oxidative stress (Fig. 3.4A), reduced thermotolerance (Fig. 3.4B), 
and accumulation of higher levels of ROS (Fig. 3.4C-D).  
Given that the expression of HSP31, HSP32 and HSP33 significantly increased 
at diauxic-shift, we tested whether the absence of these genes, as well as HSP34, 
would affect yeast survival in stationary phase – chronological lifespan (CLS). We 
included gis1∆ cells for comparison as it has a shortened chronological lifespan versus 
wild-type 85. Deletion of HSP31 family genes resulted in reduced CLS, although to a 
lesser extent than deletion of GIS1 (Fig. 3.5A). Re-introduction of Hsp genes in 
knockout strains reverted this phenotype (Fig. 3.5B-C).  
The fact that HSP31, HSP32 and HSP33 were highly upregulated at diauxic-
shift, together with the loss of cell viability in aged cultures of knockout strains, 
prompted us to further investigate the role of these genes during diauxic-shift. We 
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performed gene expression microarrays of hsp31Δ, hsp32Δ, hsp33Δ and wild-type 
strains at diauxic-shift, which was determined based upon growth rate and glucose 
consumption. The microarray analyses were validated by testing selected differentially 
expressed genes (DEGs) by quantitative real-time PCR (QPCR) (Appendix 3.1). The 
expression profiles of knockout strains were independently compared to that of the wild-
type strain, and only genes differently expressed more than two fold (p ≤ 0.05) were 
considered for subsequent analyses.  
 
Figure 3.4. hsp31Δ, hsp32Δ, hsp33Δ and hsp34Δ are more sensitive to oxidative 
and heat stress and accumulate higher levels of ROS.  
(A) Mid-log phase cultures were normalized to an optical density at 600 nm of 0.2, serially 
diluted (five-fold), and spotted onto solid media containing various concentrations of hydrogen 
peroxide (H2O2), as shown. (B) Cultures were subjected to a heat shock of 50ºC for 5, 10 or 20 
minutes and subsequently spotted onto YPD plates. (C) Superoxide levels were measured using 
the oxidation sensitive dye dihydroethidium (DHE), (D) while hydrogen peroxide levels were 
measured using the dye dihydrorhodamine 123 (DHR 123). Stained cells were scored by flow 
cytometry. (D) Dead cells were excluded prior to analysis based upon propidium iodide staining. 
 
Among the three pair-wise comparisons, hsp32Δ showed the highest number of 
differentially expressed genes with alterations in approximately one quarter of the yeast 
genome (Fig. 3.6). To identify overlapping DEGs between the three knockout strains we 
performed a separate comparison of upregulated (Fig. 3.6A) and downregulated genes 
(Fig. 3.6B). hsp32Δ and hsp33Δ strains shared a high number of DEGs that did not 
overlap with hsp31Δ, which is in agreement with the high conservation between Hsp32 
and Hsp33 protein sequences (Fig. 3.6A-B). For further analysis we selected DEGs 
common to the three knockout strains and clustered these overlapping genes using 
gene ontology (GO) analysis based upon biological process annotation (Fig. 3.7A-B; 
Appendix 3.2 and 3.3). 
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Figure 3.5. Hsp31-34 are required for normal lifespan in stationary phase. 
(A) Strains were monitored for chronological lifespan (CLS) by counting colony-forming units. 
Day zero is defined as the time when cultures reached stationary phase (survival = 100%). Mean 
and standard deviation (n=3) are indicated in the graph. Images below are representative plates 
of the lowest dilution to score CFUs at day 7. (B) Overexpression of Hsp31, Hsp33 and Hsp34 
complements reduced chronological lifespan in Hsp gene deletion strains. hsp31∆, hsp33∆ and 
hsp34∆ cells were transformed with an empty vector (p416GPD) or with a vector encoding an 
HA-tagged version of the respective deleted protein (p416GPD/Hsp31-HA, p416GPD/Hsp33-HA 
and p416GPD/Hsp34-HA). Cultures were grown on selective rich media (SC-URA) until reaching 
stationary phase – considered day zero. An aliquot of each culture was serially diluted (5 fold) 
and spotted onto solid YPD media. A representative spotting plate after 4 days in culture is 
depicted. (C) Hsp31, Hsp33, Hsp34 expression was confirmed after 1 and 4 days of growth in 
stationary phase using an antibody against the HA tag. 
 
 
Figure 3.6. Venn diagrams representing the overlap between up- (A) or 
downregulated (B) genes in hsp31Δ, hsp32Δ and hsp33Δ versus wild-type cells at 
diauxic-shift.  
Differentially expressed genes with greater than 2 fold differences (p<0.05) were selected for 
analysis.  
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Figure 3.7. Gene ontology analyses of expression profiles of hsp31Δ, hsp32Δ and 
hsp33Δ. 
Overlapping Up- (D) or downregulated (E) genes obtained by venn diagrams (Fig. 3.6) were 
grouped in terms of gene ontology (GO). The most significant gene clusters are shown. 
Frequency is the percentage of overlapping genes that are clustered in a given ontology group, 
while the yeast genome frequency is the total percentage of genes annotated for that term in the 
parental strain.  
 
Table 3.1. Gluconeogenesis genes downregulated in hsp31∆, hsp32∆ and hsp33∆ 
vs wild-type cells 
 
 
In order to further confirm that the DEGs found in our gene expression analyses 
overlap with the reprogrammed genes at diauxic-shift, we compared our results to 
existing gene expression data available at ArrayExpress 89. We first compared existing 
log-phase expression profiles with diauxic-shift profiles, allowing us to determine which 
genes change in diauxic-shift (data not shown). Next, we compared this dataset to our 
“overlapping” dataset. This analysis revealed that ~62% of the genes in our dataset 
overlapped with the reprogrammed genes (Table 3.3). However, ~59% of these genes 
were anti-correlated, indicating that normal diauxic transition is impaired in the knockout 
Standard Name Systematic Name SGD description (summarized)
TDH3 YGR192C
Glyceraldehyde-3-phosphate dehydrogenase, isozyme 3; involved in glycolysis and 
gluconeogenesis
TDH1 YJL052W
Glyceraldehyde-3-phosphate dehydrogenase, isozyme 1; involved in glycolysis and 
gluconeogenesis
TDH2 YJR009C
Glyceraldehyde-3-phosphate dehydrogenase, isozyme 2; involved in glycolysis and 
gluconeogenesis
PCK1 YKR097W Phosphoenolpyruvate carboxykinase, key enzyme in gluconeogenesis
FBP1 YLR377C
Fructose-1,6-bisphosphatase, key regulatory enzyme in the gluconeogenesis 
pathw ay
MDH2 YOL126C
Cytoplasmic malate dehydrogenase, involved in the glyoxylate cycle and 
gluconeogenesis during grow th on tw o-carbon compounds
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strains (Table 3.3). Log and diauxic-shift expression profiles were downloaded from 
ArrayExpress (E-TABM-496) and subsequently analysed to calculate the fold change 
between these two conditions. DEGs higher than 2 fold (p<0.05) were divided in up- 
and downregulated groups and where compared to the overlapping genes obtained in 
(Fig. 3.6). Due to glucose limitation at diauxic-shift genes that are under glucose 
repression are derepressed. Indeed, we found that several DEGs are involved in 
glucose transport and metabolism, including MIG2, NRG2 and HXT5 (Table 3.4). MIG2 
and NRG2, which are involved in glucose repression, were upregulated in the knockout 
strains, whereas HXT5 – a glucose transporter induced at diauxic-shift 90 – was highly 
downregulated. Interestingly, expression of HXT4, another glucose transporter induced 
at diauxic-shift, was upregulated in the knockout strains, which may represent a 
compensatory mechanism due to reduced expression of HXT5.  
 
Table 3.2. Reserve carbohydrate biosynthesis genes downregulated in hsp31∆, 
hsp32∆ and hsp33∆ vs wild-type cells 
 
 
Table 3.3. Comparison of the 
overlapping DEGs obtained in 
this study with diauxic-shift 
expression profile 
 
 
Standard Name Systematic Name SGD description (summarized)
GLC3 YEL011W Glycogen branching enzyme, involved in glycogen accumulation
GLG2 YJL137C Glycogenin glucosyltransferase; self-glucosylating initiator of glycogen synthesis
GSY2 YLR258W
Glycogen synthase; expression induced by glucose limitation, nitrogen starvation, heat 
shock, and stationary phase
PGM2 YMR105C
Phosphoglucomutase; catalyzes the conversion from glucose-1-phosphate to glucose-
6-phosphate
GAC1 YOR178C
Regulatory subunit for Glc7p type-1 protein phosphatase (PP1), tethers Glc7p to Gsy2p 
glycogen synthase
GDB1 YPR184W
Glycogen debranching enzyme; contains glucanotranferase and alpha-1,6-
amyloglucosidase activities; required for glycogen degradation
ATH1 YPR026W Acid trehalase required for utilization of extracellular trehalose
HSP104 YLL026W
Disaggregase; heat shock protein that cooperates w ith Ydj1p (Hsp40) and Ssa1p 
(Hsp70) 
NTH1 YDR001C Neutral trehalase, degrades trehalose
NTH2 YBR001C Putative neutral trehalase, required for thermotolerance
PGM2 YMR105C
Phosphoglucomutase; catalyzes the conversion from glucose-1-phosphate to glucose-
6-phosphate
TPS1 YBR126C
Synthase subunit of trehalose-6-P synthase/phosphatase complex; synthesizes the 
storage carbohydrate trehalose
TSL1 YML100W
Large subunit of trehalose 6-phosphate synthase/phosphatase complex; Tps1p-Tps2p 
complex converts uridine-5'-diphosphoglucose and glucose 6-phosphate to trehalose
Glycogen biosynthetic process
Trehalose biosynthetic process
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Table 3.4. DEGs involved in glucose transport and metabolism 
 
 
To confirm whether glucose repression is enhanced in the knockout strains, we 
next transformed both wild-type and hsp31∆ strains with a vector containing LEU2 
under the control of the GAL1 promoter. We found that while expression of Leu2 
increased progressively over time upon galactose induction in the wild-type strain, 
hsp31∆ cells exhibited lower levels of Leu2 which did not increase over the timeframe of 
the experiment (Fig. 3.8). This suggests that glucose repression is enhanced in hsp31∆ 
in comparison to the wild-type strain, confirming that Hsp31 is required for glucose 
derepression.  
 
 
 
 
Gene Saccharomyces Genome Database description
hsp31∆ vs 
WT           
(fold change)
 hsp32∆ vs 
WT            
(fold change)
hsp33∆ vs 
WT           
(fold change)
HXT1
Low -affinity glucose transporter; induced by Hxk2p in the presence of 
glucose and repressed by Rgt1p w hen glucose is limiting
- 2,07 -
HXT3
Low -affinity glucose transporter; induced in low  or high glucose 
conditions
3,19 3,44 4,29
HXT4
High-aff inity glucose transporter, induced by low  levels of glucose 
and repressed by high levels of glucose 
5,74 5,7 5,17
HXT5
Moderate aff inity for glucose, induced in the presence of non-
fermentable carbon sources, induced by a decrease in grow th rate
-3,8 -11,4 -6,33
M IG2
Zinc f inger transcriptional repressor; cooperates w ith Mig1p in 
glucose-induced repression of many genes
6,49 8,38 7,94
HXK2
catalyzes phosphorylation of glucose in the cytosol; predominant 
hexokinase during grow th on glucose; functions in the nucleus to 
repress expression of HXK1 and GLK1 and to induce expression of its 
ow n gene
5,46 6,08 6,66
GLK1
Glucokinase, catalyzes the phosphorylation of glucose at C6 in the 
f irst irreversible step of glucose metabolism; one of three glucose 
phosphorylating enzymes; expression regulated by non-fermentable 
carbon sources
- -5 -3,34
RGT1
Glucose-responsive transcription factor that regulates expression of 
HXT genes in response to glucose; binds to promoters and acts both 
as a transcriptional activator and repressor  
- -2,61 -2,13
NRG2
Transcriptional repressor that mediates glucose repression and 
negatively regulates f ilamentous grow th
3,32 2,82 3,32
SKS1
Putative serine/threonine protein kinase; involved in the adaptation to 
low  concentrations of glucose independent of the SNF3 regulated 
pathw ay
3,24 6,89 3,78
STD1
Protein involved in control of glucose-regulated gene expression; 
interacts w ith kinase Snf1p, glucose sensors Snf3p and Rgt2p, TATA-
binding Spt15p; regulator of transcription factor Rgt1p
- 3 2,22
SNF3
Plasma membrane low  glucose sensor that regulates glucose 
transport; contains 12 predicted transmembrane segments and a long 
C-terminal tail required for induction of hexose transporters; also 
senses fructose and mannose; similar to Rgt2p
- -2,36 -
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Figure 3.8. GAL1 promotor repression is stronger in 
hsp31Δ.   
BY4741 and hsp31Δ cells were transformed with a vector expressing 
Leu2 under control of the GAL1 promoter (BG1805). The strains 
were grown until mid-log phase in media containing glucose (GAL1 
repression) and then shifted to media containing galactose (GAL1 
induction). Cultures were retrieved after 1, 2 and 4 hours of growth in 
galactose. 
 
Typical stationary phase characteristics are altered in HSP31 mini-family 
knockout strains 
 
Several changes that occur in post-diauxic phase are maintained in stationary 
phase 87. Therefore, we next evaluated whether typical characteristics of stationary 
phase were altered in the knockout strains. We first tested the thermotolerance of the 
strains to a 50ºC heat shock, which is an indicator of cellular steady-state defenses. 
Consistently, the knockout strains were less thermotolerant than the wild-type strain, 
exhibiting decreased viability within 10 minutes of heat shock (Fig. 3.9A). The thickness 
of the cell wall, known to increase in cells in stationary phase, was evaluated by 
resistance to the lytic enzyme zymolyase. Cells in stationary phase were incubated with 
zymolyase in a non-osmotic environment and monitored for optical density (OD) over 
time. As the cell wall is digested, cells burst and the OD decreases. We observed that 
the cell walls of HSP31 mini-family and GIS1 knockout strains were digested faster than 
those of the wild-type strain, indicating that the cell wall of the knockout strains was less 
resistant to zymolyase and therefore thinner (Fig. 3.9B).  
We next evaluated autophagy in the knockout strains at stationary phase by 
monitoring ATG8, which is among the autophagy genes downregulated in the knockout 
strains. Atg8 is involved in the formation of autophagosomes and during this process is 
degraded in the vacuole 91. We investigated autophagy using a GFP-Atg8 reporter 
construct under control of ATG8 promoter, which permits monitoring of both autophagy 
induction and autophagic flux as Atg8 is rapidly degraded in the vacuole while GFP is 
not 92. Anti-GFP immunoblot analysis allows detection of two protein bands, the higher 
molecular weight band corresponding to cytosolic GFP-Atg8 and the lower band 
corresponding to GFP-Atg8 degraded in the vacuole 93. We analysed autophagy in wild-
type, hsp31∆, hsp33∆ and hsp34∆ strains in both stationary and log phase. Strikingly, 
we observed impaired induction of autophagy in the knockout strains during stationary 
phase and reduced levels of basal autophagy during log phase (Fig. 3.9C). These 
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results indicate that autophagy is impaired in the absence of at least one of the Hsp31 
family members.   
Finally, we evaluated cell cycle progression in the knockout strains. To measure 
DNA content, we stained cells with propidium iodide and performed flow cytometry 
analyses and found a higher percentage of cells that failed to enter G0 in knockout cells 
(Fig. 3.9D).  
 
Autophagic response is impaired during carbon starvation in hsp31Δ cells 
 
As it was previously shown that HSP31 is induced in oxidative stress conditions 
80 and that levels of ROS increase at diauxic-shift, we considered the possibility that 
ROS might trigger the observed upregulation of HSP31, HSP32 and HSP33 at diauxic-
shift (Fig. 3.3). Intriguingly, oxidative stress induced by hydrogen peroxide failed to 
increase expression of HSP32 and HSP33, and only the highest concentration – 2mM – 
was able to induce HSP31 (Fig. 3.10A). Yeast viability decreased beyond this 
concentration so we did not exceed this concentration in our experiments (data not 
shown).  
Next, we tested whether the HSP31 mini-family was induced by starvation, 
another hallmark of diauxic-shift and stationary phase. HSP32 and HSP33 expression 
was highly induced by both nitrogen and carbon starvation, but it was higher in carbon 
starvation conditions (Fig. 3.10B). On the other hand, HSP31 was significantly 
upregulated only by nitrogen depletion (Fig. 3.10B). These results suggest that 
expression of the Hsp31 mini-family members during diauxic-shift and stationary phase 
is mainly regulated by starvation rather than oxidative stress. We next assessed 
whether the autophagy impairment that we observed in the knockout strains during 
stationary phase was also observed under nutrient (nitrogen or carbon) starvation or 
upon rapamycin treatment, which is a compound widely-used to induce autophagy via 
TORC1 inactivation 94. Cells expressing GFP-Atg8 were analysed before treatment and 
1, 3 and 5 hours post-treatment. As the autophagy phenotypes of the knockout strains 
were identical, we primarily focused our efforts on the hsp31∆ strain for the subsequent 
experiments. After one hour of rapamycin treatment we observed induction of 
autophagy which increased over time in both wild-type and hsp31∆ cells (Fig. 3.11A). 
We found that nitrogen depletion also induced autophagy in hsp31∆ cells, while 
autophagic induction and flux were maintained at basal levels during carbon starvation 
(Fig. 3.11A).  
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Figure 3.9. hsp31Δ, hsp32Δ, hsp33Δ and hsp34Δ cells fail to acquire typical 
stationary phase characteristics. 
Wild-type and gene deletion strains were analysed for resistance to heat stress (A), cell wall 
integrity (B), autophagy flux (C) and cell cycle (D). (A) Yeast cultures were grown in liquid media 
until stationary phase and subjected to a 50ºC heat shock for the specified time. Cultures were 
normalized to an OD600 of 0.3 and spotted onto solid media to measure viability. (B) Stationary 
phase cultures (48 hours growth) were incubated with zymolyase and cell wall digestion was 
monitored by measuring the OD600 every 10 minutes. (C) Mid-log (Log) and stationary phase 
(SP) cells expressing GFP-Atg8 under its endogenous promoter were lysed and analysed by 
immunoblotting. The presence of free GFP is an indicator of autophagic flux. (D) To quantify 
DNA content, cells in stationary phase were stained with propidium iodide and analysed by flow 
cytometry. The histogram shows propidium iodide fluorescence intensity of wild-type and 
knockout strains. Error bars represent standard deviation of the mean for each assay (n=3). 
Statistical analysis was performed using Student’s t-test (** p<0.01; * p<0.05). 
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Figure 3.10. Expression levels of HSP31, HSP32 and HSP33 under oxidative 
stress and starvation conditions.  
Parental strain BY4741 was grown until mid-log phase on synthetic complete media (SC) and 
was incubated with hydrogen peroxide at two different concentrations or washed and starved for 
carbon (SC-C) or nitrogen (SC-N). mRNA was isolated and gene expression levels were 
quantified via QPCR and normalized relative to TAF10 and UBC6 expression. Error bars 
represent standard deviation of three independent experiments. Statistical analysis was 
performed using Student’s t-test (*** P<0.001; ** P<0.01; NS, not significant). 
 
Next, we confirmed these findings by fluorescence microscopy and found that 
while hsp31Δ cells displayed faint GFP-ATG8 fluorescence signal in cytoplasm in the 
absence of glucose, wild-type cells displayed strong GFP-Atg8 signal localized to the 
vacuole (Fig. 3.11B). On the other hand, upon nitrogen starvation or rapamycin 
treatment GFP-Atg8 was localized to the vacuole in both wild-type and hsp31Δ cells 
(Fig. 3.11B). Similar immunoblot results were obtained in hsp33Δ and hsp34Δ (Fig. 
3.11C).   
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Figure 3.11. Autophagic response in hsp31Δ, hsp33Δ and hsp34Δ strains is 
impaired in carbon starvation conditions.   
(A-C) Wild-type and deletion strains expressing pr
ATG8
-GFP-Atg8 were grown until mid-log phase 
and treated with rapamycin or starved for carbon (SC-C) or nitrogen (SC-N) for the specified 
time. (A,C) Total lysates were analysed by immunoblotting using antibodies against GFP or a 
housekeeping control Pgk1p. (B) After 5 hours of incubation with rapamycin or starvation, GFP-
Atg8 localization was analysed by fluorescence and light microscopy. Scale bar represents 5 
µm.  
 
 
TORC1 signaling is perturbed in hsp31Δ cells 
 
Entry into post-diauxic phase and progression into stationary phase is 
orchestrated by nutrient-sensing signaling pathways. Two of the major signaling 
pathways associated with this transition are the TOR complex 1 (TORC1) and protein 
kinase A (PKA) 87,95–97. These two kinases, in addition to playing a role in cellular growth 
via translation and stress response repression, also negatively regulate autophagy 98–
101. Due to the dramatic gene expression changes observed in the knockout strains at 
diauxic-shift, we next asked whether one of these signaling pathways were 
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dysregulated in hsp31Δ strains by using Atg13 as a reporter. Atg13 is a key player in 
autophagy and is regulated via direct phosphorylation by PKA and TORC1 98,102,103. As 
TORC1 hyperphosphorylates Atg13, we monitored phospho-status based upon Atg13 
mobility in SDS-polyacrylamide gels 98,99,104. 
In stationary phase TORC1 is repressed and therefore the levels of Atg13 
phosphorylation decrease. As expected for the wild-type, Atg13 migrated faster in 
stationary phase (Fig. 3.12A). In hsp31Δ cells, the difference in Atg13 migration 
between log and stationary phase was reduced (Fig. 3.12A). This suggests that Atg13 
is more highly phosphorylated in hsp31Δ cells, possibly due to TORC1 hyperactivity. To 
confirm that the differences observed in migration were caused by phosphorylation, and 
not by other posttranslational modifications, we treated stationary phase Atg13 with ʎ-
phosphatase (Ppase). After Ppase treatment we observed that Atg13 from hsp31Δ cells 
migrated side by side with Atg13 from wild-type cells confirming that migrational 
differences in stationary phase were caused by phosphorylation (Fig. 3.12B). We further 
analysed the phosphorylation status of Atg13 under carbon and nitrogen starvation 
conditions. These conditions led to Atg13 dephosphorylation in both the parental and 
hsp31Δ strains. However, Atg13 migration in hsp31Δ was slower in all the conditions 
tested (Fig. 3.12C-D), suggesting a difference in phosphorylation-status between the 
strains, which was more pronounced under carbon starvation than nitrogen starvation. 
To investigate the activity of PKA we immunoprecipitated Atg13 and analysed 
phosphorylation by immunoblotting using a PKA substrate antibody [α-(P)PKA]. The 
levels of PKA-mediated Atg13 phosphorylation were similar between wild-type and 
hsp31Δ cells in the conditions tested (stationary phase, carbon and nitrogen starvation) 
(Fig. 3.12E-F), indicating that this process is not affected in the knockout strain. 
In total, these results suggest that TORC1 is dysregulated upon HSP31 deletion, 
which is more evident in stationary phase conditions. As heat shock also leads to 
TORC1 inactivation 105,106, we next assessed whether blocking TORC1 using rapamycin 
reverts hsp31Δ lack of thermotolerance. Using growth assays we observed that 
knockout cells treated with rapamycin exhibited decreased sensitivity to heat shock, 
indicating that TORC1 inhibition restores normal heat shock response in these cells 
(Fig. 3.13), further supporting the hypothesis that absence of HSP31 affects the normal 
upstream regulation of TORC1.  
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Figure 3.12. Atg13 phosphorylation is altered in hsp31Δ.   
(A) Protein extracts were collected from cultures at mid-log phase (Log) and stationary phase 
(SP). Migration of HA-Atg13 in SDS-polyacrylamide gels was assessed using an antibody 
against HA. An antibody for Pgk1 was used as control for protein loading. (B) HA-Atg13 from SP 
cell lysates was immunoprecipitated with α-HA and treated with ʎ-phosphatase (Ppase) and then 
run on SDS-polyacrylamide gel to analyse its migration. (C, D) Atg13 migration from cell lysates 
of cultures that were starved for carbon (SC-C) or nitrogen (SC-N) was analysed. (E, F) Atg13 
from Log and SP cultures (E) or from mid-log phase cultures that were starved for carbon (SC-C) 
or nitrogen (SC-N) (F) was immunoprecipitated with α-HA and analysed for PKA mediated 
phosphorylation using phospho-(Ser/Thr) PKA substrate antibody (α-(P)PKA). 
 
 
 
Chapter 3 
80  
 
Figure 3.13. Rapamycin reverts the lack of hsp31∆ thermotolerance.  
Yeast strains in mid-log phase were treated with DMSO or rapamycin for 3 hours and subjected 
to a 5, 10 and 20 minute heat shock at 50ºC. Cultures were serial diluted and spotted on media 
plates to analyse cell survival. 
 
Discussion 
This study provides novel insights into the function of HSP31 and, to our 
knowledge, provides the first functional analysis of the remaining members of the DJ-1 
superfamily in yeast: HSP32, HSP33 and HSP34. Our findings reveal that HSP31 and 
its orthologs are required for the transition from the log phase to post-diauxic phase. 
Cells enter diauxic-shift when glucose becomes limiting in liquid cultures, which leads to 
extensive metabolic and transcriptional reprogramming. Some of the changes that 
occur at this shift include induction of genes involved in aerobic respiration and stress 
protection and repression of genes involved in mRNA translation 86–88. We showed that 
HSP31, HSP32 and HSP33 expression strikingly increased when cells entered post-
diauxic phase and was maintained at high levels in stationary phase. The lack of these 
genes led to shorter chronological lifespan, revealing an important role of this mini gene 
family at diauxic-shift. Expression microarray profiling indicated that hsp31∆, hsp32∆ 
and hsp33∆ have an abnormal expression profile at diauxic-shift. Gene ontology 
clustering of the microarray data showed that the knockout strains were incapable of 
entering diauxic-shift; knockout cells were maintained in the glucose repressed state 
even though glucose was absent from the media. Functionally, the absence of one of 
the HSP31 mini-family members led to the inability of cells to acquire several 
characteristics of stationary phase, such as induction of autophagy and acquisition of a 
thick cell wall.  
We also found that nutrient starvation induces the expression of the Hsp31 mini-
family: nitrogen starvation induced all three genes tested (HSP31, HSP32 and HSP33), 
while carbon starvation only led to HSP32 and HSP33 upregulation. Although HSP31 
was not upregulated at mRNA level under carbon starvation, we cannot exclude that it 
is induced at the protein level. Consistent with our results, the E. coli EcHsp31 (the 
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closest HSP31 homologue in the DJ-1 superfamily) is also induced in stationary phase 
and when this gene is deleted, cell survival decreases during this phase 15. In addition, 
the Caenorhabditis elegans DJ-1 homologue DJR-1.2 is induced upon starvation and 
dauer stage (starvation-induced alternative developmental stage) 107. Interestingly, 
human leukemia cell lines depleted for DJ-1 have reduced viability in serum starvation 
conditions 22. 
One of the major signaling pathways implicated in diauxic-shift and further 
progression into stationary phase is TORC1 87,95,96,108. TORC1 is a nutrient sensitive 
kinase very well conserved from yeast to humans, and has been associated with ageing 
and when dysregulated in humans (mTORC1 – mechanistic TORC1) is implicated in 
several pathologies including cancer and neurodegeneration 109. TORC1 controls yeast 
growth by promoting processes such as transcription, protein translation and mRNA 
stability and repressing stress responses and autophagy 110. TORC1 signaling pathway 
has been extensively studied, but due to its complexity, there are still many unanswered 
questions, such as how the availability of carbon is signaled to TORC1 110. The study of 
this particular question is likely difficult due to the crosstalk with other signaling 
pathways like PKA (another key kinase that signals the entry into diauxic shift) and also 
due to their overlapping readouts. Much of what is known about the role of TORC1 is 
based upon the inhibition of its activity by rapamycin, which has enabled the 
understanding of the downstream actions of TORC1, independently of the upstream 
effectors. Nevertheless, rapamycin treatment revealed that TORC1 controls glucose 
metabolic pathways 111. Our data revealed for the first time that HSP31 mini-family 
members are potential TORC1 upstream effectors. We initially observed a dramatic 
transcriptional effect due to deletion of the Hsp31 mini-family members and the 
consequent absence of typical stationary phase characteristics. Interestingly, some of 
the phenotypes caused by deletion of HSP31 mini-family members, such as deficient 
G0 arrest and reduced thermotolerance, are similar to the ones observed by deletion of 
RIM15. RIM15 encodes a protein kinase that integrates signals from Sch9, PKA and 
TORC1 112 and transduces it to Gis1 (the transcription factor responsible for expression 
of post-diauxic-shift (PDS) genes 84) and to Msn2/Msn4 – transcription factors 
responsible for expression of stress-induced genes. Next, by monitoring GFP-Atg8 
processing, we found that autophagy in the knockout strains was completely blocked 
when the carbon source was depleted from the media, but it was identical to the wild-
type response upon rapamycin treatment and nitrogen starvation. This is consistent with 
the impairment observed in stationary phase, since the entry in this phase is 
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characterized by the depletion of any carbon source. These results indicate that Hsp31 
is involved in transducing the carbon starvation signal that leads to autophagy induction. 
It also shows that the autophagic machinery is working properly and importantly, that 
Hsp31 has no role downstream of TORC1.  
To further explore autophagy and dissect the pathway that is affected in the 
knockout strains, we assessed the kinase activity of TORC1 and PKA using Atg13 as a 
reporter. Atg13 is a key protein in autophagy that is a substrate for both kinases, and 
phosphorylation of Atg13 mediated by one of these kinases represses autophagy. Our 
results showed striking differences in terms of Atg13 phosphorylation levels mediated 
by TORC1 in stationary phase between the parental strain and hsp31∆ cells, 
suggesting that TORC1 is hyperactive in the knockout strain. We also found differences 
in TORC1 mediated phosphorylation in carbon starvation conditions and, unexpectedly, 
in nitrogen starvation as well, although to a smaller degree. Interestingly, the differences 
in phosphorylation levels were detected in log-phase cells growing in rich media, 
suggesting that deleting HSP31 not only blocks TORC1 inactivation upon carbon 
starvation and during stationary phase, but also that the basal activation state of 
TORC1 is higher. Furthermore, we confirmed that phosphorylation of Atg13 mediated 
by PKA is not affected by HSP31 deletion. Importantly, we found that the sensitivity of 
hsp31∆ cells to heat shock was decreased after TORC1 inactivation via rapamycin, 
supporting our genetic data. Altogether, our findings suggest that the Hsp31 mini-family 
modulates TORC1 activity in yeast, likely playing a role as negative regulators (Fig. 
3.13). Therefore, these proteins are likely required to regulate autophagy, a process 
that needs to be tightly controlled. Human DJ-1 has already been associated with 
autophagy, however the precise mechanisms underlying this are still unclear. In 
agreement with our data, it was found that loss of human DJ-1 leads to lower levels of 
basal autophagy 113. In contrast, loss of DJ-1 induces autophagy, whereas 
overexpression represses it 114,115. Further studies will be required to further elucidate 
the role of DJ-1 in autophagy.  
Overall, this study describes a novel role for the Hsp31 mini-family members at 
diauxic-shift. Deletion of these proteins led to impaired transcriptional reprogramming at 
diauxic-shift and an inability to acquire normal stationary phase characteristics, in 
addition to reduced chronological lifespan and a striking impairment of autophagy in 
stationary phase. Altogether, our study provides important insight into the function of 
DJ-1 family members, opening novel avenues for intervention in pathways that are 
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related both to normal ageing as well as disease, such as cancer and 
neurodegeneration. 
 
 
Figure 3.13. Hsp31 mini-family members modulate TORC1 activity. 
(A) Yeast cells grow exponentially (Logarithmic - log phase) in the presence of nutrient-rich 
media containing glucose. TORC1, a conserved kinase, positively regulates processes that 
contribute to growth, such as ribosome biogenesis and transcription, and represses processes 
related to stress, including autophagy. (B) Upon stress, treatment with rapamycin, or nutrient 
depletion (post-diauxic or stationary phase), TORC1 decreases its activity and, therefore, 
autophagy and stress genes are induced. In parallel, ribosome biogenesis and transcription are 
repressed. Our data suggest that Hsp31 mini-family members have a role in controlling the 
repression of TORC1 upon stress or carbon starvation.  
 
 
Materials and Methods  
 
Strains and genotyping 
All strains used in this study were derived from the parental BY4741, BY4742 or 
BY4743 strains (Appendix 3.4). The hsp31Δ strain was a kind gift from Marek 
Skoneczny (Institute of Biochemistry and Biophysics) and hsp32Δ was obtained by 
sporulation of the BY4743 strain heterozygous for the HSP32 deletion (Thermo 
Scientific Open Biosystems). hsp33Δ and hsp34Δ strains (in the BY4742 background) 
were generated by PCR-based gene disruption as previously described 116. Since the 
flanking regions of these genes are identical, the same pair of primers was used to 
amplify the MX cassettes and delete the genes. The primers used are listed on 
(Appendix 3.5). The strategy for gene deletion verification is represented in (Figure 
3.14) and consisted in performing the following PCR reactions: 1) Amplification of 
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HSP32 and HSP33 – forward primer complementary to HSP32, HSP33 and HSP34 
(HSP32/33/34F) together with a reverse primer that hybridizes with HSP32 and HSP33 
3’ flanking regions (HSP32/33R); 2) Amplification of HSP34 – forward primer 
HSP32/33/34 and a reverse primer specific to HSP34 3’ flanking region (HSP34R); 3) 
Amplification of the cassette integrated either on HSP32 or HSP33 locus (forward 
primer complementary to the cassette (MX4F) and HSP32/33R); 4) Amplification of the 
cassette integrated in HSP34 locus (MX4F + HSP34R).  
 
Figure 3.14. Schematic representation of the PCR strategy to screen for hsp32Δ 
hsp33Δ and hsp34Δ clones.  
HSP32, HSP33, HSP34 and flanking regions are represented. White bars indicate the presence 
of non-conserved nucleotides between the sequences of the three genes. When either HSP32 or 
HSP33 is deleted, amplification is positive for PCR reaction 1, 2 and 3 and negative for reaction 
4. When HSP34 is deleted an amplicon is obtained in reactions 1 and 4, while the other two are 
negative. To differentiate between HSP32 or HSP33 deletion, the PCR products obtained in 
reactions 1 and 3 were digested with Bsg1, as this restriction site is only present in HSP32 3’ 
flanking region.    
 
To distinguish between HSP32 and HSP33, the 3’ flanking region was amplified and 
digested with BsgI, which had a unique restriction digestion site on HSP32 flanking 
region. To further confirm the knockout strains, the flanking regions of the deleted 
genes were analysed by DNA sequencing and real time quantitative PCR (QPCR). The 
knockout strains were crossed to generate a heterozygous diploid quadruple knockout. 
By sporulation and tetrad dissection of the diploid strain, wild-type and single knockouts 
strains were selected (Lx strains). Experiments were performed on the original strains 
and repeated with Lx strains with no differences observed among the phenotypes 
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analysed. Microarrays were performed with RNA retrieved from Lx strains. The 
remaining knockout strains used: gis1Δ, sod1Δ and yap1Δ were obtained from 
EUROSCARF (Appendix 3.4). 
 
Plasmids  
HSP31, HSP32, HSP33 and HSP34 open reading frames (ORFs) were subcloned 
using the Gateway® Cloning technology. ORFs were moved from entry clones (kindly 
provided by Tony Hazbun, Purdue University) into the expression vector pAG416GPD-
ccdB-HA (Addgene). The plasmid pRS316 GFP-Atg8 117 was kindly given by Yoshinori 
Ohsumi (Tokyo Institute of Technology) and pRS315 HA-Atg13 by Daniel Klionsky 
(University of Michigan) 118. Both genes are under control of their endogenous 
promoters. The plasmid BG1805 (encoding the Leu2-His6-HA-protease-3Csite-ZZ 
domain) was obtained from the ORF library (Thermo Scientific Open Biosystems). The 
protein is expressed under control of the GAL1 promoter.  
 
Media and growth conditions 
Yeast strains were grown on standard media: YPD (2%), synthetic complete media 
containing all the amino acids (SC) or lacking uracil (SC-URA) or leucine (SC-LEU). SC 
contains yeast nitrogen base (YNB), 2% glucose and a mixture of all the amino acids or 
a URA or LEU drop out powder. For starvation experiments, cultures were grown until 
mid-log phase in SC, SC-URA or SC-LEU, washed once with water and then were 
resuspended either on carbon starvation media (SC-C), which is the respective 
synthetic complete media without any carbon source, or resuspended on nitrogen 
starvation media (SC-N) that contains of 0.17% of YNB without amino acids and 
ammonium sulfate and glucose at 2%. Rapamycin (Sigma) was added to mid-log phase 
cultures growing on SC-URA at a final concentration of 200 ng/ml. For GAL1 induction 
analysis, cultures were grown in SC-URA with 2% glucose until mid-log phase, washed 
and resuspended in SC-URA with 2% galactose. Cultures were harvested for protein 
extraction at the indicated time points. Optical densities at wavelength 600 nm (OD600) 
were measured on a microplate reader (Tecan Infinite M200TM).  
 
Quantitative real-time PCR (QPCR) 
For oxidative stress treatments, liquid cultures of cells in mid-log phase were treated 
with hydrogen peroxide (0.5 mM and 2 mM) for one hour. Starvation was performed as 
described above for one hour. After treatment, cells were harvested, pelleted and stored 
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at -80ºC until needed. RNA was extracted using Qiagen Rneasy Midi kits following 
manufacturer instructions. Genomic DNA contamination was removed from RNA using 
Turbo DNAse (Ambion®) according to the manufacturer’s protocol. 500 ng of total RNA 
was used as a template to synthesize cDNA with the Qiagen QuantiTect® Reverse 
Transcription kit. To insure that RNA had no genomic DNA contamination a control 
reaction was included in which no reverse transcription was carried out. Primers used 
for QPCR are listed in Table S5. Reactions were carried out using a LightCycler Real-
Time PCR System (Roche) with the Thermo Scientific Maxima SYBR Green/ROX 
qPCR Master Mix (Thermo Fisher Scientific Inc.). Primers were analysed for specificity 
and efficiency. PCR efficiencies ranged from 0.80 to 1.0. Specificity was assessed by 
melting curve profile analysis; for HSP32 and HSP33 primers, due to their high 
homology, specificity was ensured by the absence of amplification when cDNA of the 
respective knockout strain was used as template. The crossing thresholds (CT) were 
calculated by the second derivative method using the LightCycler® Relative 
Quantification Software. The relative quantification was corrected for PCR efficiency. 
TAF10 and UBC6 were used as housekeeping genes to normalize the cDNA input 
between samples. Three independent cDNA samples were analysed. Statistical 
significance was determined using Student’s t-test.   
 
Microarray analysis and validation 
Wild-type, hsp31Δ, hsp32Δ and hsp33Δ were harvested when cultures reached diauxic-
shift. RNA was obtained as described above for QPCR. Three independent RNA 
samples of each strain were used. RNA integrity was determined on the Agilent 2100 
bioanalyser. cDNA was synthetized from total RNA and amplified as fluorescent cRNA 
(cyanine 3-labeled CTP) using Agilent's Low Input Quick Amp Labeling Kit (one color 
label) following manufacturer instructions. Labeled cRNA was purified and hybridized to 
Agilent yeast gene expression microarrays (containing 6256 60-mer probes). Scanning 
was done on GenePix 4200A and normalization was performed in ArrayTrackTM using 
mean median scaling without background subtraction. wild type expression profiles 
were compared individually to each knockout strain profile. Statistical significance was 
obtained using the Welch’s t-test in ArrayTrackTM. Technical validation of the 
microarrays was performed by relative quantification of the expression of 11 genes by 
QPCR, using as a template cDNA obtained from the RNA used for the microarrays. The 
QPCR primers are listed in Table S5. Gene ontology was analysed using the online 
DAVID Functional Annotation Tool 119 (http://david.abcc.ncifcrf.gov/). 
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Survival assays 
Sensitivity to oxidative stress or thermotolerance was evaluated by spotting assays. 
Fresh colonies were grown in liquid YPD overnight, serially diluted, normalized to an 
OD600 of 0.1 and spotted on solid SC media containing hydrogen peroxide at different 
concentrations (1.6 mM and 2.3 mM). For heat shock, cultures were normalized for the 
number of cells and incubated at 50ºC at the indicated time points. For chronological 
lifespan determination, cultures were grown on SC media containing 2% glucose, 
diluted back to synchronize their growth and allowed to grow until cultures cease 
dividing (beginning of stationary phase). This time point was considered as day zero. 
Survival was measured by counting colony forming units (CFUs) or by spotting assays, 
considering 100% survival, the number of CFU or the spots growth at day zero. CFU or 
spotting assays were performed by taking an aliquot of each culture at the indicated 
time points, serial diluting and plating or spotting the dilutions on YPD plates.  
 
Zymolyase assay  
Cells were collected by centrifugation and resuspended on Tris-HCl (10mM) containing 
β-mercaptoethanol (40 mM) and 50ug/ml of zymolyase-20T (Seikagaku) and incubated 
at 30ºC. OD600 was measured every 10 minutes.  
 
Cell cycle analysis 
Cells in early stationary phase were fixed and stained with propidium iodide (PI) as 
previously described 120. Briefly, cells were pelleted and resuspended by vortexing in 
cold 70% ethanol. After fixation, they were washed and resuspended on sodium citrate 
pH 7, containing RNAse A (Sigma) to a final concentration of 0.1 mg/ml. After 2 hours of 
incubation at 37ºC, cells were stained with propidium iodide (final concentration 4 
µg/ml) and analysed by flow cytometry on a BD LSR FortessaTM and detected on the 
575/26 nm channel. DNA content was quantified on FlowJoTM v9.6.2.  
 
Immunoblotting, immunoprecipitation and kinase assays 
At the indicated time points, the volume of cells equivalent to OD600=1.5 was collected 
and precipitated with TCA. For precipitation with TCA, cells were resuspended in 1 ml of 
media and TCA was added to a final concentration of 10%. The samples were 
incubated 20 minutes at -20ºC and subsequently were centrifuged at 15000 g for 3 min. 
The pellet was washed twice with 500 ul of acetone and air dried. The pellet was 
resuspended in MURB (50 mM sodium phosphate, 25 mM MES, pH 7.0, 1% SDS, 3 M 
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urea, 0.5% 2-mercaptoethanol, 1 mM sodium azide) and disrupted by vortex with glass 
beads. Before loading the samples into the SDS-polyacrylamide gel, the samples are 
incubated 10 min at 70ºC and centrifuged at 10000 for 5 minutes to pellet unlysed cells. 
Protein extracts were separated by SDS-polyacrylamide gel electrophoresis, transferred 
to nitrocellulose membranes (Bio-Rad) followed by immunoblotting with α-GFP (UC 
Davis/NIH NeuroMab Facility), α-HA (Santa Cruz Biotechnology Inc.) or α-Pgk1 
(Invitrogen) antibodies overnight depending on the protein of interest. α-GFP was used 
at a dilution of 1:1000 followed by incubation with α-Mouse Ig horseradish peroxidase 
conjugated antibody (Amersham Bioscience, Piscataway, NJ). For HA-Atg13 
immunoprecipitation, the volume corresponding to an OD600=7 was harvested and 
lysed. The resulting protein extract was incubated with α-HA (Roche Applied Science) 
for 3 hours followed by one hour incubation with Protein G agarose beads (Invitrogen) 
with rotatory agitation at 4ºC. Beads were washed 6 times, resuspended on 2x loading 
buffer (200mM Tris-HCl, 8% SDS, 40% glycerol, 0.4% bromophenol blue, 6% -
mercaptoethanol), boiled at 95ºC for 10 minutes and loaded on an SDS-polyacrylamide 
gel. After protein separation, the protein extracts were transferred to nitrocellulose 
membranes and blotted for phospho-(Ser/Thr) PKA substrate antibody (Cell Signaling) 
at the diltution 1:500 overnight followed by incubation at room temperature with α-
Rabbit Ig horseradish peroxidase conjugated antibody (Amersham Bioscience, 
Piscataway, NJ). After incubation with the secondary antibody and exposure to X-ray 
film, the membrane was washed with a stripping solution (25 nM glycine hydrochloride, 
SDS 1%, pH 2) and incubated with α-HA (Santa Cruz Biotechnology, Inc). For 
phosphatase treatment, HA-Atg13 was immunoprecipitated and incubated with 200 
units of ʎ phosphatase (New England Biolabs) for one hour at 30ºC and subsequently 
run on SDS-polyacrylamide gel electrophoresis followed by immunoblotting as 
described above.  
 
Fluorescence microscopy 
After 5 hours of starvation or rapamycin treatment, GFP-Atg8 expressing cells were 
observed on a Zeiss Axiovert 200M microscope, either to generate bright field or 
fluorescence images using a 100X objective. Images were further processed on ImageJ 
software (http://rsbweb.nih.gov/ij/index.html).  
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Measurement of ROS 
To quantify ROS, 5x106 cells/ml cells were incubated in the dark at 30ºC with 5 µM 
dihydroethidium (DHE)(Molecular Probes) for 10 minutes and washed 3 times with 
PBS, or incubated with dihydrorhodamine 123 (DHR 123) (Molecular Probes) at 15 µM 
for 90 minutes and washed 1 time with PBS, followed by staining with propidium iodide 
(500ug/ml) to exclude dead cells for 10 minutes and washed 3 times with PBS. Positive 
cells were counted by flow cytometry.  
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Chapter 4. DJ-1 modulates huntingtin aggregation and toxicity 
in models of Huntington’s disease 
 
Abstract 
Neurodegenerative diseases such as Parkinson’s (PD) and Huntington’s 
disease (HD) share common pathogenic mechanisms including the misfolding and 
aggregation of proteins. Molecular chaperones are the first line of defense against 
misfolded proteins and thus are potential drug targets against neurodegeneration. 
Mutations in the DJ-1 protein are associated to familial PD. DJ-1 has been proposed to 
function as a redox-regulated chaperone that prevents α-synuclein aggregation. Here, 
we investigated whether DJ-1 also plays a role in HD. Overexpression of DJ-1 in yeast 
and Drosophila suppressed the toxicity of mutant huntingtin (Htt). DJ-1 expression 
levels and oxidation state were abnormally increased in brains of HD patients and 
various experimental models of HD. DJ-1 directly interacted with mutant Htt and 
modulated polyglutamine aggregation and toxicity in a redox-dependent manner. 
Altogether, our findings support a general role for DJ-1 as a redox-regulated chaperone 
and provide the basis for further studies into the protective effect of DJ-1 in 
neurodegenerative disorders and other human pathologies involving protein misfolding 
and aggregation. 
 
Introduction 
Huntington’s disease (HD) is caused by the expansion of a CAG repeat in the 
IT-15 gene, which encodes a polyglutamine (polyQ) tract in the N-terminal region of the 
huntingtin (Htt) protein 1. The CAG repeat number is polymorphic in the general 
population, with repeat lengths ranging from 6 to 35. When the polyQ tract exceeds 35 
glutamines, Htt becomes prone to misfold and aggregate, and individuals develop HD. 
The length of the polyQ expansion correlates directly with Htt aggregation in vitro and 
with severity of the disease in HD patients, and inversely with age of disease onset 2.  
The first line of defense against misfolded proteins is represented by molecular 
chaperones that have the ability to help proteins in the folding process 3. Molecular 
chaperones are able to modulate polyQ aggregation and toxicity in vitro and in vivo 4–6. 
Therefore, they are considered as potential therapeutic targets for HD 5. Redox-
regulated chaperones are a specific class of chaperones that are activated by oxidation 
instead of ATP. These are particularly important in stress conditions in which the levels 
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of ATP are low and the intracellular space becomes more oxidative, such as 
Parkinson´s disease (PD), HD and other neurodegenerative disorders 7,8. 
DJ-1 is a protein which mutation has been associated with Parkinson’s disease 
(PD) 9,10. It is thought to play a role as a redox-dependent chaperone 11,12, as well as 
numerous functions generally related with protection against oxidative stress (described 
in further detail on Chapter 3). Mild oxidation of DJ-1 has been associated with its 
activation, whereas extensive oxidation is thought to cause its dysfunction (Fig. 4.1) 13. 
Interestingly, ageing causes overoxidation of DJ-1 in different models and human brain 
samples 14. Moreover, DJ-1 is irreversibly oxidized at Cys106 in the brains of patients 
with PD and Alzheimer’s disease (AD), suggesting that DJ-1 may be not only linked to 
familial PD but also may contribute for the pathogenesis of AD and idiopathic PD 15. 
 
 
Figure 4.1. Proposed functions for human DJ-1 associated with the major 
oxidized forms of cysteine 106. 
The human DJ-1 can be oxidized in several cysteine and methione residues. Different oxidation 
status of the cysteine residue 106 is likely related with different roles played by DJ-1. Cysteine 
106 can be oxidized to cysteine-sulfenic (SOH) to cysteine-sulfinic (SO2H) or cysteine-sulfonic 
acid (SO3H). Scheme adapted from 
13
. 
 
Here, we provide data that support DJ-1 as a potential therapeutic target for HD. 
We demonstrate that DJ-1 expression and oxidation is abnormally increased in the 
human HD brain, in the brain of an HD mouse model and in various HD cell models. 
Importantly, DJ-1 overexpression conferred protection against toxicity in Drosophila and 
yeast models of HD. Furthermore, we found that DJ-1 directly interacted with an 
expanded fragment of Htt exon 1 in the test tube and in cell models, providing a basis 
for the effects of DJ1 in Htt aggregation and toxicity. Our work serves as the base for 
future studies to elucidate the precise mode of action of DJ-1 during HD, as well as to 
confirm its validity as a therapeutical target for HD.  
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Results 
 
DJ-1 overexpression ameliorates mutant Htt toxicity in yeast and fruit flies 
 
To test whether DJ-1 plays a role in HD pathogenesis, we first interrogated its 
potential function in Saccharomyces cerevisiae and Drosophila melanogaster models of 
HD. As already mentioned in Chapter 1, expression of a mutant Htt fragment with an 
expanded polyQ stretch (Htt72Q) leads to Htt aggregation and cellular toxicity in yeast 
(Fig. 4.2A). We found that overexpression of Hsp31 – one of the yeast DJ-1 
homologues – suppresses Htt72Q toxicity (Fig. 4.2A), which correlated with a reduction 
in aggregated mutant Htt protein (Fig. 4.2B). Information about the yeast DJ-1 
homologues can be found on Chapter 3. In contrast, overexpression of DJ-1 led to an 
increase in Htt72Q aggregation and did not prevent Htt toxicity. We could not determine 
whether DJ-1 enhanced Htt toxicity, as Htt72Q completely suppresses the yeast growth.  
 
Figure 4.2. Modulation of mutant Htt aggregation and toxicity by human DJ-1 and 
its yeast homologue Hsp31.  
(A) Hsp31 overexpression protects yeast against Htt72Q toxicity. Yeast cells expressing Htt72Q 
were independently transformed with DJ-1, Hsp31 or an empty vector. Equal numbers of cells 
were serially diluted five-fold and plated on media containing glucose to assess cell numbers 
and galactose to induce expression of Htt72Q. Control cells carrying empty vector and 
expressing Htt25Q were used as reference for normal cell growth. (B) Human DJ-1 and Hsp31 
modulate mutant Htt aggregation. Protein extracts were subjected to SDS-PAGE for detection of 
soluble Htt72Q or filter trap to detect SDS-insoluble Htt, followed by immunoblotting using an 
anti-GFP antibody.  
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Figure 4.3. Overexpression of DJ-1α ameliorates neurodegeneration in HD model 
flies.  
Quantification of mean rhabdomeres (± SEM) per ommatidum in flies pan-neuronally expressing 
both Htt93Q and either DJ-1α or DJ-1β under the control of the elavGAL4 driver. Overexpression 
of DJ-1α at day 1, 4, and 7 post eclosion (F1,48 = 88.52, p < 0.0001) (A), and DJ-1β (F1,47 = 1.59, 
P = 0.2138) (B) Statistical significance was assessed by a one-way ANOVA followed by a 
Bonferroni post hoc test. n = 5–13 samples per genotype (****p < 0.0001). Error bars represent 
standard deviation. 
 
DJ-1 expression and its oxidation is increased in the HD brain and in cell 
and animal models of HD 
 
Human HD frontal cortex (Vonsattel Grade 2), but not the cerebellum of the 
same patients, showed a significant increase in DJ-1 levels versus age-matched 
controls (Fig. 4.4 A-F). Seventeen weeks-old R6/2 HD mice (overexpressing mutant Htt 
exon 1) also showed higher levels of DJ-1 in the frontal cortex, but not in the cerebellum 
(Fig. 4.4 G-L). At this age, HD behavioural and pathological features are already 
present. These results were confirmed in three different cell models of HD, also 
expressing Htt exon 1 under different types of promoters (data not shown). 
Irreversible oxidation of DJ-1 at Cys106 (sulfonate) was significantly increased 
in the frontal cortex (Fig. 4.5) of HD patients, consistent with previous reports on DJ-1 
oxidation in PD and AD patients brains 15.  
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Figure 4.4. DJ-1 expression is increased in the frontal cortex of HD patients and 
R6/2 mouse tissue. 
Immunoblot analysis showing expression levels of DJ-1 in the frontal cortex (A,G) and 
cerebellum (D,J) of brains of HD patients (A-F) and R6/2 mouse model (G-L). Their respective 
loading controls (coomassie gels B,H and E,K) and band intensity quantification (C,I and F,L) 
(DJ-1 bands were normalized versus loading control signals) are shown. Error bars represent 
standard deviation. Statistical significance was determined by means of an unpaired t-test (*P < 
0.05, n = 5, frontal cortex and cerebellum, HD = Huntington’s disease patient tissue and C = age 
matched control tissue).  
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Figure 4.5. Enhanced DJ-1 oxidation in the frontal cortex of HD brain tissue. 
Immunoblot analysis of frontal cortex (A) and cerebellum (D) tissues using an antibody against 
DJ-1 oxidised at cysteine 106. (C, D) Corresponding coomassie gels (loading control) and the 
respective graph showing the quantification of the bands intensity normalized versus the loading 
control. (F) Error bars represent standard deviation. Statistical significance was determined by 
means of an unpaired t-test (n=5 patients and control samples, *P< 0.05 for frontal cortex and 
P= 0.13 for cerebellum).  
 
DJ-1 directly modulates aggregation and toxicity of mutant Htt in an 
oxidation-sensitive manner 
 
We next evaluated whether DJ-1 modulated mutant Htt toxicity and aggregation 
in mammalian systems. Surprisingly, in contrast to the results obtained in yeast and 
flies, DJ-1 significantly increased the toxicity and the number of cells with Htt97Q-mRFP 
aggregates in HeLa cells (Fig. 4.6A and C) and astrocytes (Fig. 4.6B and D). These 
results were further supported by filter trap assays, which indicated a trend towards an 
increase in SDS-insoluble Htt aggregates. Although it did not reach statistical 
significance, higher levels of Htt97Q-mRFP were retained in a filter when co-expressed 
with DJ-1 in HeLa cells (Fig. 4.6E). DJ-1 transfection was confirmed by immunoblotting 
analysis (data not shown).  
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Figure 4.6. DJ-1 increases mutant Htt aggregation and toxicity in an oxidation-
dependent manner. 
HeLa cells (A,C,E) and primary astrocytes (B,D) were transfected with Htt93Q in combination 
with either an empty vector or a vector containing DJ-1. Cells were treated with 5 μM of the pro-
oxidant antimycin A or 100μM hydrogen peroxide (H2O2) or left untreated as a control. After 3 
days of transfection, cells were analysed by microscopy to score aggregate-positive cells (% of 
cells with aggregates), (A,B) or were analysed for toxicity (C,D). Cell death was measured by 
scoring abnormal nuclear morphology of cells co-transfected with DJ-1 or control vector and 
HttQ97-mRFP. The % of cell death was normalized by the cell death of untreated cells 
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transfected with DJ-1 and Htt97Q.(A-D) Error bars represent standard deviation. One sample t-
test was used for statistical analysis (*p < 0.05, **p <0.01 and ***p <0.001). (E) DJ-1 
overexpression under mild oxidative stress decreases the SDS insoluble aggregates detected on 
a filter trap assay. Immunoblot analyses were performed with an anti-Htt antibody. The graph 
represents the mean of three independent experiments and the error bars represent the 
standard deviation. Statistical analysis was performed using One-sample t-test. 
 
We next asked whether this effect of DJ-1 on Htt was due to direct interaction 
between the two proteins. We found that endogenous or exogenous DJ-1 co-localized 
with Htt in HeLa cells (Fig. 4.7B-D) and occasionally surrounded Htt97Q aggregates in 
a ring-like pattern (Fig. 4.7C and D), which were found more frequently when DJ-1 was 
overexpressed. To assess whether this interaction occurred in living cells we used the 
bimolecular fluorescence complementation (BiFC) assay, which we had previously 
developed to visualize Htt oligomerization and aggregation 18. We transfected 
constructs encoding either a Htt exon1 fragment (with either 25Q or 103Q tracts) or DJ-
1 fused to two non-fluorescent halves of the Venus fluorescent reporter into human 
neuroglioma H4 cells (Fig. 4.8A). If DJ-1 and Htt interact, the non-fluorescent halves are 
brought together and reconstitute the functional Venus fluorophore. Confirming our 
previous results, DJ-1 not only interacted directly with both Htt25Q and Htt103Q (Fig. 
4.8B,C), but also DJ-1 co-aggregated with Htt103Q. While DJ-1 did not modify the 
number of aggregates per cell (Fig. 4.8D) or the percentage of small- and medium-size 
aggregates (<3 µm), it produced a significant increase in the percentage of large 
aggregates (>3 µm) (Fig. 4.8E).  
Consistent with the results obtained in HeLa cells and primary astrocytes, 
Htt103Q toxicity was significantly increased upon co-expression of DJ-1 Htt103Q BiFC 
constructs. Interestingly, DJ-1 expression also increased Htt25Q toxicity.  
Our results strongly suggest that DJ-1 interacts with Htt and enhances its 
aggregation in mammalian cell models, whereas overexpression of the organism-
specific DJ-1 homologs in yeast and fly models of HD is protective. We hypothesized 
that DJ-1 exerted different functions depending on its oxidation status, since it is well 
established that oxidation affects directly the chaperone function of DJ-1 13. HeLa cells 
or primary astrocytes (co-transfected with Htt97Q and an empty vector or a DJ-1 
plasmid) were exposed to sub-lethal doses of oxidative stressors: hydrogen peroxide 
(H2O2) or antimycin A. The higher levels of Htt97Q aggregation and toxicity caused by 
DJ-1 overexpression were reduced back to basal levels upon treatment with H2O2 or 
antimycin A (Fig. 4.8A-D). Filter trap assays further supported these results (Fig. 4.8E). 
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Figure 4.7. Endogenous and exogenous DJ-1 occasionally co-localize with HttQ97 
inclusion bodies in HeLa cells.  
(A) Untransfected control HeLa cells after staining with a DJ-1 antibody. (B) DJ-1 staining after 
co-transfection with HttQ25-mRFP and the empty vector. (C) DJ-1 staining after co-transfection 
with HttQ97-mRFP and the empty vector. (D) DJ-1 staining after co-transfection with HttQ97-
mRFP and DJ-1 vector. White arrowhead points to DJ-1 surrounding an aggregate in a ring-like 
structure. Scale bar represents 50 µm. 
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Figure 4.8. DJ-1 interacts with mutant Htt and potentiates its toxicity in 
mammalian cells. 
(A) Representation of Htt and DJ-1 BiFC constructs. (B-F) H4 cells were transfected with 
Htt25Q-Venus1 together with Htt25Q-Venus2 or DJ-1-YFP2 (B and F) or Htt103Q-Venus1 in 
combination either with Htt103Q-Venus2 or DJ-1-YFP2 BiFC constructs (B-F). After 24 hours, 
cells were analysed by flow cytometry (B) and widefield fluorescence microscopy (C-E). (D,E) 
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The number of aggregates per cell was counted and classified according to their longer diameter 
in three classes: smaller than 1 µm, larger than 1 µm but smaller than 3 µm, and larger than 3 
µm. Scale bar, 20 µm. Statistical significance was determined by means of Student t-test. 
Results depicted are the mean ± SEM of 3 independent experiments (*p < 0.05). (F) Cell toxicity 
after 24 hours determined by the levels of extracellular adenylate kinase activity. Statistical 
significance was assessed by means of a one-way ANOVA followed by a Student-Newman-
Keuls post hoc test. Results depicted are the mean ± SEM of 3 independent experiments (* p < 
0.05 vs 25Q/25Q; # p < 0.05 vs 103Q/103Q).  
 
 
Figure 4.9. Modulation of Htt aggregation by DJ-1 is regulated by cysteine 106 
redox status.  
HeLa cells (A) and primary astrocytes (B) were co-transfected with HttQ97-mRFP and wild-type 
DJ-1 or C106S-DJ-1 constructs. Transfected cells were treated with 100 µM of H2O2 or 5 µM of 
antimycin A or left untreated. The number of cells with aggregates was counted after 3 days of 
transfection. Error bars represent standard deviation. Unpaired t-test was performed for 
statistical analysis (*P < 0.05, **P <0.01 and ***P <0.001, n = 3-6) 
 
As mentioned above, oxidation of DJ-1 has been shown to have an important 
role in the activation of DJ-1 function, specially the oxidation of the cysteine residue 106 
(Cys106) 13. Co-expression of HttQ97-mRFP with a mutant version of DJ-1, in which 
Cys106 was replaced by a serine (C106S-DJ-1) that cannot be oxidized, increased the 
formation of aggregates compared to cells co-transfected with wild-type DJ-1 both in 
HeLa cells (Fig. 4.9A) and primary astrocytes (Fig. 4.9B). In addition, it increased 
cellular toxicity and the number of aggregates per cell (data not shown). As expected, 
Htt97Q-mRFP aggregation and toxicity were not changed upon exposure to H2O2 or 
antimycin (Fig. 4.9A, B). Altogether, our results indicate that modulation of Htt 
aggregation and toxicity by DJ-1 depends on its oxidation state.  
We next tested whether DJ-1 was able to modulate Htt oligomerization and fibril 
formation in vitro. For that, we incubated recombinant DJ-1 (both oxidized and non-
oxidized forms) in the presence of Htt53Q and analysed the formation of oligomers and 
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fibers by atomic force microscopy (data not shown). We found that non-oxidized DJ-1 
significantly enhanced Htt53Q oligomerization and fibril formation. The oxidized form of 
DJ-1 had no effect on Htt oligomerization, but slightly decreased its fibrillization. These 
results further support that DJ-1 modulates Htt aggregation in a redox-dependent 
manner.  
 
Discussion 
In our study, we identified a potential novel role for DJ-1 in modulating 
aggregation and toxicity of polyQ-expanded Htt in a redox-dependent manner. We 
found that DJ-1 homologs in yeast and Drosophila (Hsp31 and DJ-1α, respectively) 
suppress mutant Htt toxicity. Hsp31 not only suppressed Htt toxicity but also caused a 
reduction in the levels of SDS-insoluble Htt. In contrast, heterologous expression of 
human DJ-1 in yeast resulted in increased levels of SDS-insoluble Htt. One possible 
explanation for this intriguing result is that human DJ-1 might be dysfunctional in yeast, 
possibly due to aberrant folding, defects in essential post-translational modifications, 
abnormal interactions with yeast proteins or even because of its oxidation state.  
We found that DJ-1 was significantly more abundant and more oxidized in the 
frontal cortex of HD patients and in several HD models, including R6/2 HD mice. 
Interestingly, DJ-1 has already been shown to be upregulated and oxidatively damaged 
in the brains of patients with other neurodegenerative diseases, such as PD and 
Alzheimer’s disease 15,19,20. It is still unclear why DJ-1 levels are elevated in these 
diseases. 
We showed that DJ-1 physically interacts with Htt (both WT and mutant forms) 
and co-aggregates with the mutant form. In contrast to what we observed with Hsp31 
overexpression in yeast, DJ-1 exacerbated Htt aggregation. This aggregation-
enhancing action likely does not contribute to eliminate toxic misfolded protein species 
or to shift the balance to less toxic Htt species, since we observed an increase in 
toxicity. DJ-1 effects on Htt were dependent on cys106 oxidation state, consistent with a 
redox-dependent chaperone function of DJ-1 12. 
Although our results strongly suggest that DJ-1 modulates Htt toxicity and 
aggregation via a direct interaction, possibly as a redox-dependent chaperone, it is 
unclear why DJ-1 did not protect mammalian cells against mutant Htt toxicity. It is also 
unclear why DJ-1 interacted with Htt in the absence of mild oxidative stress, since we 
were expecting that DJ-1 would bind to Htt only after Cys106 oxidation, as redox-
dependent chaperones need to be oxidized in order to bind to their targets 7. 
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Nevertheless, we hypothesize that in the initial stages of HD, in which ROS are likely 
high 21, DJ-1 is upregulated and oxidized in cys106 as a protective response. With the 
progression of the disease, and further increase in the generation of ROS, DJ-1 
becomes irreversibly oxidized and dysfunctional, which may contribute to the 
pathogenesis in HD. It is noteworthy that DJ-1 is mainly expressed in astrocytes  22, 
which are cells that play a crucial role in providing protection against oxidative stress 
23,24. Thus, in late stages of HD, the loss of DJ-1 function may be especially deleterious 
for astrocytes. Since we did not evaluate exactly the oxidation state of DJ-1, we cannot 
exclude the hypothesis that DJ-1 in the normal experimental conditions used was 
already oxidized and therefore interacted with Htt. The addition of an oxidant to the 
media would cause further DJ-1 oxidation, leading to its inactivation. In these conditions 
DJ-1 no longer would bind to Htt and therefore no enhanced toxicity would be observed.   
Our results altogether suggest that it will be critical to further elucidate the 
mechanistic underpinnings of how DJ-1 modulates the pathogenesis of HD and other 
neurodegenerative disorders involving oxidative stress, protein misfolding and 
aggregation. Such studies could lay the groundwork for the development of effective 
treatments for these devastating and currently incurable disorders.  
 
 
Materials and Methods 
 
Plasmids, cell culture and transfection experiments 
The chemicals used in this study were purchased from Sigma unless otherwise stated. 
Plasmids (pcDNA3.1) contained the sequence for Htt exon 1 (HttEx1) with either 25 or 
97 glutamine repeats fused to monomeric Red Fluorescent Protein (mRFP) at the C-
terminus were used for transfections or adenoviral infections (MOI 10-20) as described 
previously 25. HeLa cells were cultured in DMEM with 2 mM L-glutamine, 10% fetal 
bovine serum (FBS) and 100U/ml penicillin with 100µg/ml streptomycin at 37°C, 10% 
CO2. After 24 hours of seeding, HeLa cells were exposed to the appropriate DNA 
construct/s and lipofectamine (Invitrogen) for 5 hours in serum-free medium (OPTI-
MEM, Invitrogen) for both transfection and co-transfection procedures as described 
previously 26,27Mouse primary astrocytes were cultured by dissecting P0 mouse cortices 
and meninges were removed. Cortices were cut into small cubes (<1mm3), suspended 
in 20ml of DMEM (maximum of 5 brains) and subsequently vortexed at maximum speed 
for 90 seconds in a 50ml centrifuge tube (Greiner Bio One) and then the cell suspension 
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was sieved through a 40µm cell strainer (BD Falcon). Cell filtrate was mixed with 
DMEM supplemented by 10% Hybond FBS (characterised, Hyclone) and 100 U/ml 
penicillin with 100 µg/ml streptomycin (Sigma, UK) and seeded in a 1x T75cm2 laminin 
(20µg/ml, Sigma, UK) coated flask. 24 hours after seeding, the cells were washed twice 
with 1x PBS (GIBCO, UK) and the media was replaced. Cell media was changed every 
3 days and cells reached confluency after 9-12 days. Confluent flasks lids were sealed 
with parafilm, and shaken for 15 hours at 180 rpm in a 37ºC heated incubator. After 15 
hours the media was removed and cells were washed with PBS. Cells were then 
trypsinised with 0.025% trypsin/EDTA (GIBCO, UK) and seeded in a 6 well poly-L-lysine 
coated plate with/without coverslips (200,000 cells per well for 6 well plate). These 
secondary cultures were then used after 3-4 days of seeding for transfection- and other 
studies (final age of astrocyte were normally between 15-20 days).  Cells in astrocyte 
cultures were >80% GFAP positive and >99% cells were connexin 43 positive hence 
suggesting a high astrocyte purity. No oligodendrocyes or microgial cells could be 
detected by ICC (data not shown).  
 
Protein extraction, Immunoblot and dot blot analysis 
Cells transiently transfected and primary astrocytes were collected at different time 
points. Samples were lysed in SDS containing lysis buffer (65.2mM Tris-HCl (pH 6.8), 
2% (w/v) SDS and 10% sucrose and complete protease inhibitor cocktail) followed by a 
20 minutes incubation on ice and then stored at -20°C. 17 weeks old R6/2 28 and WT 
littermates were sacrificed and cortex and cerebellum brain regions were collected. 
Samples were extracted initially with 10% W/V homogenisation buffer (20mM Hepes 
and 100mM KCl (pH 7.4) with complete protease inhibitors). Subsequently, total SDS 
soluble protein extraction was then performed by boiling the samples (both soluble and 
insoluble material) at 95°C for 4 minutes with 2% SDS. Samples were then spin at 6000 
rpm for 3 minutes to remove the SDS insoluble material. Supernatants were collected 
and stored at -80°C until further needed.  
Pre-dissected brain regions (cortex and cerebellum) from human HD patients and 
control groups were extracted with an ice-cold lysis buffer (40mM β-glycerolphosphate, 
1 mM EDTA, 1mM NaF, 50 mM Tris-HCl (pH 7.5), 1% (v/v) NP-40, 120 mM NaCl, 1mM 
Benzamidine, antifoam (1:1000, Sigma) and complete protease inhibitors (Roche)). 
Human HD patients and control samples were then re-extracted using 2% SDS. 
Samples were stored until further required. Samples were thawed and Bio-Rad DC 
protein assay was performed to quantify total soluble protein. Western blot was 
A novel role for DJ-1 in HD 
111 
performed as described previously 26,29. Membranes were incubated with primary 
antibodies, rabbit anti-DJ-1 antibody (1:2500; Neuromics, USA), rabbit anti-DJ-1 
antibody (1:1000; cell signaling), human anti-oxidised DJ-1 (1:50; Serotec, UK), for 1 
hour at room temperature, unless otherwise stated. Membranes were washed 3 x 10 
minutes with 1x TBS-T followed by incubation with secondary antibodies (sheep anti-
rabbit 800 (1:10000) Rockland, USA; Goat anti-rabbit HRP (1:10000), Vector, UK and 
Human F(ab')2 HRP (1:5000), Jackson Immunoresearch, USA). Fluorescent secondary 
antibody labeled membranes were scanned with a Li-COR scanner at 800nm and 
quantified by using odyssey v1.2 while HRP labeled secondary antibodies were 
analysed by using ECL detection kit (GE Healthcare Life Sciences, UK). 
For dot blot analysis, HeLa cells were co-transfected with HttQ25/Q97-mRFP and DJ-
1/EV (1:3) and treated with 5μM antimycin A and 100 μM H2O2 as mentioned earlier. 
Cells lysates were collected after 72 hours of transfection and processed as described 
previously 29. Dot blot lysates were normalized for total protein and filtered through a 2% 
SDS pre-equilibrated cellulose acetate membrane with a pore size of 0.2 μm andhese 
samples. Membranes were washed twice with 0.2% SDS followed by incubation with 
3% skimmed milk in 1x TBS. The membranes were then incubated with sheep anti-
HttEx1 (S830, Gilian Bates, Kings College London, London) antibody at a concentration 
of 1:5000 for 1 hour at room temperature followed by an incubated with anti-sheep HRP 
(1:10000, Jackson Immunoresearch, USA) secondary antibody. Finally membranes 
were developed by using Enhanced Chemiluminescence (ECL) kit. Dot blot 
quantification was performed by using image J software.  
 
Analysis of cellular HttEx1 polyQ-aggregation and interaction studies, toxicity 
and immunocytochemistry 
For the Bimolecular fluorescent complementation (BiFC) interaction analysis the Htt-
Venus BiFC constructs were used and have been previously described 18. The DJ-1 
BiFC construct was generated by PCR-based subcloning of DJ-1 and either the N-
terminal or C-terminal fragment of the fluorescent protein into the NheI and XhoI sites of 
pcDNA3.1. H4 human neuroglioma cells were transfected with complementary pairs of 
BiFC constructs using the Xtremegene reagent (Roche diagnostics, Mannheim, 
Germany). After 24 hours of incubation, cell cultures were processed and analysed by 
flow cytometry, microscopy and toxicity assays as previously described 18,30. Briefly, 5 µl 
of cell culture medium were collected for determination of toxicity following 
manufacturer´s instructions (Toxilight, Lonza Rockland Inc., Rockland, ME, USA). 
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Cultured cells were either collected by trypsinization for flow cytometry analyses (10000 
cells per group) or left on plates for bioimageing. Microscopy pictures were acquired 
from live cultures using an Axiovert 200M widefield fluorescence microscope equipped 
with a CCD camera (Carl Zeiss MicroImageing GmbH, Germany) and a stage 
incubator. A total of 150 cells per group (from 3 independent experiments) were 
analysed, and images were processed using ImageJ software (http://rsbweb.nih.gov/ij/). 
Aggregates were counted and classified according to their largest diameter in three 
classes for some experiments: smaller than 1 µm, larger than 1 µm but smaller than 3 
µm, and larger than 3 µm. Aggregates were scored by counting the total number of cells 
positive for aggregates. Similarly, cellular toxicity was measured by counting the cells 
expressing HttEx1Q25/Q97-mRFP with fragmented nuclei as described previously 25 or 
using the MTS assay (Promega). Cell death endpoints were analysed by scoring the 
proportion of HttEx1mRFP/EGFP-expressing cells with fragmented or pyknotic nuclei, 
showing that both apoptotic and non-apoptotic types of death can be detected. IB and 
toxicity counts analyses were performed in parallel.  
For immunocytochemistry (ICC) cells on coverslips were washed with 1× PBS, fixed 
with 4% paraformaldehyde in 1× PBS for 20 minutes and then processed for ICC or 
mounted in Fluoromount G medium (SouthernBiotech) supplemented with 1 µg/ml 4',6-
diamidino-2-phenylindole (DAPI) to allow visualization of nuclear morphology. ICC was 
performed as described 26. Cells were counted as aggregate-positive if one/several IB 
were visible. We counted 200–300 mRFP/EGFP-positive cells in multiple random visual 
fields per coverslip in duplicate for independent experiments. Cells were incubated with 
primary antibody (polyclonal rabbit anti-DJ-1) at a concentration of 1:200 for 1 hour at 
room temperature. Subsequently, cells were washed with dH2O and allowed to dry then 
mounted on glass slides with Fluoromount G (Southern Biotech, USA). Cells were 
finally imaged using a Zeiss LSM 510 Meta Axioscope-2 confocal microscope.  
 
Analysis of mutant Htt toxicity and aggregation in yeast 
Yeast strains used in this study are in the W303 (MATa can1-100 ade2-1 his3-11, 15 
trp1-1 ura3-1 leu23,112) genetic background and carry an integrated human Htt 
fragment construct, encoding either 25Q or 72Q glutamines 3132. Yeast were 
transformed independently with pYX212/DJ-1, pBG1805/HSP31 [Open Biosystems 33] 
or an empty vector control. Yeast cultures were grown overnight in complete media 
lacking uracil (SC-URA), containing yeast nitrogen base and glucose (2%). Yeast 
growth was synchronized by diluting the cultures to an optical density (OD600) of 0.1. 
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After reaching mid log phase, cultures were normalized for the same OD600, serially 
diluted (5-fold), and spotted onto SC-URA solid media containing glucose (2%) or 
galactose (2%) as carbon sources. These carbon sources were used to repress or 
induce Htt and Hsp31p expression, respectively.  DJ-1 was under control of the TPI 
constitutive promoter. 
For protein extraction, mid-log phase cultures were washed twice to remove glucose 
from the media and were diluted to an OD600 of 0.1 in SD-URA containing 2% of 
galactose. Cells were harvested after 8 hours of induction and lysed by mechanical 
disruption with acid-washed glass beads (425-600 nm, Sigma, St. Louis, MO) in lysis 
buffer (50 mM Tris pH 7.5; 1X protease inhibitor cocktail, Roche), vortexing three times 
for 30 sec each in a mini-bead beater (Biospec), with 1 min incubations on ice in 
between. Glass beads and cell debris were removed by centrifugation and protein 
extracts were quantified using the BCA protein assay kit (Pierce Biotechnology, Inc). 
For SDS-PAGE, extracts were mixed with 4X Protein Sample Buffer (200mM Tris-HCl, 
8% SDS, 40% glycerol, 0.4% bromophenol blue, 6% -mercaptoethanol), boiled 10 min, 
and subjected to electrophoresis using a 12% SDS-polyacrylamide gel. The proteins 
were transferred to nitrocellulose membranes and detected by immunoblotting. Htt 
tagged with CFP was identified by a monoclonal α-GFP antibody (Santa Cruz 
Biotechnology, Inc), used at a 1:1000 dilution. Hsp31p, tagged with HA, was detected 
with a polyclonal α-HA antibody (Santa Cruz) diluted 1:500. DJ-1 was detected with a 
polyclonal α-DJ-1 (Chemicon), used at 1:5000. α-CFP detection was done by an α-
Mouse Ig horseradish peroxidase conjugated antibody (Amersham Bioscience, 
Piscataway, NJ) at 1:10000, whereas α-DJ-1 and α-HA were done by an α-Rabbit Ig 
horseradish peroxidase conjugated antibody (Amersham Bioscience, Piscataway, NJ) 
also at 1:10000. Immunoblots were developed by ECL (Millipore, Billerica, MA, USA) 
and exposed to X-ray films. For filter trap experiments, cell lysates were obtained as 
described above and mixed with 1% SDS. A total of 100 ug of protein extract was 
loaded in a dot blotting apparatus and filtered by vacuum in acetate cellulose 
membranes (0.22 μ pore; GE Water & Process Technologies, Fairfield, CT, USA). Slots 
were washed two times with PBS 1% SDS. Detection of Htt in the filter was performed 
by immunoblotting as described above. 
Analysis of mutant Htt-mediated neurodegeneration in fruit flies 
Flies were raised on maize media, in LD12:12 at 25°C. The elav-GAL4c155 driver, and 
the DJ-1αΔ72 and DJ-1βΔ93 deficiency lines [described in 34] were obtained from the 
Bloomington Stock Centre, Indiana. The w;+;UAS Htt93Q exon 1 flies were a gift from 
Chapter 4 
114  
Larry Marsh and Leslie Thompson (University of California, Irvine) 16.  The UAS DJ-1α 
and DJ-1β over-expression lines were a gift from Alex Whitworth, and are described in 
35. Neurodegeneration was assayed using the pseudopupil assay. Briefly, the number of 
visible rhabdomeres per ommatidium was scored for 50-200 ommatidia per fly, with 5-
13 flies examined per genotype at day 1, 4 or 7 post-eclosion. Heads from appropriately 
aged flies were fixed to glass slides using clear fingernail polish and rhabdomeres were 
examined at 500X magnification using an Olympus BH2 microscope.  
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Chapter 5. General discussion, future perspectives and 
conclusion 
 
Protein misfolding and aggregation are key molecular features shared by a large 
family of human pathologies known as protein misfolding diseases. This diverse group 
includes the majority of neurodegenerative disorders, such as Alzheimer’s (AD), 
Parkinson’s (PD) and Huntington’s disease (HD). In general, each disease is associated 
with a different misfolded protein, a different affected brain region and different clinical 
symptoms. Despite extensive research on these diseases, the exact molecular 
mechanisms underlying neurodegeneration are still poorly understood. In the work 
described in this thesis, we used yeast as a model system to investigate the molecular 
mechanisms underlying HD, to find novel insights into the general function of the yeast 
DJ-1 homologues, which may have relevance to PD, and to characterize the potential 
role of DJ-1 in HD.  
 
Translational dysfunction is associated with HD 
Although HD is genetically well defined, the disease progression is influenced by 
several genetic modifiers 1, indicating that several potential therapeutic targets may be 
available. These genetic modifiers and the mechanisms of how mutant huntingtin (Htt) 
leads to neurodegeneration are still poorly characterized. Yeast has been successfully 
used to unravel the molecular mechanisms underlying HD as well as other 
neurodegenerative diseases. In addition, it has led to the identification of several 
potential therapeutic targets and drugs with therapeutic application for many diseases 2.  
 In Chapter 2 we suggest that translational dysfunction contributes to mutant Htt 
toxicity and we identify several candidate therapeutic targets for HD. Translation is a 
fundamental molecular mechanism that needs to be tightly controlled. Dysregulation of 
this process can be extremely deleterious for cells and thus the number of diseases 
associated with this process is continuously rising. These include cancer 3–5, 
neurological diseases 6 and metabolic diseases 7. Several studies suggest that 
translational dysfunction may also underlie neurodegeneration 8,9. Reduced translation 
fidelity (due to mischarged tRNAs or increased translation speed) leads to an increased 
rate of missense translation errors, which could affect protein folding and lead to the 
accumulation of misfolded proteins in neurons. Ultimately, this accumulation could 
cause neurodegeneration 8,9. Compelling evidence, although still scarce, supports that 
translational dysregulation is implicated in HD (discussed in Chapter 2).  
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We found that expression of several genes encoding ribosome biogenesis proteins, 
including proteins involved in rRNA processing are downregulated in Htt103Q-
expressing cells. Repression of ribosome biogenesis is a typical response to stress, 
which leads to a reduction in general translation and protein synthesis 10. Repression of 
general protein synthesis is a strategy that cells use to save energy 11,12 and to release 
the burden of the quality control system, which becomes more available to degrade 
misfolded/aggregated proteins allowing cells to recover. However, if the stress (in this 
case mutant Htt expression) is sustained, the decrease in protein synthesis may be 
deleterious for cells, since protein synthesis is fundamental for cell growth and survival. 
Interestingly, a recent study showed that persistent inhibition of protein synthesis 
through phosphorylation of eukaryotic translation initiation factor 2, subunit 1 α (eIF2α) 
contributes to neurodegeneration in prion infected mice 13 and that inhibition of this 
phosphorylation prevents it. High levels of eIF2α phosphorylation have also been 
observed in hippocampal neurons from AD patients 14 and differentiated dopaminergic 
cells treated with MPP+ and 6-hydroxydopamine (6-OHDA) (Parkinsonism-inducing 
neurotoxins) 15, suggesting translational dysfunction. Whether this process is indeed 
involved in neurodegeneration in AD or PD is unknown. In addition, inhibition of eIF2α  
phosphorylation enhances cortex-dependent memory consolidation, which deteriorates 
with ageing 16.  
We showed that rRNA processing genes that were downregulated in Htt-expressing 
yeast cells are able to suppress Htt toxicity. Among these genes, several have human 
homologues, and we propose that these rRNA processing proteins are potential 
therapeutic targets for HD. It is unclear and surprising that overexpression of just one of 
these proteins is sufficient to suppress Htt toxicity. We could speculate that single 
overexpression of these proteins may lead to an increase of general translation and 
consequently an increase in protein synthesis, which would be beneficial. However, 
unless overexpression of these proteins causes a feedback loop which would lead to 
upregulation of other genes encoding essential players in translation, overexpression of 
a single gene should be limited by the expression of the remaining genes 
downregulated upon Htt expression. Moreover, many of these suppressors, such as 
Rrp9 and Utp9 17,18, belong to large protein complexes, and thus it is surprising that 
overexpression of only one of the components could have an effect. Upon stress cells 
require a fast way to attenuate translation, thus besides repressing ribosome biogenesis 
at the transcriptional level, cells suppress translational initiation by mechanisms that 
affect mainly the activity of the initiation factors eIF2α, eIF4E, and eIF4A 12. Therefore, 
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overexpression of these proteins involved in rRNA processing should also be able to 
bypass these inhibitory mechanisms. However, it is still unknown whether cells 
expressing mutant Htt repress translation initiation. Indeed, increased phosphorylation 
of eIF2 was not observed in HeLA cells expressing mutant Htt when compared to wt Htt 
19. It would be interesting to evaluate the phosphorylation of this factor in other HD 
models. We hypothesize that although translation is not totally reverted to its basal 
levels – which in fact could be deleterious for cells due to the increase in energy 
consumption, higher burden in UPS and likely decreased translation of stress related 
genes – it is slightly increased and this supports cell survival and promotes growth.  
Downregulation of a subset of genes involved in translation could be also caused by 
transcriptional dysregulation via GCN4. Gcn4 is a transcriptional coactivator that 
requires MBF1, a deletion suppressor of Htt toxicity, to become activated 20. We 
hypothesize that deletion of MBF1 suppress mutant Htt toxicity by impairing Gcn4 
function (further discussed in Chapter 2). To test whether translation is affected through 
Gcn4 we could delete this gene and analyse its effect on Htt toxicity. We expect this 
deletion to be protective as it is observed upon deleting MBF1. Again, this hypothesis 
does not explain why overexpressing only one gene involved in rRNA processing is 
enough to suppress Htt toxicity. We cannot exclude the hypothesis that the suppressor 
genes identified have a protective function independent of rRNA processing. 
As we identified common differentially expressed genes in three toxicity suppressor 
strains expressing mutant Htt (bna4∆, mbf1∆, and ume1∆), these genes may also be 
considered candidate therapeutic targets for HD. Therefore, in the future, we could test 
whether these can rescue mutant Htt toxicity (by modulating their expression), first in 
yeast and later in mammalian HD models.  
Recently, the connection between translation and HD was suggested to be via 
direct binding of Htt with components of the translation machinery 19. Further studies 
should be carried out to confirm the effect of mutant Htt in translation and its relevance 
in HD pathogenesis, since our findings were mainly at the transcriptional level. To 
assess translation directly, we could perform ribosome profiling, which is a powerful 
technique based on deep sequencing of ribosome protected mRNA fragments 21. It can 
be used to quantify gene expression at the level of protein synthesis, since each mRNA 
fragment corresponds to a translating ribosome, and the number of fragments is 
proportional to the amount of protein being synthetized and the time required to produce 
it. In addition, this method can also be used to identify which genes are being translated 
and where the ribosomes are positioned at the mRNA. We could also use reporter-
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based assays for translation efficiency/fidelity in various HD models to ascertain the role 
of translational dysfunction and the impact of the identified genes in this process. 
Overall, our work shows that translation is impaired in HD and contributes to the 
pathogenesis of this disease. Therefore, we propose that targeting translation is an 
attractive therapeutic approach for this devastating disease, which is critical as there 
are still no treatments for onset or progression of symptoms. 
 
Yeast DJ-1 homologues are involved in diauxic-shift 
PD is not as well defined genetically as HD. Indeed, only ~10% of the PD cases 
are associated to genetic mutations, which are found in different genes 22. DJ-1 is 
encoded by PARK7, one of the genes associated with this disease 23,24. S. cerevisiae 
has four proteins that belong to the DJ-1 superfamily – the Hsp31 mini-family: Hsp31, 
Hsp32, Hsp33 and Hsp34. The function of both human and yeast members of the DJ-1 
superfamily is unclear, but it has been associated with protection against stress.  
In Chapter 3, we provide a significant advance in our understanding of the 
function of the Hsp31 mini-family. We showed that the proteins of this family have a role 
in the metabolic reprogramming that occurs in diauxic-shift. The transition from log 
phase to post-diauxic and stationary phase, in terms of global mRNA expression and 
several physiological mechanisms, is abolished upon deleting individually the members 
of the Hsp31-mini family, suggesting that cells fail to respond to glucose deprivation. 
The absence of this reprogramming caused knockout strains to age faster in stationary 
phase. Our results led us to propose a novel function for these proteins in regulating the 
activity of TORC1, one of the kinases responsible for this transition 25–28.  
Since TORC1 negatively regulates autophagy, we monitored this process as 
readout of TORC1 activity. We found that the members of the Hsp31 mini-family are 
required to maintain the basal levels of autophagy and to induce autophagy upon 
glucose starvation, via regulation of TORC1 activity. The number of diseases 
associated with mTORC1 dysfunction is continuously rising, and include cancer, type 2 
diabetes and neurodegeneration 29. Autophagy has been implicated in several 
neurodegenerative diseases, including PD 30. Indeed, conditional neuronal knockout 
mice for essential genes for autophagy (Atg5 or Atg7) exhibited striking 
neurodegeneration, formation of inclusion bodies and importantly locomotion deficits 
31,32, showing that autophagy is a critical process for neuronal cell survival. 
Dysregulation of autophagy also has an impact on α-synuclein (α-syn) homeostasis, 
which consequently accumulates in the cytoplasm and causes toxicity 30,33. Several 
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proteins genetically linked to PD were shown to have a role in autophagy, such as 
PINK1 and Parkin, which were shown to be particularly involved in mitophagy 
(degradation of mitochondria) 34. Compelling evidence suggest that DJ-1 also plays a 
role in autophagy, however the mechanism remains unclear and some findings are 
controversial 35–37. Consistent with our results, mouse embryonic fibroblasts (MEFs) 
depleted for DJ-1 and fibroblast from patients with the DJ-1 mutation E64D showed 
reduced basal autophagy 35. In addition, the absence of DJ-1 led to accumulation of 
dysfunctional mitochondria, which may be due to impaired autophagy 35. In contrast, 
another study that also used MEFs from DJ-1 knockout mice showed enhanced 
autophagic flux, but also mitochondrial defects 36.  
mTORC1 is considered an attractive therapeutic target for neurodegenerative 
diseases, since the use of rapamycin, which inhibits the activity of mTORC1, has 
already been shown to be neuroprotective in models of AD, PD and HD 38–42. Besides 
increasing autophagy, rapamycin showed beneficial effects by modulating other 
mechanisms regulated by mTORC1, such as translation 42. Rapamycin is already used 
as an immunosuppressant to prevent tissue rejection 43, but since neurodegenerative 
diseases need prolonged treatment, it may cause deleterious effects 42. Ideally, 
autophagy should be correctly balanced and therefore the mechanisms involved in this 
process should be thoroughly dissected. The role of DJ-1 in mTORC1 should therefore 
be further investigated, so that this pathway can be specifically modulated.  
 Dysfunctional mTOR signaling is also associated with several cancers 44. 
Indeed, the oncogenic properties of DJ-1 may be mediated by the PI3K/AKT pathway, 
which positively regulates mTORC1 45. Curiously, DJ-1 levels increased in response to 
high levels of glucose and led to the activation of AKT and mTORC1, resulting in 
mesangial cell hypertrophy 46. These results support our hypothesis that DJ-1 plays a 
role upstream TORC1, likely by transducing carbon signaling, however it suggests that 
DJ-1 is an activator rather than a repressor as shown for yeast proteins. One question 
that arises from these contrasting results is whether human DJ-1 behaves differently in 
different types of cells, as different effectors could lead to different responses. Although 
TORC1 pathway is a conserved pathway in eukaryotes, it has changed and diverged 
throughout evolution 47. Moreoever, it should be noted that the pathways associated 
with glucose starvation in mammalian cells are not very well studied and there are some 
controversies for instance whether glucose deprivation leads to inhibition or activation of 
autophagy 48.  
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Future studies should be performed to provide further mechanistic insights into 
how the Hsp31 family is playing its role in the diauxic shift through TORC1. We could 
address several questions: What is the level of function overlap of the members of the 
Hsp31 mini-family? Can overexpression of one protein compensate the absence of 
another? Since individual deletion of each family member leads to similar phenotypes, 
do they form a complex and upon the deletion of one protein does the complex become 
dysfunctional? What is the intracellular localization of these proteins? Does the 
localization change in stationary phase or in conditions of glucose starvation? Do these 
proteins interact with known upstream effectors of the TORC1 pathway? In parallel, the 
role of the human DJ-1 as a regulator of mTORC1 could be further explored.  
Altogether, our results open a new window for research in PD by showing a new 
perspective on the role of DJ-1. Moreover, it provides novel insights into the function of 
the yeast Hsp31 mini-family, which were not characterized in detail until now.   
 
A novel role for DJ-1 in HD 
The work described in Chapter 4 shows that DJ-1 interacts with Htt and 
modulates its aggregation and toxicity. As already described in patients with PD and 
AD, DJ-1 was found more abundant and hyperoxidized in cys106 in the brains of 
patients with HD 49, although it is unclear why DJ-1 is upregulated and whether its 
upregulation is protective.  
We found that Hsp31 and one of the fly homologues of DJ-1 suppressed Htt 
toxicity, and that Hsp31 reduced Htt aggregation. Surprisingly, overexpression of DJ-1 
in mammalian cells was not protective against mutant Htt and actually enhanced Htt 
toxicity and aggregation. Upon rendering the environment of cultured cells more 
oxidative, DJ-1 no longer enhanced Htt toxicity and aggregation. We further showed 
that this effect was mediated by oxidation of the cys106 residue. Oxidation of this 
residue is required to activate the protein for certain functions, namely to act as a redox-
dependent chaperone and prevent α-syn aggregation 50. It is unclear why DJ-1 in 
mammalian cells is not protective against mutant Htt, while its yeast and fly homologues 
are. A possible explanation is that the overexpression of Htt in these two models 
induces enough ROS to trigger DJ-1 oxidation, while in mammalian cells it does not. 
However, if the redox state of the yeast cell is enough to trigger the activation of Hsp31, 
it is still unanswered why human DJ-1 did not suppress Htt toxicity in yeast. Although 
human DJ-1 was actually expressed in yeast (detected by immunoblotting) it might be 
dysfunctional, due to abnormal folding, differences in post-translational modifications or 
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even by abnormal interactions with yeast proteins. Another possibility is that human DJ-
1 is sufficiently diverged from the yeast orthologs that it responds to different levels of 
cellular ROS.  
To further understand the role of DJ-1 in modulating mutant Htt toxicity and 
aggregation, it is important to clarify what is the exact redox status of cys106 in each 
experimental condition. In our basal experimental conditions was cys106 reduced or 
already mildly-oxidized (active) (Fig. 4.1)? And in an oxidizing environment, did cys106 
become mildly-oxidized (active) or hyperoxidized (inactive)? The oxidation status of 
cys106 could be measured by mass spectrometry 50. Alternatively, we could 
complement the experiments done with C106S DJ-1 (mutation that prevents oxidation), 
with a C106DD DJ-1 construct in which cys106 is replaced by two aspartates to mimic 
DJ-1 active form 51. In addition, we could also complement the experiment in which we 
increased the oxidative environment and use an antioxidant compound such as N-
acetylcysteine, to guarantee that the effects observed are caused by reduced DJ-1 and 
not by mild-oxidized DJ-1. It would also be important to verify the redox state of the 
corresponding cys106 in the DJ-1 homologues in yeast and fly upon mutant Htt 
expression, which could help us to understand why in these organisms DJ-1 
homologues suppress Htt toxicity. Furthermore, it would be interesting to verify whether 
DJ-1 still interacts with Htt upon mild oxidative stress and whether mutant DJ-1 C106S, 
which cannot be oxidized in this residue, also interacts with mutant Htt. This would 
inform us whether modulation of cys106 redox state is required for mutant Htt and DJ-1 
interaction. 
To further study the role of cys106 oxidation we can use available compounds 
that bind to the cys106 region when it is reduced or partially oxidized 52–55. These 
compounds are thought to activate DJ-1 or prevent its excessive oxidation 53,56, and 
have been shown to inhibit ROS production and toxicity induced by oxidative stress in 
SH-SY5Y cells and primary neurons 52–55. Importantly, they also prevented 6-
hydroxydopamine- and rotenone-induced dopaminergic cell death in vivo and reduced 
the infarct size in a mouse model of stroke 54,55. These are attractive compounds that 
may be beneficial for therapeutic intervention in HD and should therefore be tested in 
future experiments. 
It is also important to clarify whether hyperoxidized DJ-1 in the brains of HD 
patients can contribute to disease progression. Assuming that upregulation of DJ-1 is 
beneficial, as shown in yeast and fly models, DJ-1 could exert a neuroprotective role as 
a redox-chaperone in the initial stages of the disease, which is lost with the progression 
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of neurodegeneration and consequent increase in oxidative stress. We, however, 
cannot formally exclude the possibility that DJ-1 is modulating mutant Htt toxicity and 
aggregation by other functions aside from its chaperone activity, as DJ-1 has been 
shown to have several other functions. 
Altogether, our results show a potential novel role for DJ-1 in modulating Htt 
aggregation and toxicity, but whether the interaction between these two proteins is 
protective or not needs to be further explored, as DJ-1 may indeed contribute to HD 
pathology. Our findings provide the basis for future studies in understanding the role of 
DJ-1 in HD and other human pathologies involving protein misfolding and aggregation.  
 
CONCLUSION 
 
The increase of life expectancy, especially in developed countries, is leading to 
an increase in the incidence and prevalence of neurodegenerative diseases - as ageing 
is the main risk factor for the majority of these diseases. These are devastating 
diseases without a cure or effective treatment, causing a social and economic burden 
for society. Therefore, it is urgent to elucidate the molecular mechanisms that underlie 
these neurodegenerative diseases and find novel therapeutic targets.   
The work presented in this thesis shows that translational dysfunction is 
implicated in the pathogenesis of HD. The impairment of this mechanism has recently 
been associated with other misfolding diseases, strongly suggesting that translation is a 
pathogenic mechanism shared by several diseases. Importantly, we identified several 
novel suppressors of Htt toxicity, including many proteins involved in translation. These 
are attractive potential therapeutic targets for HD that will be further validated in the 
future. 
We also provide novel clues into the role of the yeast members of the DJ-1 
superfamily. These proteins are required to mount a stress response and change yeast 
metabolism at diauxic-shift, likely through TORC1. TORC1 is a highly conserved 
pathway that is implicated in several diseases because it controls several fundamental 
mechanisms, including autophagy. This work provides the basis for future studies to 
understand the function of the human protein DJ-1 that may bring not only novel 
insights into the pathogenesis of PD but also of other diseases. 
Finally, we propose a novel role for DJ-1 in modulating the toxicity and 
aggregation of Htt, possibly acting as a redox-chaperone. We observed that the yeast 
and fly homologues suppress Htt toxicity, suggesting that DJ-1 has a protective role, 
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however, in mammalian cells DJ-1 enhances Htt toxicity in a redox dependent manner. 
DJ-1 was found upregulated and irreversibly oxidized in the brains of patients with HD, 
as it is found in the brains of AD and PD patients. The increase in oxidative stress 
associated to protein misfolding diseases may lead to DJ-1 hyperoxidation and 
consequently to its inactivation, which in turn may contribute to the pathogenesis of 
these disorders. Whether DJ-1 is beneficial or deleterious at early stages of the 
pathology is still unclear. Nevertheless, these findings provide clues for the general role 
of DJ-1 in these disorders and therefore it may have implications in treating not only HD 
and idiopathic PD, but also other disorders that are associated with oxidative stress and 
protein misfolding.  
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Chapter 6. Appendix 
 
Appendix 2.1. Validation of differentially expressed genes identified via 
microarray analysis by QPCR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The majority of DEGs identified by microarray analysis were validated by QPCR (9/17; 53%, indicated by astericks). An 
additional 3 genes were found to be differentially expressed via QPCR analysis in the same direction as observed by 
mRNA profiling, but failed to reach statistical significance. 
  
Gene 
Fold Change 
Microarray 
Fold Change 
QPCR 
P-value Expression 
AQR1* -10.22 -2.19 0.002 Down 
BAG7* 13.68 2.19 < 0.001 Up 
DAK2* 25.27 1.86 < 0.001 Up 
HSP26 5.80 0.57 0.102 No change 
HXT2 -5.52 1.55 0.008 Up 
PHM6 -9.53 1.31 0.676 No change 
PHO84 -4.80 1.22 0.261 No change 
PRM7 -5.71 -1.31 0.238 No change 
SPL2* -4.74 -1.52 0.021 Down 
SRX1* 8.58 2.51 0.001 Up 
TMA10* 9.76 2.01 < 0.001 Up 
YDR034W-B* 11.72 3.61 0.001 Up 
YGR079W -5.03 1.00 0.964 No change 
YLR194C* 15.02 3.07 < 0.001 Up 
YOR338W -6.02 1.54 0.055 No change 
YPK2 4.28 1.27 0.223 No change 
YPR077C* 4.17 8.73 < 0.001 Up 
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Appendix 2.2. Gene ontology groups significantly upregulated in Htt103Q versus 
Htt25Q expressing yeast cells  
Gene Ontology Group Count % P-value Enrichment 
response to unfolded protein 11 5.0 6.2E-06 6.3 
response to stimulus 42 18.9 1.9E-04 1.7 
response to stress 31 14.0 2.1E-04 2.0 
response to chemical stimulus 27 12.2 2.9E-04 2.1 
protein folding 13 5.9 7.8E-04 3.1 
ubiquitin cycle 12 5.4 1.7E-03 3.1 
cell wall organization and 
biogenesis 
15 6.8 2.1E-03 2.5 
protein metabolic process 58 26.1 2.9E-03 1.4 
protein ubiquitination 8 3.6 3.0E-03 4.1 
cellular macromolecule 
metabolic process 
58 26.1 3.2E-03 1.4 
cellular protein metabolic 
process 
55 24.8 6.2E-03 1.4 
post-translational protein 
modification 
24 10.8 6.5E-03 1.8 
chitin- and beta-glucan-cell 
wall biogenesis 
6 2.7 8.6E-03 4.6 
protein modification by small 
protein conjugation 
8 3.6 1.1E-02 3.2 
cellular carbohydrate 
metabolic process 
14 6.3 2.2E-02 2.0 
catabolic process 23 10.4 2.4E-02 1.6 
protein refolding 3 1.4 2.9E-02 10.9 
cotranslational protein 
targeting to membrane 
3 1.4 3.5E-02 9.9 
hexose metabolic process 8 3.6 3.7E-02 2.5 
glucose metabolic process 7 3.2 3.7E-02 2.8 
carbohydrate metabolic 
process 
15 6.8 3.9E-02 1.8 
signal transduction 14 6.3 4.0E-02 1.8 
vacuolar protein catabolic 
process 
3 1.4 4.1E-02 9.1 
monosaccharide metabolic 
process 
8 3.6 4.8E-02 2.4 
Gene ontology groups determined by the DAVID Functional Annotation tool. Count refers 
to number of genes within input gene list that fall into the specified GO group. % denotes 
what percentage of the total input genes analysed fall within the specific GO group. P-
value represents the threshold of EASE Score, a modified Fisher Exact P-value, for gene-
enrichment analysis. Enrichment category denotes the overall enrichment of the particular 
GO group over background. 
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Appendix 2.3. Gene ontology groups significantly downregulated in Htt103Q 
versus Htt25Q expressing expressing yeast cells 
Gene Ontology Group Count % P-value Enrichment 
ribosome biogenesis and assembly 74 31.2 7.5E-40 5.9 
ribonucleoprotein complex biogenesis  75 31.7 3.6E-35 5.0 
rRNA metabolic process 42 17.7 2.2E-21 5.9 
rRNA processing 41 17.3 5.1E-21 6.0 
RNA processing 54 22.8 6.9E-16 3.3 
organelle organization and biogenesis 95 40.1 5.0E-13 1.9 
ribosomal large subunit biogenesis and assembly 19 8.0 2.2E-12 8.5 
RNA metabolic process 73 30.8 6.4E-08 1.8 
ribosome assembly 14 5.9 2.9E-07 6.1 
maturation of 5.8S rRNA from tricistronic rRNA  10 4.2 1.0E-06 8.8 
maturation of SSU-rRNA from tricistronic rRNA  11 4.6 1.2E-06 7.4 
maturation of SSU-rRNA 12 5.1 1.5E-06 6.4 
maturation of 5.8S rRNA 10 4.2 1.7E-06 8.3 
cellular component organization and biogenesis 109 46.0 8.2E-06 1.4 
ribosomal large subunit assembly  9 3.8 7.1E-05 6.2 
ribosomal subunit assembly 10 4.2 1.2E-04 5.1 
protein-RNA complex assembly 15 6.3 3.7E-04 3.0 
cleavages during rRNA processing 6 2.5 5.8E-04 8.3 
nucleobase, nucleoside, nucleotide metabolism 85 35.9 8.2E-04 1.3 
maturation of LSU-rRNA 5 2.1 1.0E-03 10.4 
gene expression 73 30.8 1.1E-03 1.4 
endonucleolytic cleavage mature 5'-end of SSU-
rRNA  5 2.1 2.8E-03 8.1 
establishment of organelle localization 8 3.4 3.4E-03 4.0 
endonucleolytic cleavage of tricistronic rRNA  5 2.1 3.5E-03 7.6 
RNA modification 9 3.8 3.5E-03 3.5 
transcription from RNA polymerase I promoter 6 2.5 6.3E-03 5.0 
positive regulation of  RNA pol I transcription 3 1.3 6.7E-03 21.8 
tRNA processing 10 4.2 6.9E-03 2.9 
processing of 27S pre-rRNA 4 1.7 8.8E-03 8.9 
biopolymer metabolic process 96 40.5 9.4E-03 1.2 
tRNA modification 7 3.0 1.2E-02 3.6 
tRNA methylation 4 1.7 1.3E-02 7.7 
biopolymer methylation 6 2.5 1.5E-02 4.0 
ribosome export from nucleus 5 2.1 1.8E-02 4.8 
endonucleolytic cleavage 5'-ETS of tricistronic 
rRNA  4 1.7 1.9E-02 6.8 
RNA methylation 4 1.7 2.2E-02 6.4 
tRNA metabolic process 11 4.6 3.0E-02 2.2 
organelle localization 8 3.4 3.2E-02 2.6 
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Appendix 2.4. Gene ontology groups significantly differentially expressed in 
bna4∆ Htt103Q-expressing yeast versus wild-type Htt103Q expressing cell 
Gene ontology groups determined by the DAVID Functional Annotation tool. Count refers to number of genes within 
input gene list that fall into the specified GO group. % denotes what percentage of the total input genes analysed fall 
within the specific GO group. P-value represents the threshold of EASE Score, a modified Fisher Exact P-value, for 
gene-enrichment analysis. Enrichment category denotes the overall enrichment of the particular GO group over 
background. 
 
 
 
 
 
Gene ontology groups determined by the DAVID Functional Annotation tool. Count refers to number of genes 
within input gene list that fall into the specified GO group. % denotes what percentage of the total input genes 
analysed fall within the specific GO group. P-value represents the threshold of EASE Score, a modified Fisher 
Exact P-value, for gene-enrichment analysis. Enrichment category denotes the overall enrichment of the particular 
GO group over background. 
 
 
Gene Ontology Group Count % P-value Enrichment 
carboxylic acid metabolic process 23 11.7 2.6E-05 2.7 
translational elongation 8 4.1 3.1E-04 6.0 
amino acid catabolic process 6 3.1 3.2E-04 9.6 
nitrogen compound metabolic process 18 9.2 3.3E-04 2.6 
amino acid and derivative metabolism 16 8.2 3.6E-04 2.9 
organic acid transport 8 4.1 4.1E-04 5.7 
amine catabolic process 6 3.1 5.9E-04 8.5 
amino acid metabolic process 15 7.7 6.0E-04 2.9 
amine metabolic process 16 8.2 1.1E-03 2.6 
carboxylic acid transport 7 3.6 2.2E-03 5.1 
glutamine family amino acid metabolism 6 3.1 6.4E-03 5.0 
monocarboxylic acid metabolic process 10 5.1 6.5E-03 2.9 
biopolymer biosynthetic process 8 4.1 8.6E-03 3.4 
water-soluble vitamin metabolic process 7 3.6 2.2E-02 3.2 
water-soluble vitamin biosynthesis  5 2.6 3.1E-02 4.2 
alcohol metabolic process 10 5.1 3.2E-02 2.2 
urea cycle intermediate metabolism 3 1.5 3.9E-02 9.3 
sterol transport 3 1.5 3.9E-02 9.3 
arginine metabolic process 3 1.5 3.9E-02 9.3 
tyrosine catabolic process 2 1.0 4.2E-02 46.5 
L-phenylalanine catabolic process 2 1.0 4.2E-02 46.5 
vesicle organization and biogenesis 3 1.5 4.4E-02 8.7 
cellular biosynthetic process 27 13.8 4.5E-02 1.4 
catabolic process 18 9.2 4.7E-02 1.6 
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Appendix 2.5. Gene ontology groups significantly differentially expressed in 
mbf1 Htt103Q-expressing yeast versus wild-type Htt103Q expressing cells 
 
 
 
 
Gene Ontology Group Count % P-value Enrichment 
amino acid metabolic process 28 14.0 2.7E-12 5.0 
nitrogen compound metabolic process 29 14.5 2.4E-10 4.0 
lysine metabolic process 8 4.0 3.1E-10 34.7 
lysine biosynthetic process via aminoadipic acid 7 3.5 3.4E-09 38.0 
carboxylic acid metabolic process 30 15.0 1.2E-08 3.3 
aspartate family amino acid biosynthesis  10 5.0 3.0E-07 10.3 
aspartate family amino acid metabolic process 11 5.5 6.5E-07 8.1 
amine biosynthetic process 16 8.0 1.6E-06 4.5 
amine catabolic process 8 4.0 7.1E-06 12.0 
urea cycle intermediate metabolic process 6 3.0 1.4E-05 17.4 
nonprotein amino acid metabolic process 5 2.5 4.9E-05 21.7 
glutamine family amino acid metabolic process 8 4.0 2.5E-04 6.2 
ornithine metabolic process 4 2.0 3.8E-04 24.8 
cellular biosynthetic process 36 18.0 4.1E-04 1.8 
arginine biosynthetic process 4 2.0 1.2E-03 17.4 
translational elongation 7 3.5 2.7E-03 4.9 
carboxylic acid transport 7 3.5 3.2E-03 4.7 
serine family amino acid catabolic process 3 1.5 7.3E-03 21.7 
amine transport 6 3.0 8.0E-03 4.7 
serine family amino acid metabolic process 5 2.5 1.5E-02 5.2 
glutamine family amino acid catabolic process 3 1.5 2.1E-02 13.0 
glycine metabolic process 3 1.5 2.1E-02 13.0 
amino acid transport 5 2.5 2.2E-02 4.6 
biosynthetic process 37 18.5 2.3E-02 1.4 
polyamine transport 3 1.5 2.9E-02 10.8 
glutamine family amino acid biosynthesis 4 2.0 3.3E-02 5.6 
biopolymer biosynthetic process 7 3.5 3.9E-02 2.8 
tyrosine catabolic process 2 1.0 4.5E-02 43.4 
L-phenylalanine catabolic process 2 1.0 4.5E-02 43.4 
arginine catabolic process 2 1.0 4.5E-02 43.4 
Translation 17 8.5 4.9E-02 1.6 
Gene ontology groups determined by the DAVID Functional Annotation tool. Count refers to number of genes within 
input gene list that fall into the specified GO group. % denotes what percentage of the total input genes analysed fall 
within the specific GO group. P-value represents the threshold of EASE Score, a modified Fisher Exact P-value, for 
gene-enrichment analysis. Enrichment category denotes the overall enrichment of the particular GO group over 
background. 
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Appendix 2.6. Gene ontology groups significantly differentially expressed in 
ume1∆ Htt103Q-expressing yeast versus wild-type Htt103Q expressing cells 
Gene Ontology Group Count % P-value Enrichment 
water-soluble vitamin biosynthetic process 8 4.0 1.2E-03 4.8 
NAD biosynthetic process 4 2.0 1.9E-03 14.8 
nitrogen compound metabolic process 20 10.1 2.6E-03 2.1 
monocarboxylic acid metabolic process 13 6.5 2.6E-03 2.7 
response to pheromone 10 5.0 3.9E-03 3.2 
G-protein coupled receptor protein signaling  6 3.0 5.0E-03 5.3 
response to chemical stimulus 25 12.6 5.2E-03 1.8 
pyridine nucleotide biosynthetic process 4 2.0 7.4E-03 9.5 
response to pheromone / conjugation 7 3.5 8.5E-03 3.9 
regulation of catalytic activity 7 3.5 8.5E-03 3.9 
water-soluble vitamin metabolic process 9 4.5 1.1E-02 2.9 
signal transduction during conjugation  5 2.5 1.1E-02 5.6 
carboxylic acid transport 7 3.5 1.2E-02 3.6 
ammonium transport 3 1.5 1.2E-02 16.7 
glutamate metabolic process 4 2.0 1.3E-02 7.8 
regulation of conjugation with cellular fusion 5 2.5 1.4E-02 5.2 
carboxylic acid metabolic process 21 10.6 1.5E-02 1.7 
regulation of cyclin-dependent protein kinases 4 2.0 1.5E-02 7.4 
Transport 49 24.6 1.6E-02 1.3 
amine transport 6 3.0 2.3E-02 3.6 
Localization 50 25.1 2.4E-02 1.3 
amine metabolic process 16 8.0 2.5E-02 1.8 
NAD metabolic process 4 2.0 2.6E-02 6.1 
cell surface receptor linked signal transduction 6 3.0 2.7E-02 3.5 
tricarboxylic acid cycle metabolism 4 2.0 3.0E-02 5.8 
conjugation with cellular fusion 9 4.5 3.4E-02 2.4 
glyoxylate cycle 3 1.5 3.4E-02 10.0 
response to unfolded protein 6 3.0 3.9E-02 3.2 
glyoxylate metabolic process 3 1.5 4.1E-02 9.1 
Gene ontology groups determined by the DAVID Functional Annotation tool. Count refers to number of genes within 
input gene list that fall into the specified GO group. % denotes what percentage of the total input genes analysed fall 
within the specific GO group. P-value represents the threshold of EASE Score, a modified Fisher Exact p-value, for 
gene-enrichment analysis. Enrichment category denotes the overall enrichment of the particular GO group over 
background. 
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Appendix 2.7. Validation of differentially expressed genes identified via 
microarray analysis in suppressor strains by QPCR. 
 bna4∆103Q vs WT103Q mbf1∆103Q vs WT103Q ume1∆103Q vs WT103Q 
Gene Microarray 
Fold 
Chang
e 
P-value Microarray 
Fold 
Change 
P-value Microarray 
Fold 
Change 
P-
value 
AQR1 Up* 7.86 <0.001 Up -3.04 0.088 Up* 2.216 0.002 
DAK2 Down 1.984 0.097 Down* -2.72 0.024 Down 1.606 0.01 
YGR035
C Up* 6.543 0.008 Up† 3.087 0.197 Up* 5.044 <0.001 
YMC2 Up† 1.974 0.099 Up* 2.83 0.031 Up* 4.31 <0.001 
Four DEGs (AQR1, DAK2, YGR035C, and YMC2) that were identified by microarray comparison of the three deletion 
suppressor strains (bna4∆ mbf1∆ ume1∆ expressing Htt103Q versus WT expressing Htt103Q were validated by QPCR. 
Of the 12 comparisons, 7 were significantly confirmed by QPCR analysis (7/12; 58%, indicated by astericks). An 
additional 2 genes were found to be differentially expressed via QPCR analysis in the same direction as observed by 
mRNA profiling, but failed to reach statistical significance (indicated by †). Fold changes and P-values refer to QPCR 
data. 
 
Appendix 3.1. Validation of microarrays by real-time quantitative PCR 
 
11 DEGs found in both the gene expression microarrays of hsp32∆ and hsp33∆ strains were 
validated by QPCR. Among these 11 genes, 9 were also differentially expressed in hsp31∆ cells. 
The table indicates the fold change obtained by microarray and QPCR analyses. In addition, it 
shows the standard deviation and p-value obtained by QPCR. (n.c. – genes that were not 
changed and n.s. – statistically not significant) 
 
 
 
 
 
 
 
 
 
 
Chapter 6 
140 
Appendix 3.2. Gene ontology groups significantly upregulated in hsp31∆, hsp32∆ 
and hsp33∆ vs wild-type cells 
  No. of genes Frequency (%)         
Gene ontology process List Genome List Genome 
Total 
DEG 
Pop 
Total 
p-
value 
Benjamini 
Translation and ribosomal biogenesis           
endonucleolytic cleavage of 
tricistronic rRNA transcript 
7 38 5,00 0,78 127 4870 0,000 0,013 
rRNA export from nucleus 8 42 5,71 0,86 127 4870 0,000 0,003 
maturation of 5.8S rRNA 
from tricistronic rRNA 
transcript  
8 69 5,71 1,42 127 4870 0,002 0,045 
ribosome assembly 11 69 7,86 1,42 127 4870 0,000 0,001 
ribonucleoprotein complex 
assembly 
11 117 7,86 2,40 127 4870 0,001 0,022 
maturation of SSU-rRNA 
from tricistronic rRNA 
transcript  
15 83 10,71 1,70 127 4870 0,000 0,000 
regulation of translation 18 180 12,86 3,70 127 4870 0,000 0,000 
rRNA processing 21 239 15,00 4,91 127 4870 0,000 0,000 
ribosomal subunit assembly 23 335 16,43 6,88 127 4870 0,000 0,002 
ncRNA metabolic process 26 393 18,57 8,07 127 4870 0,000 0,001 
ribosome biogenesis 38 351 27,14 7,21 127 4870 0,000 0,000 
translation 60 677 42,86 13,90 127 4870 0,000 0,000 
Cellular metabolic processes             
cellular amino acid 
biosynthetic process 
11 134 7,86 2,75 127 4870 0,002 0,050 
organic acid biosynthetic 
process 
14 172 10,00 3,53 127 4870 0,000 0,015 
sulfur amino acid metabolic 
process 
7 47 5,00 0,97 127 4870 0,001 0,031 
ergosterol biosynthetic 
process 
6 24 4,29 0,49 127 4870 0,000 0,012 
Number of overlapping genes that have a known ontology term associated - downregulated: 286; upregulated: 127 
Number of yeast genes with an ontology term associated - 4870 
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Appendix 3.3. Gene ontology groups significantly downregulated in hsp31∆, 
hsp32∆ and hsp33∆ vs wild-type cells 
  No. of genes Frequency (%)         
Gene ontology process List Genome List Genome 
Total 
DEG 
Pop 
Total 
p-
value 
Benjamini 
Stress response             
response to temperature 
stimulus 
65 217 17,71 4,46 286 4870 0,000 0,000 
response to abiotic stimulus 74 344 20,16 7,06 286 4870 0,000 0,000 
response to oxidative stress 25 82 6,81 1,68 286 4870 0,000 0,000 
cellular response to stress 66 562 17,98 11,54 286 4870 0,000 0,000 
Aerobic respiration                 
aerobic respiration 15 102 4,09 2,09 286 4870 0,002 0,047 
tricarboxylic acid cycle 9 30 2,45 0,62 286 4870 0,000 0,006 
acetyl-CoA metabolic 
process  
10 34 2,72 0,70 286 4870 0,000 0,003 
coenzyme metabolic 
process 
25 149 6,81 3,06 286 4870 0,000 0,000 
Cellular metabolic processes             
glycogen biosynthetic 
process 
6 12 1,63 0,25 286 4870 0,000 0,010 
generation of precursor 
metabolites and energy 
42 264 11,44 5,42 286 4870 0,000 0,000 
oxidation reduction 57 353 15,53 7,25 286 4870 0,000 0,000 
disaccharide metabolic 
process 
7 24 1,91 0,49 286 4870 0,002 0,046 
trehalose metabolic process 
(biosynthesis) 
7 11 1,91 0,23 286 4870 0,000 0,001 
glycoside metabolic process 7 12 1,91 0,25 286 4870 0,000 0,001 
glucose metabolic process 22 100 5,99 2,05 286 4870 0,000 0,000 
hexose metabolic process 26 122 7,08 2,51 286 4870 0,000 0,000 
pentose metabolic process 8 19 2,18 0,39 286 4870 0,000 0,002 
monosaccharide metabolic 
process 
30 136 8,17 2,79 286 4870 0,000 0,000 
alcohol catabolic process 18 65 4,90 1,33 286 4870 0,000 0,000 
energy reserve metabolic 
process 
13 42 3,54 0,86 286 4870 0,000 0,000 
carbohydrate biosynthetic 
process 
17 94 4,63 1,93 286 4870 0,000 0,003 
carbohydrate catabolic 
process 
25 84 6,81 1,72 286 4870 0,000 0,000 
Others                 
vacuolar protein catabolic 
process 
54 117 14,71 2,40 286 4870 0,000 0,000 
autophagy 20 143 5,45 2,94 286 4870 0,001 0,015 
ascospore formation/sexual 
sporulation 
16 113 4,36 2,32 286 4870 0,002 0,047 
 
Chapter 6 
142 
Appendix 3.4. Genotypes of the strains used in this study 
Strain Genotype Reference 
BY4741 MATa his3∆0 leu2∆0 met15∆0 ura3∆0 Open Biosystems 
BY4742 MATα his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 Open Biosystems 
hsp32∆ 2n 
MATas3Δ1 leu2Δ0 ura3Δ0 lys2Δ0/LYS2 met15Δ0/MET15 can1Δ::LEU2-
MFA1pr-HIS3/CAN1+ hsp32::URA3MX/HSP32 
Open Biosystems 
hsp31∆ MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 hsp31::kanMX4 Marek Skoneczny lab  
hsp32∆ 
MATa ura3Δ0 leu2Δ0 his3Δ1 lys2Δ0 met15Δ0 can1Δ::LEU2+-MFA1pr-
HIS3 hsp32::URA3MX 
This study 
hsp33∆ MATα his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 hsp33::NatMX This study 
hsp34∆ MATα his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 hsp34::HygMX This study 
Lx Wild-type MATa ura3Δ0 leu2Δ0 lys2Δ0  his3Δ1 can1Δ::LEU2-MFA1pr-HIS3 This study 
Lx1 
(hsp31∆) 
MATa his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0  can1Δ::LEU2-MFA1pr-HIS3  
hsp31::kanMX4 
This study 
Lx2 
(hsp32∆) 
MATa  his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 can1Δ::LEU2-MFA1pr-HIS3 
hsp32::URA3MX 
This study 
Lx3 
(hsp33∆) 
MATα his3Δ1 leu2Δ0 lys2Δ0  met15Δ ura3Δ0 can1Δ::LEU2-MFA1pr-HIS3 
hsp33::NatMX 
This study 
Lx4 
(hsp34∆) 
MATa his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 can1Δ::LEU2-MFA1pr-HIS3 
hsp34::HygMX 
This study 
gis1Δ MATa his3∆0 leu2∆0 met15∆0 ura3∆0 gis1::kanMX4 Open Biosystems 
sod1Δ MATa his3∆0 leu2∆0 met15∆0 ura3∆0 sod1::kanMX4 Open Biosystems 
yap1Δ MATa his3∆0 leu2∆0 met15∆0 ura3∆0 yap1::kanMX4 Open Biosystems 
 
Appendix 3.5. Primers used in this study 
Primer Forward sequence (5' to 3') Reverse sequence (5' to 3') Comments 
HSP33 
flanking 
regions 
ACACTTTTCTCCTTCATTCAAAAAG
AAAACTGGCCTTGCACGTACGCTG
CAGGTCGAC 
CATTAGAAGCCTCCCCTTCAACAAT
TCCCTTGTCTTTTGTTATCGATGAA
TTCGAGCTCG 
Excision of HSP33 or 
HSP34 
GIS1 TAACACCTCTGCAGCCGCATCTAT TTGTCATCGTTATCGCCGCCTAGA QPCR 
HSP31 ATCTGCAGGCCACGGTACCTTATT TGCGACAACACCACCGTTAGCATA QPCR 
HSP32 TTTTGCGGTCGTTCGATACT GGTCCATGACAGATGGCA QPCR 
HSP33 ATTTTGCGATCGTTCGATACA GGTCCATGACAGATGGCA QPCR 
TAF10 
ATATTCCAGGATCAGGTCTTCCGTA
GC 
GTAGTCTTCTCATTCTGTTGATGTT
GTTGTTG 
QPCR – control 
UBC6 AGCAGGCTCACAAGAGATTGACGA TACCGTGATATTGACCGCCCTTGT QPCR – control 
GTT1 TGGCAGACAAGATCAGTCAGGCAT CCTCTGGTGCGGCAAACTTTCTTT 
QPCR - validate 
microarrays 
HEM13  AAACTTGGTGGTTTGGTGGTGGTG GCATCCTTGTGCAGTTGGTGGAAT 
QPCR - validate 
microarrays 
HXK2 GGCCGATGTGCCAAAGGAATTGAT TACCACCCTTCTTGGACAAACCCT 
QPCR - validate 
microarrays 
HXT4 TAGGTCTAGGTTTCGCTTGGGCTT TGGATCGTCTGCGCTGACCTTATT 
QPCR - validate 
microarrays 
MIG2 CATTCATGCCTCCGCTGCATCTTT TTGGCACAGAGCGTGGAGTGTTTA 
QPCR - validate 
microarrays 
OM45 AAACAGCCGCTCAACTTTCCAAGG ACTGTTTCAAGTCCTCCTTCGCCT 
QPCR - validate 
microarrays 
Appendix 
143 
POT1 CTTTCAAGCATCAGGCCTGCCTTT AGCGACCTAGCACAGGCAGATTTA 
QPCR - validate 
microarrays 
RPS24A TGTTGGCCAGAAAGCAATTCGTCG ACCGAAACCAACAGACTTACCACC 
QPCR - validate 
microarrays 
SOL4 AGGATCGATGAACCAAGCGCTGTA AATTGGTTGCCCTGATGCACTAGC 
QPCR - validate 
microarrays 
SSA3 TTGCTTATGGTGCAGCCGTTCAAG TATGCCGCCTGCAGTTTCAATTCC 
QPCR - validate 
microarrays 
TRX3 TTGTCAAGTGCGACGTGGACGAAT GCCATCCTTGCCAAGAACAAAGGT 
QPCR - validate 
microarrays 
HSP32/33 
R  
CATGGTGCAACGTGGTAAAA 
Verify cassette 
integration 
HSP32/33
/34 F 
AAGATGGTGCGAAAACAGGC 
 
Verify cassette 
integration 
HSP34 R 
 
GTAGAGACTCAAGAATGTCG 
Verify cassette 
integration 
MX4 F TGGTCGCTATACTGCTGTCG   
Verify cassette 
integration 
 
 
 
